
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" encoding="utf-8"?-->


     <title></title>
<meta http-equiv="Content-Type" content="text/html">

<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2021_currency -->
<!-- Field: Set; Name: xdx; ID: xdx_039_avxl_anavex.com_20210930 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20201001_20210930 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001314052 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DDocumentFiscalYearFocus_2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->

<div style="display: none">
<ix:header>
 <ix:hidden>
  <span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityCentralIndexKey" inside-table="false" id="fact-identifier-0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0001314052</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt:booleanfalse" name="dei:AmendmentFlag" inside-table="false" id="fact-identifier-1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">false</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:DocumentFiscalPeriodFocus" inside-table="false" id="fact-identifier-2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FY</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:DocumentFiscalYearFocus" inside-table="false" id="fact-identifier-3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">2021</ix:nonnumeric></span>
  <ix:nonfraction id="xdx2ixbrl0091" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0092" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0253" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0260" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0261" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0267" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0268" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0274" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0279" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0281" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0284" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0285" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0298" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0305" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0306" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0312" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0319" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0326" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0333" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0338" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0340" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0343" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0344" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0775" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0777" unitref="USDPShares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0874" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0875" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0894" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0897" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0903" unitref="USD" xs:nil="true"></ix:nonfraction>
  </ix:hidden>
 <ix:references>
  <link:schemaref xlink:href="avxl-20210930.xsd" xlink:type="simple">
  </link:schemaref></ix:references>
 <ix:resources>
    <xbrli:context id="From2020-10-01to2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-19">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_ParkinsonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:ParkinsonMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-012017-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2016-10-01</xbrli:startdate>
        <xbrli:enddate>2017-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-012021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-06-01</xbrli:startdate>
        <xbrli:enddate>2021-06-22</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-06-06</xbrli:startdate>
        <xbrli:enddate>2019-06-07</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_PurchaseWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice1Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice2Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice3Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice4Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avxl:OptionPrice5Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-10-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012021-09-30_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">avxl:FederalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-10-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_ForeignCountryMember_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitnumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitnumerator>
        <xbrli:unitdenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitdenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 10pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Washington, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_900_edei--DocumentType_c20201001__20210930_zViMFgJhC6X2"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:DocumentType" inside-table="false" id="fact-identifier-4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10-K</ix:nonnumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(Mark One)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--DocumentAnnualReport_c20201001__20210930_zLkVAPqswCDb"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt:booleantrue" name="dei:DocumentAnnualReport" inside-table="false" id="fact-identifier-5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span>&nbsp;ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
the fiscal year ended <b><span style="text-decoration: underline"><span id="xdx_904_edei--DocumentPeriodEndDate_c20201001__20210930_zsuYnkFUyjod"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" inside-table="false" id="fact-identifier-6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span id="xdx_90D_edei--CurrentFiscalYearEndDate_c20201001__20210930_znormpxJBkN8"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" inside-table="false" id="fact-identifier-7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">September 30</ix:nonnumeric></span></span>, 2021</ix:nonnumeric></span></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&nbsp;</b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_edei--DocumentTransitionReport_c20201001__20210930_zbMvytQf8UQ6"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" inside-table="false" id="fact-identifier-8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span>&nbsp;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE A</span>CT OF 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from ______________
to________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission file number<b>: <span style="text-decoration: underline"><span id="xdx_90F_edei--EntityFileNumber_c20201001__20210930_zrh24o6MtfO"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityFileNumber" inside-table="false" id="fact-identifier-9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">001-37606</ix:nonnumeric></span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90E_edei--EntityRegistrantName_c20201001__20210930_zDdc9unjmCnf"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityRegistrantName" inside-table="false" id="fact-identifier-10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ANAVEX LIFE SCIENCES CORP.</ix:nonnumeric></span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="border-bottom: windowtext 1pt solid; padding: 0; width: 57%; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20201001__20210930_zzGB7SKwEK24"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" inside-table="true" id="fact-identifier-11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Nevada</ix:nonnumeric></span></span></span></td>
<td style="padding: 0; width: 7%; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="border-bottom: windowtext 1pt solid; padding: 0; width: 36%; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20201001__20210930_zszbdTw7Wrof"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityTaxIdentificationNumber" inside-table="true" id="fact-identifier-12" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">98-0608404</ix:nonnumeric></span></span></span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">(State
or other jurisdiction of incorporation or organization)</span></td>
<td style="padding: 0; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S.
Employer Identification No.)</span></td></tr>
<tr style="vertical-align: top">
<td style="border-top: windowtext 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="border-top: windowtext 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="border-bottom: windowtext 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--EntityAddressAddressLine1_c20201001__20210930_zEevIliWva98"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityAddressAddressLine1" inside-table="true" id="fact-identifier-13" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">630 5<sup>th</sup> Avenue</ix:nonnumeric></span></span>, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20201001__20210930_zvZvkyNZ8Ggk"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityAddressAddressLine2" inside-table="true" id="fact-identifier-14" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20<sup>th</sup> Floor</ix:nonnumeric></span></span>, <span id="xdx_904_edei--EntityAddressCityOrTown_c20201001__20210930_z5DWKaEC3Ee8"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityAddressCityOrTown" inside-table="true" id="fact-identifier-15" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">New York</ix:nonnumeric></span></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
<span id="xdx_90F_edei--EntityAddressStateOrProvince_c20201001__20210930_zUVzwCOvpLEl"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityAddressStateOrProvince" inside-table="true" id="fact-identifier-16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">NY</ix:nonnumeric></span></span></span> <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--EntityAddressCountry_c20201001__20210930_z56rUbcozl0e"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" inside-table="true" id="fact-identifier-17" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">USA</ix:nonnumeric></span></span></span></td>
<td style="padding: 0; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="border-bottom: windowtext 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_edei--EntityAddressPostalZipCode_c20201001__20210930_zSKw6FW3FSad"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityAddressPostalZipCode" inside-table="true" id="fact-identifier-18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10111</ix:nonnumeric></span></span></span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Address
of principal executive offices)</span></td>
<td style="padding: 0; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Zip
Code)</span></td></tr>
</tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant’s telephone number, including
area code <span style="text-decoration: underline">1-<span id="xdx_907_edei--CityAreaCode_c20201001__20210930_zLCCyMTqSPrf"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:CityAreaCode" inside-table="false" id="fact-identifier-19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">844</ix:nonnumeric></span></span>-<span id="xdx_903_edei--LocalPhoneNumber_c20201001__20210930_zsRYEqZjR2ri"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:LocalPhoneNumber" inside-table="false" id="fact-identifier-20" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">689-3939</ix:nonnumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities registered under Section 12(b) of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="border-bottom: windowtext 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">Common Stock, $0.001 par value</span></td>
<td style="border-bottom: windowtext 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">AVXL</span></td>
<td style="border-bottom: windowtext 1pt solid; padding: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">NASDAQ Stock Market LLC</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">Title of each class</span></td>
<td style="padding: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">Trading Symbol</span></td>
<td style="padding: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">Name of each exchange on which registered</span></td></tr>
</tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities registered pursuant to Section 12(g)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">None</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Title of class)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10.5pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by checkmark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. 	</span></p>

<p style="font: 10.5pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;<span id="xdx_900_edei--EntityWellKnownSeasonedIssuer_c20201001__20210930_zOpylRl3hl1j"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityWellKnownSeasonedIssuer" inside-table="false" id="fact-identifier-21" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span>&nbsp;☒&nbsp;
No&nbsp;</span><span style="font-family: Times New Roman, Times, Serif">☐</span></p>

<p style="font: 10.5pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10.5pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by checkmark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. 	</span></p>

<p style="font: 10.5pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Yes
☐&nbsp;<span id="xdx_90A_edei--EntityVoluntaryFilers_c20201001__20210930_zkfw8nOEacZ3"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityVoluntaryFilers" inside-table="false" id="fact-identifier-22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span> </span><span style="font-family: Times New Roman, Times, Serif">☒</span></p>

<p style="font: 10.5pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10.5pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by checkmark whether the registrant has (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. 	</span></p>

<p style="font: 10.5pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityCurrentReportingStatus_c20201001__20210930_zRjblQv6JBZj"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityCurrentReportingStatus" inside-table="false" id="fact-identifier-23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span>&nbsp;☒
No </span><span style="font-family: Times New Roman, Times, Serif">☐</span></p>

<p style="font: 10.5pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10.5pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months&nbsp;</span><span style="font-family: Times New Roman, Times, Serif">(or
for such shorter period that the registrant was required to submit and post such files).</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 9.15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">	<span id="xdx_909_edei--EntityInteractiveDataCurrent_c20201001__20210930_zqnRPmH5D37g"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="dei:EntityInteractiveDataCurrent" inside-table="false" id="fact-identifier-24" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span>&nbsp;☒
No ☐</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 9.15pt; text-align: right"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 10pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 9.15pt; text-align: right">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">Indicate
by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of ―large accelerated filer, ―accelerated filer , ―smaller
reporting company and ―emerging growth company in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 20%; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--EntityFilerCategory_c20201001__20210930_zfVTNBGDMUkj"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" inside-table="true" id="fact-identifier-25" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Large accelerated filer</ix:nonnumeric></span></span></span></td>
<td style="width: 3%; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;☒</span></td>
<td style="width: 44%; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 30%; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Accelerated filer</span></td>
<td style="width: 3%; line-height: 115%"><span style="font-family: Times New Roman, Times, Serif">☐<span style="font-size: 10pt">&nbsp;</span></span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Non-accelerated filer</span></td>
<td style="line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;☐</span></td>
<td style="line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Smaller reporting company</span></td>
<td style="line-height: 115%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--EntitySmallBusiness_c20201001__20210930_zpfWcWFwDJW6"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness" inside-table="true" id="fact-identifier-26" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span></span></td></tr>
<tr style="vertical-align: top">
<td colspan="2" style="line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Emerging growth company</span></td>
<td style="line-height: 115%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20201001__20210930_zuNNQiw9wfuh"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" inside-table="true" id="fact-identifier-27" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></span></td></tr>
</tbody></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">I<span style="font-size: 10pt">f
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act</span></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness
of its internal controls over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Yes&nbsp;<span id="xdx_90E_edei--IcfrAuditorAttestationFlag_c20201001__20210930_zQCEhd1Wb31c"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt:booleantrue" name="dei:IcfrAuditorAttestationFlag" inside-table="false" id="fact-identifier-28" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span>
No</span><span style="font-family: Times New Roman, Times, Serif">☐</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). 	</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Yes&nbsp;☐
<span id="xdx_907_edei--EntityShellCompany_c20201001__20210930_zavmhUbKhyLl"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt:booleanfalse" name="dei:EntityShellCompany" inside-table="false" id="fact-identifier-29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span></span><span style="font-family: Times New Roman, Times, Serif">&nbsp;☒</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">State
the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price
at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day
of the registrant’s most recently completed second fiscal quarter: $<span id="xdx_909_edei--EntityPublicFloat_iI_c20210331_zYvBRKLjg5Pl"><span><ix:nonfraction name="dei:EntityPublicFloat" contextref="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-30" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,011,843,276</ix:nonfraction></span></span> based on a price of $14.95 per share,
being the closing price of the registrant’s common stock on March 31, 2021.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date:
<span id="xdx_90B_edei--EntityCommonStockSharesOutstanding_iI_c20211119_zpgEVjgxLRpb"><span><ix:nonfraction name="dei:EntityCommonStockSharesOutstanding" contextref="AsOf2021-11-19" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">76,018,053</ix:nonfraction></span></span> issued and outstanding as of November 19, 2021.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">DOCUMENTS
INCORPORATED BY REFERENCE</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 10pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">TABLE OF CONTENTS</span></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 91%; line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_001" tabindex="18">PART I</a></span></td>
<td style="width: 9%; line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">1</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_002" tabindex="18">ITEM 1. BUSINESS</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">1</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_003" tabindex="18">ITEM 1A. RISK FACTORS</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">22</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_004" tabindex="18">ITEM 1B. UNRESOLVED STAFF COMMENTS</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">37</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_005" tabindex="18">ITEM 2. PROPERTIES</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">37</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_006" tabindex="18">ITEM 3. LEGAL PROCEEDINGS</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">37</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_007" tabindex="18">ITEM 4. MINE SAFETY DISCLOSURES</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">37</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_008" tabindex="18">PART II</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">38</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_009" tabindex="18">ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">38</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_010" tabindex="18">ITEM 6 SELECTED FINANCIAL DATA</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">38</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_011" tabindex="18">ITEM 7 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">38</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_012" tabindex="18">ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">43</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_013" tabindex="18">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">43</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_014" tabindex="18">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">65</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_015" tabindex="18">ITEM 9A. CONTROLS AND PROCEDURES</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">65</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_016" tabindex="18">ITEM 9B OTHER INFORMATION</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">65</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_017" tabindex="18">PART III</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">66</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_018" tabindex="18">ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">66</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_019" tabindex="18">ITEM 11. EXECUTIVE COMPENSATION</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">69</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_020" tabindex="18">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a>.</span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">72</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_021" tabindex="18">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">75</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_022" tabindex="18">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">75</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_023" tabindex="18">PART IV</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">77</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_024" tabindex="18">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">77</span></td></tr>
<tr style="vertical-align: top">
<td style="line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif"><a href="#a_025" tabindex="18">ITEM 16. FORM 10-K SUMMARY</a></span></td>
<td style="line-height: 115%; text-align: right"><span style="font: 10pt/115% Times New Roman, Times, Serif">78</span></td></tr>
</tbody></table>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #365F91"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 10pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #365F91">&nbsp;</p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Forward Looking Statements.</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">This Annual Report on Form 10-K includes
forward-looking statements. All statements other than statements of historical facts contained in this Annual Report on Form 10-K,
including statements regarding our anticipated future clinical and regulatory milestone events, future financial position, business
strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,”
“may,” “estimate,” “continue,” “anticipate,” “intend,” “expect”
“should,” “forecast,” “could,” “suggest,” “plan” and similar expressions,
as they relate to us, are intended to identify forward-looking statements. Such forward-looking statements include, without limitation,
statements regarding:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tbody><tr style="vertical-align: top">
<td style="width: 20.65pt"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">volatility in our stock and in the markets
in general;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to successfully conduct clinical
and preclinical trials for our product candidates;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to raise additional capital
on favorable terms and the impact of such activities on our stockholders and stock price;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the impact of the COVID-19 outbreak and
its effect on us;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to generate any revenue or
to continue as a going concern;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to execute our research and
development plan on time and on budget;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our products ability to demonstrate efficacy
or an acceptable safety profile of our product candidates;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to obtain the support of qualified
scientific collaborators;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability, whether alone or with commercial
partners, to successfully commercialize any of our product candidates that may be approved for sale;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to identify and obtain additional
product candidates;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our reliance on third parties in non-clinical
and clinical studies;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to defend against product liability
claims;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to safeguard against security
breaches;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to obtain and maintain sufficient
intellectual property protection for our product candidates;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to comply with our intellectual
property licensing agreements;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to defend against claims of
intellectual property infringement;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to comply with the maintenance
requirements of the government patent agencies;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to protect our intellectual
property rights throughout the world;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">competition;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the anticipated start dates, durations
and completion dates of our ongoing and future clinical studies;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the anticipated designs of our future clinical
studies;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the impact of fast track designation on
receipt of actual FDA approval;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our anticipated future regulatory submissions
and our ability to receive regulatory approvals to develop and market our product candidates, including any orphan drug or fast
track designations; and </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our anticipated future cash position.</span><span style="font: 10pt Webdings">
</span></td></tr>
</tbody></table>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have based these forward-looking
statements largely on our current expectations and projections about future events, including the responses we expect from the
U.S. Food and Drug Administration, (“FDA”), and other regulatory authorities and financial trends that we believe may
affect our financial condition, results of operations, business strategy, preclinical and clinical trials, and financial needs.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions including without limitation the
risks described in “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K. These risks are not exhaustive.
Other sections of this Annual Report on Form 10-K include additional factors which could adversely impact our business and financial
performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to
time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our
business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those
contained in any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events.
We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and
actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable
laws including the securities laws of the United States, we assume no obligation to update or supplement forward-looking statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As used in this Annual Report on Form
10-K, the terms “we,” “us,” “our,”, “Company” and “Anavex” mean Anavex
Life Sciences Corp., unless the context clearly requires otherwise.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 10pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>




<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="a_001"></span>PART I</p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_002"></span>ITEM 1. BUSINESS
</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Overview and Strategy</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp. is a clinical stage
biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous
system (“CNS”) diseases with high unmet need. We analyze genomic data from clinical studies to identify biomarkers,
which we use to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental
diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our lead compound, ANAVEX<sup>®</sup>2-73,
is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases,
including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked
gene, methyl-CpG-binding protein 2 (“MECP2”).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have two core programs and two
seed programs. Our core programs are at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental
diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes key information about our programs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><img alt="" style="height: 250.5pt; width: 468pt" data-src="https://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/image_001.jpg" src="https://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/image_001.jpg"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>* = Orphan Drug Designation by the FDA;
Dashed lines indicate planned clinical studies</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex has a portfolio of compounds varying
in sigma-1 receptor (S1R) binding activities. The SIGMAR1 gene encodes the S1R protein, which is an intracellular chaperone protein
with important roles in cellular communication. S1R is also involved in transcriptional regulation at the nuclear envelope and
restores homeostasis and stimulates recovery of cell function when activated. In order to validate the ability of our compounds
to activate quantitatively the S1R, we performed, in collaboration with Stanford University, a quantitative Positron Emission Tomography
(PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX<sup>®</sup>2-73 target engagement or receptor occupancy
(RO) with S1R in the brain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img alt="" style="height: 310pt; width: 468pt" data-src="https://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/image_002.jpg" src="https://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/image_002.jpg">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Source: Reyes S et al., Sci Rep. 2021 Aug 25;11(1):17150</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cellular Homeostasis</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Many diseases are possibly directly caused
by chronic homeostatic imbalances or cellular stress of brain cells. In pediatric diseases like Rett syndrome or infantile spasms,
the chronic cellular stress is possibly caused by the presence of a constant genetic mutation. In neurodegenerative diseases, such
as Alzheimer’s and Parkinson’s diseases, chronic cellular stress is possibly caused by age-correlated buildup of cellular
insult and hence chronic cellular stress. Specifically, defects in homeostasis of protein or ribonucleic acid (“RNA”)
lead to the death of neurons and dysfunction of the nervous system. The spreading of protein aggregates resulting in a proteinopathy,
a characteristic finding in Alzheimer’s and Parkinson’s diseases that results from disorders of protein synthesis,
trafficking, folding, processing or degradation in cells. The clearance of macromolecules in the brain is particularly susceptible
to imbalances that result in aggregation and degeneration in nerve cells. For example, Alzheimer’s disease pathology is characterized
by the presence of amyloid plaques, neurofibrillary tangles, which are aggregates of hyperphosphorylated Tau protein that are a
marker of other diseases known as tauopathies as well as inflammation of microglia. With the SIGMAR1 activation through SIGMAR1
agonists like ANAVEX<sup>®</sup>2-73, our approach is to restore cellular balance, i.e. homeostasis. Therapies that correct
defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental and neurodegenerative disease progression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>ANAVEX</i></b><sup>®</sup><b><i>2-73-specific Biomarkers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A full genomic analysis of Alzheimer’s
disease (AD) patients treated with ANAVEX<sup>®</sup>2-73 resulted in the identification of actionable genetic variants. A
significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<sup>®</sup>2-73 and COMT, a gene involved
in memory function, on the drug response level was identified, leading to an early ANAVEX<sup>®</sup>2-73-specific biomarker
hypothesis. It is expected that <i>excluding</i> patients with SIGMAR1 identified biomarker variant (approximately 10%-20% of
the population) in prospective studies would identify approximately 80%-90% patients that would display clinically significant
improved functional and cognitive scores. The consistency between the identified DNA and RNA data related to ANAVEX<sup>®</sup>2-73,
which are considered independent of AD pathology, as well as multiple endpoints and time-points, provides support for precision
medicine clinical development of ANAVEX<sup>®</sup>2-73 by using genetic biomarkers identified within the study population
itself to target patients who are most likely to respond to ANAVEX<sup>®</sup>2-73 treatment in AD as well as indications
like Parkinson’s disease dementia (PDD) or Rett syndrome (RTT) in which ANAVEX<sup>®</sup>2-73 is currently studied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Clinical Studies Overview</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Alzheimer’s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, we completed a Phase 2a clinical
trial, consisting of PART A and PART B, which lasted a total of 57 weeks, for ANAVEX<sup>®</sup>2-73 in mild-to-moderate Alzheimer’s
patients. This open-label randomized trial met both primary and secondary endpoints and was designed to assess the safety and exploratory
efficacy of ANAVEX<sup>®</sup>2-73 in 32 patients. ANAVEX<sup>®</sup>2-73 targets sigma-1 and muscarinic receptors, which
have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and to reverse
the pathological hallmarks observed in Alzheimer’s disease. The Phase 2a trial demonstrated positive pharmacokinetic (PK)
and pharmacodynamic (PD) data, which established a concentration-effect relationship between ANAVEX<sup>®</sup>2-73 and study
measurements. These measures obtained from all patients who participated in the entire 57 weeks include exploratory cognitive and
functional scores as well as biomarker signals of brain activity. Additionally, the study appears to show that ANAVEX<sup>®</sup>2-73
activity is enhanced by its active metabolite (ANAVEX19-144), which also targets the sigma-1 receptor and has a half-life approximately
twice as long as the parent molecule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Two consecutive trial extensions for the Phase
2a trial have allowed participants who completed the 52-week PART B of the study to continue taking ANAVEX<sup>®</sup>2-73,
providing an opportunity to gather extended safety data for a cumulative time period of five years. In August 2020, patients completing
these Phase 2a trial extensions were granted continued access to treatment with ANAVEX<sup>®</sup>2-73 through the Australian
Government Department of Health – Therapeutic Goods Administration (TGA) compassionate use Special Access Scheme.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A larger Phase 2b/3 double-blind, placebo-controlled
study of ANAVEX<sup>®</sup>2-73 in Alzheimer’s disease commenced in August 2018. The Phase 2b/3 study enrolled 509 patients
for 48 weeks, randomized 1:1:1 to two different ANAVEX<sup>®</sup>2-73 doses or placebo. The trial commenced in Australia;
and during fiscal 2020 additional regions were added in the United Kingdom, The Netherlands, Germany, and Canada. The ANAVEX<sup>®</sup>2-73
Phase 2b/3 study design incorporates genomic precision medicine biomarkers identified in the ANAVEX<sup>®</sup>2-73 Phase 2a
study. Primary and secondary endpoints will assess safety and both cognitive and functional efficacy, measured through Alzheimer’s
Disease Assessment Scale – Cognition (ADAS-Cog), ADCS-ADL and Clinical Dementia Rating – Sum of Boxes for cognition
and function (CDR-SB). The study completed enrollment in June 2021, exceeding the 450 patients enrollment target at 52 sites across
North America, Europe and Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2019, we initiated a long-term open
label extension study of ANAVEX<sup>®</sup>2-73, entitled the ATTENTION-AD study, for patients who have completed the 48-week
Phase 2b/3 placebo-controlled trial referenced above. This study is expected to last two years and will give patients the opportunity
to continue their treatment. Upon request by patients, caretakers and investigators, this extension study was extended by one further
year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Rett Syndrome </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, we presented positive preclinical
data for ANAVEX<sup>®</sup>2-73 in Rett syndrome, a rare neurodevelopmental disease. The study was funded by the International
Rett Syndrome Foundation (“Rettsyndrome.org”). In January 2017, we were awarded a financial grant from Rettsyndrome.org
of a minimum of $0.6 million to cover some of the costs of a multicenter Phase 2 clinical trial of ANAVEX<sup>®</sup>2-73 for
the treatment of Rett syndrome. This award was received in quarterly instalments which commenced during fiscal 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2019, we commenced the first Phase
2 clinical trial in a planned Rett syndrome program of ANAVEX<sup>®</sup>2-73 for the treatment of Rett syndrome. The studies
are being conducted in a range of patient age demographics and geographic regions, utilizing a convenient oral liquid once-daily
formulation of ANAVEX<sup>®</sup>2-73.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The first Phase 2 study, which took
place in the United States, was completed in December 2020. This trial was a randomized double-blind, placebo-controlled safety,
tolerability, pharmacokinetic and efficacy study of oral liquid ANAVEX<sup>®</sup>2-73 formulation in 25 adult female patients
with Rett syndrome over a 7-week treatment period including ANAVEX<sup>®</sup>2-73-specific genomic precision medicine biomarkers.
The primary endpoint of the trial was safety. The dosing of 5 mg ANAVEX<sup>®</sup>2-73 was well-tolerated and demonstrated
dose-proportional PK (pharmacokinetics). All secondary efficacy endpoints of the trial showed statistically significant and clinically
meaningful, drug exposure-dependent response in the Rett Syndrome Behaviour Questionnaire (RSBQ) Total scores, when compared to
placebo, in the ITT cohort (all participants, p = 0.048). 66.7% of ANAVEX<sup>®</sup>2-73 treated subjects showed a statistically
significant improvement in drug exposure-dependent RSBQ response as compared to 10% of the subjects on placebo in the ITT cohort
(all participants, p = 0.011). ANAVEX<sup>®</sup>2-73 treatment resulted in a sustained improvement in Clinical Global Impression
Improvement (CGI-I) scores throughout the 7-week study, when compared to placebo in the ITT cohort (all participants, p = 0.014).
86.7% of ANAVEX<sup>®</sup>2-73 treated subjects showed a statistically significant CGI-I response, defined as sustained improvement
to treatment, as compared to 40% of the subjects on placebo in the ITT cohort (all participants, p = 0.014). Consistent with previous
ANAVEX<sup>®</sup>2-73 clinical trials, patients carrying the common form of the SIGMAR1 gene treated with ANAVEX<sup>®</sup>2-73
experienced stronger improvements in the prespecified efficacy endpoints.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The second Phase 2 study of ANAVEX<sup>®</sup>2-73
for the treatment of Rett syndrome, called the AVATAR study, commenced in June 2019. This study is taking place in Australia and
the United Kingdom using a higher dose than the U.S. based Phase 2 study for Rett syndrome. This randomized, placebo-controlled
study will evaluate the safety and efficacy of ANAVEX<sup>®</sup>2-73 in approximately 33 patients over a 7-week treatment
period including ANAVEX<sup>®</sup>2-73 specific precision medicine biomarkers. All patients who participate in the study will
be eligible to receive ANAVEX<sup>®</sup>2-73 under a voluntary open label extension protocol. The AVATAR study is expected
to read out topline data around year end 2021.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the third
study of ANAVEX<sup>®</sup>2-73 for the treatment of Rett syndrome, called the EXCELLENCE study. This Phase 2/3 study in pediatric
patients with Rett syndrome will evaluate the safety and efficacy of ANAVEX<sup>®</sup>2-73 in approximately 84 pediatric patients,
aged 5 to 18, over a 12-week treatment period incorporating ANAVEX<sup>®</sup>2-73 specific precision medicine biomarkers.
All patients who participate in the study will be eligible to receive ANAVEX<sup>®</sup>2-73 under a voluntary open label extension
protocol.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Parkinson’s Disease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2016, we presented positive
preclinical data for ANAVEX<sup>®</sup>2-73 in an animal model of Parkinson’s disease, which demonstrated significant
improvements on behavioral, histopathological, and neuroinflammatory endpoints. The study was funded by the Michael J. Fox Foundation.
Additional data announced in October 2017 indicates that ANAVEX<sup>®</sup>2-73 induces robust neurorestoration in experimental
Parkinsonism. The encouraging results we have gathered in this model, coupled with the favorable profile of this compound in the
Alzheimer’s disease trial, support the notion that ANAVEX<sup>®</sup>2-73 is a promising clinical candidate drug for
Parkinson’s disease dementia.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2020, we completed a double-blind,
randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>®</sup>2-73 in Parkinson’s Disease Dementia
(PDD), to study the effect of the compound on both the cognitive and motor impairment of Parkinson’s disease. The Phase 2
study enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>®</sup>2-73 doses, 30mg
and 50mg, or placebo. The ANAVEX<sup>®</sup>2-73 Phase 2 PDD study design incorporated genomic precision medicine biomarkers
identified in the ANAVEX<sup>®</sup>2-73 Phase 2a Alzheimer’s disease study.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Within this study ANAVEX<sup>®</sup>2-73
was safe and well tolerated in oral doses up to 50mg once daily. The results show clinically meaningful, dose-dependent, and statistically
significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis. Treatment with ANAVEX<sup>®</sup>2-73
also resulted in clinically meaningful improvements as measured by the global composite score of Parkinson’s disease symptom
severity, MDS-UPDRS Total score on top of standard of care including dopaminergic therapy, levodopa and other anti-PD medications
after 14 weeks of treatment, suggesting ANAVEX<sup>®</sup>2-73’s potential global capability of slowing and reversing
symptoms that progress in Parkinson’s disease. The study confirmed the precision medicine approach of targeting SIGMAR1 as
a genetic biomarker in response to ANAVEX<sup>®</sup>2-73.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2021, we announced we were
awarded a research grant of $1.0 million from&nbsp;<span style="text-underline-style: none; color: windowtext">The Michael J. Fox
Foundation for Parkinson’s Research</span>&nbsp;(MJFF) to develop ANAVEX<sup>®</sup>2-73 for the treatment of Parkinson’s
disease. The award will explore utilization of PET imaging biomarkers to enable measurement of target engagement and pathway activation
of the sigma-1 receptor (SIGMAR1) with clinically relevant doses in people with Parkinson’s disease.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Frontotemporal Dementia</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the First-in-Human
Phase 1 clinical trial of ANAVEX<sup>®</sup>3-71, which was previously granted orphan drug designation for the treatment of
Frontotemporal Dementia (FTD) by the FDA. ANAVEX<sup>®</sup>3-71 is an orally administered small molecule targeting sigma-1
and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases. In preclinical studies, <span style="background-color: white">ANAVEX<sup>®</sup>3-71
demonstrated disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice,
including cognitive deficits, amyloid and tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Phase
1 clinical trial will be a prospective double-blind, randomized, placebo-controlled study. A total of at least 36 healthy male
and female subjects will be included. Single escalating doses of ANAVEX<sup>®</sup>3-71 will be administered in order to evaluate
the safety, tolerability, and pharmacokinetics (PK) of ANAVEX<sup>®</sup>3-71 and the effects of food and gender on its PK
in healthy volunteers. This study is expected to be followed by longer duration dosing including patients with FTD or other dementia
indications with unmet medical need, incorporating exploratory efficacy and disease biomarker measures<span style="color: #1F1F1F">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Pipeline</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development pipeline includes
ANAVEX<sup>®</sup>2-73 currently in three different clinical study indications, and several other compounds in different stages
of clinical and pre-clinical study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our proprietary SIGMACEPTOR™ Discovery
Platform produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma
receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer’s
disease, as well as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate ligands, sigma receptors influence
the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease. Multiple
viruses including SARS-CoV-2 (COVID-19) induce cellular stress by intrinsic mitochondrial apoptosis and other related cellular
processes, in order to ensure survival and replication. Hence, it is possible that S1R could play a role in modulating the cellular
response to viral infection and ameliorate pathogenesis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Compounds that have been subjects of our research
include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>®</sup>2-73 <i>(blarcamesine)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>®</sup>2-73 may offer a disease-modifying
approach in neurodegenerative and neurodevelopmental diseases by activation of sigma-1 receptors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Rett syndrome, administration of ANAVEX<sup>®</sup>2-73
resulted in both significant and dose related improvements in an array of behavioral paradigms in the MECP2 HET Rett syndrome disease
model. In addition, in a further experiment sponsored by Rettsyndrome.org, ANAVEX<sup>®</sup>2-73 was evaluated in automatic
visual response and respiration tests in 7-month old mice, an age at which advanced pathology is evident. Vehicle-treated MECP2
mice demonstrated fewer automatic visual responses than wild-type mice. Treatment with ANAVEX<sup>®</sup>2-73 for four weeks
significantly increased the automatic visual response in the MECP2 Rett syndrome disease mouse. Additionally, chronic oral dosing
daily for 6.5 weeks of ANAVEX<sup>®</sup>2-73 starting at ~5.5 weeks of age was conducted in the MECP2 HET Rett syndrome disease
mouse model assessed the different aspects of muscular coordination, balance, motor learning and muscular strengths, some of the
core deficits observed in Rett syndrome. Administration of ANAVEX<sup>®</sup>2-73 resulted in both significant and dose related
improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome disease model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2019, we commenced the first Phase
2 clinical trial in a planned Rett syndrome program of ANAVEX<sup>®</sup>2-73 for the treatment of Rett syndrome. This study,
which took place in the United States, was completed in December 2020, however two other clinical trials in Rett syndrome, the
AVATAR study and the EXCELLENCE study, are still underway. The studies are being conducted in a range of patient age demographics
and geographic regions, as more fully described above under <i>Clinical Studies Overview – Rett Syndrome</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2016 and June 2016, the FDA granted
Orphan Drug Designation to ANAVEX<sup>®</sup>2-73 for the treatment of Rett syndrome and infantile spasms, respectively. In
November 2019, the FDA granted to ANAVEX<sup>®</sup>2-73 the Rare Pediatric Disease (RPD) designation for the treatment of
Rett syndrome. The RPD designation provides priority review by the FDA to encourage the development of treatments for rare pediatric
diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, in February 2020, the FDA granted
Fast Track designation for the ANAVEX<sup>®</sup>2-73 clinical development program for the treatment of Rett syndrome. The
FDA Fast Track program is designed to facilitate and expedite the development and review of new drugs to address unmet medical
needs in the treatment of serious and life-threatening conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For Parkinson’s disease, data demonstrates
significant improvements and restoration of function in a disease modifying animal model of Parkinson’s disease. Significant
improvements were seen on all measures tested: behavioral, histopathological, and neuroinflammatory endpoints. In October 2020,
we completed a double-blind, randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>®</sup>2-73 in Parkinson’s
Disease Dementia (PDD), to study the effect of the compound on both the cognitive and motor impairment of Parkinson’s disease.
The Phase 2 study enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>®</sup>2-73
doses, 30mg and 50mg, or placebo. The ANAVEX<sup>®</sup>2-73 Phase 2 PDD study design incorporated genomic precision medicine
biomarkers identified in the ANAVEX<sup>®</sup>2-73 Phase 2a Alzheimer’s disease study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The study found that ANAVEX<sup>®</sup>2-73
was safe and well tolerated in oral doses up to 50mg once daily. The results show clinically meaningful, dose-dependent, and statistically
significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis. We anticipate conducting
further clinical trials of ANAVEX<sup>®</sup>2-73 in Parkinson’s disease dementia after submitting the results of the
study to the FDA to obtain regulatory guidance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In Alzheimer’s disease (AD) animal models,
ANAVEX<sup>®</sup>2-73 has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic,
anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to sigma-1 receptors and moderate affinities
to M1-4 type muscarinic receptors. In addition, ANAVEX<sup>®</sup>2-73 has shown a potential dual mechanism which may impact
amyloid, tau pathology and inflammation. In a transgenic AD animal model Tg2576, ANAVEX<sup>®</sup>2-73 induced a statistically
significant neuroprotective effect against the development of oxidative stress in the mouse brain, as well as significantly increased
the expression of functional and synaptic plasticity markers that is apparently amyloid-beta independent. It also statistically
alleviated the learning and memory deficits developed over time in the animals, regardless of sex, both in terms of spatial working
memory and long-term spatial reference memory.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the results of pre-clinical testing,
we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<sup>®</sup>2-73. In this Phase 1
SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent dose shown
to have positive effects in mouse models of AD. There were no significant changes in laboratory or electrocardiogram (ECG) parameters.
ANAVEX<sup>®</sup>2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some subjects. Observed
adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity
and reversible. These side effects are often seen with drugs that target CNS conditions, including AD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2014, a Phase 2a clinical trial
was initiated for ANAVEX<sup>®</sup>2-73, for the treatment of Alzheimer’s disease. The open-label randomized trial was
designed to assess the safety and exploratory efficacy of ANAVEX<sup>®</sup>2-73 in 32 patients with mild-to-moderate Alzheimer’s
disease. ANAVEX<sup>®</sup>2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1
and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s.
The Phase 2a study met both primary and secondary objectives of the study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In July 2018, we presented
the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a study. More than 33,000 genes were analyzed
using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA &amp; RNA data in patients
exposed to ANAVEX<sup>®</sup>2-73. The analysis identified genetic variants that impacted response to ANAVEX<sup>®</sup>2-73,
among them variants related to the Sigma-1 receptor (SIGMAR1), the target for ANAVEX<sup>®</sup>2-73. Results showed that study
participants with the common SIGMAR1 wild type gene variant, which is about 80 percent of the population worldwide, demonstrated
improved cognitive (MMSE) and the functional (ADCS-ADL) scores. The results from this evaluation have been used to establish a
precision medicine approach in subsequent clinical trials, since these signatures can now be applied to neurological indications
tested in clinical studies with ANAVEX<sup>®</sup>2-73 including Alzheimer’s disease, Parkinson’s disease dementia
and Rett syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">ANAVEX<sup>®</sup>2-73
data presented met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled study. On July 2, 2018, the
Human Research Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled
48-week safety and efficacy trial of ANAVEX<sup>®</sup>2-73 for the treatment of early Alzheimer’s disease. Clinical
trial sites in Canada, the United Kingdom, the Netherlands and Germany were also added. This Phase 2b/3 study design incorporates
inclusion of genomic precision medicine biomarkers identified in the ANAVEX<sup>®</sup>2-73 Phase 2a study. The Phase 2b/3
study, which has completed enrollment, randomized 1:1:1 to either two different ANAVEX<sup>®</sup>2-73 doses or placebo, commenced
in October 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data also validates ANAVEX<sup>®</sup>2-73
as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer’s disease, Parkinson’s disease
or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis and,
more recently, tuberous sclerosis complex (TSC). ANAVEX<sup>®</sup>2-73 demonstrated significant improvements in all of these
indications in the respective preclinical animal models.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a study sponsored by the Foundation for
Angelman Syndrome, ANAVEX<sup>®</sup>2-73 was assessed in a mouse model for the development of audiogenic seizures. The results
indicated that ANAVEX<sup>®</sup>2-73 administration significantly reduced audiogenic-induced seizures. In a study sponsored
by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<sup>®</sup>2-73 restored hippocampal
brain-derived neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed in many neurodevelopmental
and neurodegenerative pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory synapses. ANAVEX<sup>®</sup>2-73
normalization of BDNF expression could be a contributing factor for the positive data observed in both neurodevelopmental and neurodegenerative
disorders like Angelman and Fragile X syndromes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data presented also indicates that
ANAVEX<sup>®</sup>2-73 demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions, which,
if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data on ANAVEX<sup>®</sup>2-73
related to multiple sclerosis indicates that ANAVEX<sup>®</sup>2-73 may promote remyelination in multiple sclerosis disease.
Further, data also demonstrates that ANAVEX<sup>®</sup>2-73 provides protection for oligodendrocytes (“OL’s”)
and oligodendrocyte precursor cells (“OPC’s”), as well as central nervous system neurons in addition to helping
repair by increasing OPC proliferation and maturation in tissue culture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2018, we presented preclinical data
of ANAVEX<sup>®</sup>2-73 in a genetic mouse model of tuberous sclerosis complex (“TSC”). TSC is a rare genetic
disorder characterized by the growth of numerous benign tumors in many parts of the body with a high incidence of seizures. The
new preclinical data demonstrates that treatment with ANAVEX<sup>®</sup>2-73 significantly increases survival and reduces seizures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>®</sup>3-71</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>®</sup>3-71 is a clinical drug
candidate with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric modulation, which has been
shown to enhance neuroprotection and cognition in Alzheimer’s disease models. ANAVEX<sup>®</sup>3-71 is a CNS-penetrable
potential disease modifying treatment for cognitive impairments. It is highly effective in very small doses against the major Alzheimer’s
hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects
on inflammation and mitochondrial dysfunctions. ANAVEX<sup>®</sup>3-71 indicates extensive therapeutic advantages in Alzheimer’s
and other protein-aggregation-related diseases given its ability to enhance neuroprotection and cognition via sigma-1 receptor
activation and M1 muscarinic allosteric modulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A preclinical study examined the response of
ANAVEX<sup>®</sup>3-71 in aged transgenic animal models and showed a significant reduction in the rate of cognitive deficit,
amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. In April 2016, the FDA granted Orphan Drug Designation
to ANAVEX<sup>®</sup>3-71 for the treatment of Frontotemporal dementia (FTD).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During pathological conditions ANAVEX<sup>®</sup>3-71
demonstrated the formation of new synapses between neurons (synaptogenesis) without causing an abnormal increase in the number
of astrocytes. In neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, synaptogenesis is believed
to be impaired. Additional preclinical data presented also indicates that in addition to reducing oxidative stress, ANAVEX<sup>®</sup>3-71
demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions, which, if impaired, are believed
to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, we commenced the first Phase
1 clinical trial of ANAVEX<sup>®</sup>3-71, with focus on the treatment of Frontotemporal Dementia (FTD) and <span style="background-color: white">other
dementia indications with unmet medical need</span>. The study is more fully described above under <i>Clinical Studies Overview
– Frontotemporal Dementia</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ANAVEX<sup>®</sup>1-41</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>®</sup>1-41 is a sigma-1 receptor
agonist. Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death)
through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell viability.
In addition, in animal models, ANAVEX<sup>®</sup>1-41 prevented the expression of caspase-3, an enzyme that plays a key role
in apoptosis (programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning, emotion
and memory. These activities involve both muscarinic and sigma-1 receptor systems through a novel mechanism of action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Preclinical data presented also indicates that
ANAVEX<sup>®</sup>1-41 demonstrates protective effects of mitochondrial enzyme complexes during pathological conditions, which,
if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>®</sup>1066</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>®</sup>1066, a mixed
sigma-1/sigma-2 ligand is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<sup>®</sup>1066 was
tested in two preclinical models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic
constriction injury model of neuropathic pain, a single oral administration of ANAVEX<sup>®</sup>1066 dose-dependently restored
the nociceptive threshold in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. Efficacy
was rapid and remained significant for two hours. In a model of visceral pain, chronic colonic hypersensitivity was induced by
injection of an inflammatory agent directly into the colon and a single oral administration of ANAVEX<sup>®</sup>1066 returned
the nociceptive threshold to control levels in a dose-dependent manner. Companion studies in rats demonstrated the lack of any
effects on normal gastrointestinal transit with ANAVEX<sup>®</sup>1066 and a favorable safety profile in a battery of behavioral
measures.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>ANAVEX<sup>®</sup>1037 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ANAVEX<sup>®</sup>1037 is designed for
the treatment of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for
sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In
advanced pre-clinical studies, this compound revealed antitumor potential. It has also been shown to selectively kill human cancer
cells without affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient mice models. Scientific
publications highlight the possibility that these ligands may stop tumor growth and induce selective cell death in various tumor
cell lines. Sigma receptors are highly expressed in different tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands
can induce selective apoptosis. In addition, through tumor cell membrane reorganization and interactions with ion channels, our
drug candidates may play an important role in inhibiting the processes of metastasis (spreading of cancer cells from the original
site to other parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our compounds are in the pre-clinical and clinical
testing stages of development, and there is no guarantee that the activity demonstrated in pre-clinical models will be shown in
human testing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We continue to identify and initiate discussions
with potential strategic and commercial partners to most effectively advance our programs and realize maximum shareholder value.
Further, we may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property
to further our goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our Target Indications</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have developed compounds with potential
application to two broad categories and several specific indications. including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Central Nervous System Diseases</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Alzheimer’s disease – In 2021, an estimated 5.7 million
Americans were suffering from Alzheimer’s disease. The Alzheimer’s Association<sup>®</sup> estimates that by 2050,
this number will rise to nearly 14 million Americans. Medications on the market today treat only the symptoms of Alzheimer’s
disease and do not have the ability to stop its onset or its progression. There is an urgent and unmet need for both a disease
modifying cure for Alzheimer’s disease as well as for better symptomatic treatments.</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Parkinson’s disease – Parkinson’s disease is a progressive
disease of the nervous system marked by tremors, muscular rigidity, and slow, imprecise movement. It is associated with degeneration
of the basal ganglia of the brain and a deficiency of the neurotransmitter dopamine. Parkinson’s disease afflicts more than
10 million people worldwide, typically middle-aged and elderly people. The Parkinson’s disease market is expected to expand
to $11.5 billion by 2029, according to business intelligence provider GBI Research.</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Rett syndrome – Rett syndrome is a rare X-linked genetic neurological
and developmental disorder that affects the way the brain develops, including protein transcription, which is altered and as a
result lead to severe disruptions in neuronal homeostasis. It is considered a rare, progressive neurodevelopmental disorder and
is caused by a single mutation in the MECP2 gene. Because males have a different chromosome combination from females, boys who
have the genetic MECP2 mutation are affected in devastating ways. Most of them die before birth or in early infancy. For females
who survive infancy, Rett syndrome leads to severe impairments, affecting nearly every aspect of the child’s life; severe
mental retardation, their ability to speak, walk and eat, sleeping problems, seizures and even the ability to breathe easily.
Rett syndrome affects approximately 1 in every 10,000-15,000 females.</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Depression – Depression is a major cause of morbidity worldwide
according to the World Health Organization. Pharmaceutical treatment for depression is dominated by blockbuster brands, with the
leading nine brands historically accounting for approximately 75% of total sales. However, the dominance of the leading brands
is waning, largely due to the effects of patent expiration and generic competition.</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Epilepsy – Epilepsy is a common chronic neurological disorder
characterized by recurrent unprovoked seizures. These seizures are transient signs and/or symptoms of abnormal, excessive or synchronous
neuronal activity in the brain. According to the Centers for Disease Control and Prevention, in 2015 epilepsy affected 3.4 million
Americans. Today, epilepsy is often controlled, but not cured, with medication that is categorized as older traditional anti-epileptic
drugs and second generation anti-epileptic drugs. Because epilepsy afflicts sufferers in different ways, there is a need for drugs
used in combination with both traditional anti-epileptic drugs and second generation anti-epileptic drugs.</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Neuropathic Pain – We define neuralgia, or neuropathic pain,
as pain that is not related to activation of pain receptor cells in any part of the body. Neuralgia is more difficult to treat
than some other types of pain because it does not respond well to normal pain medications. Special medications have become more
specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants.</span></td></tr>
</tbody></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cancer</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Malignant Melanoma – Predominantly a skin cancer, malignant melanoma
can also occur in melanocytes found in the bowel and the eye. Malignant melanoma accounts for 75% of all deaths associated with
skin cancer. The treatment includes surgical removal of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy.
According to iHealthcareAnalyst, Inc. the worldwide malignant melanoma market is expected to grow to $6.4 billion by 2027.</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Prostate Cancer – Specific to men, prostate cancer is a form
of cancer that develops in the prostate, a gland in the male reproductive system. The cancer cells may metastasize from the prostate
to other parts of the body, particularly the bones and lymph nodes. Drug therapeutics for prostate cancer are expected to increase
to nearly $13.5 billion in 2024 according to Datamonitor Healthcare.</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Pancreatic Cancer – Pancreatic cancer is a malignant neoplasm
of the pancreas. In the United States, approximately 55,000 new cases of pancreatic cancer will be diagnosed this year and approximately
44,000 patients will die as a result of their cancer, according to the American Cancer Society. Sales predictions by FutureWise
forecast that the market for the global pharmaceutical treatment of pancreatic cancer will increase to $4.7 billion by 2027.</span></td></tr>
</tbody></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Competition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The drug discovery and development industry
is very competitive, characterized by rapid advancements in technology, where protection of proprietary advancements is essential.
Any product candidates that we may successfully develop and commercialize, may compete with existing therapies, or new therapies
that may become available in the future. Our commercial opportunities could be reduced or eliminated if our competitors develop
and commercialize products that are more effective, have fewer side effects, are more convenient or are less expensive than any
products that we may develop.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our approach to the treatment of Alzheimer’s
disease and other CNS diseases differs from our competitors. Our platform may offer a disease-modifying approach in neurodegenerative
and neurodevelopmental diseases by activation of sigma-1 receptors. When activated by SIGMAR1 agonists, such as ANAVEX<sup>®</sup>2-73,
SIGMAR1 reduces cellular stress before and after RNA gene transcription. Studies confirm the predictive biomarker of response established
through SIGMAR1 mRNA expression. Because of its role in maintaining neuronal homeostasis, sigma receptors show significant promise
as viable targets for therapeutic molecules in an effort to treat Alzheimer’s disease and other CNS diseases and disorders,
including Parkinson’s disease and Rett syndrome, by restoring healthy gene expression.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At this time, our competitors are primarily
other biomedical development companies that are aiming to discover and develop compounds to be used in the treatment of Alzheimer’s
disease and other CNS diseases, and those companies already doing so. We also face competition from academic institutions and government
agencies, both in the United States and abroad.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our competitors may have significantly
greater financial resources, an established presence in the market, expertise in research and development, manufacturing, preclinical
and clinical testing, may be in the process of obtaining regulatory approvals and marketing of approved products. These competitors
also compete with us in recruiting and retaining qualified scientific and technical personnel, establishing clinical study sites
and patient registration for clinical studies, as well as in acquiring or developing technologies complementary to, or necessary
for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For additional discussion of the risks
related to competition, see Item 1A “Risk Factors.”</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Patents, Trademarks and Intellectual
Property </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We hold ownership or exclusive rights
to fifteen U.S. patents, sixteen U.S. patent applications, and various PCT or ex-U.S. patent applications relating to our drug
candidates, methods associated therewith, and to our research programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We own one issued U.S. patent entitled
“ANAVEX<sup>®</sup>2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection” claims
a composition of matter of ANAVEX<sup>®</sup>2-73 directed to a novel and synergistic neuroprotective compound combined with
donepezil and other cholinesterase inhibitors. This patent is expected to expire in June 2034, absent any patent term extension
for regulatory delays. We own three issued U.S. patents each with claims directed to crystalline forms of ANAVEX<sup>®</sup>2-73.
The first of these three patents claims crystalline forms of ANAVEX<sup>®</sup>2-73, dosage forms and compositions containing
crystalline ANAVEX<sup>®</sup>2-73, and methods of treatment for Alzheimer’s disease using them. This patent is expected
to expire in July 2036, absent any patent term extension for regulatory delays. The second of these three patents claims pharmaceutical
compositions containing a crystalline form of ANAVEX<sup>®</sup>2-73, and methods of treatment for Alzheimer’s disease
using the compositions. This patent is expected to expire in June 2037, absent any patent term extension for regulatory delays.
The third of these three patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>®</sup>2-73,
and methods of treatment for Alzheimer’s disease using the compositions. This patent is expected to expire in June 2037,
absent any patent term extension for regulatory delays. We also own two issued U.S. patents for seizure treatment. The first of
these two patents claims methods and dosage forms for treating seizures, the dosage forms containing a low-dose anti-epilepsy drug
combined with either: (i) ANAVEX<sup>®</sup>2-73 and its active metabolite ANAVEX<sup>®</sup>19-144; or (ii) ANAVEX<sup>®</sup>19-144.
The second of these two patents further claims a combination seizure treatment involving administration of an anti-epilepsy drug
combined with (i) ANAVEX<sup>®</sup>19-144, or (ii) ANAVEX 19-144<sup>®</sup> and ANAVEX 2-73<sup>®</sup>. Both patents
are expected to expire in October 2035, absent any patent term extension for regulatory delays. We also own two issued U.S. patents
with claims directed to treating neurodevelopmental disorders. These patents claim methods for treating a neurodevelopmental disorder
or multiple sclerosis by administering ANAVEX<sup>®</sup>2-73, ANAVEX<sup>®</sup>19-144, and/or ANAVEX<sup>®</sup>1-41
(another sigma receptor ligand similar to ANAVEX<sup>®</sup>2-73), or compositions thereof. Both patents are expected to expire
in January 2037, absent any patent term extension for regulatory delays. In addition, we own one issued U.S. Patent with claims
directed to methods of treating melanoma with a compound related to ANAVEX<sup>®</sup>2-73. This patent is expected to expire
in February 2030, absent any patent term extension for regulatory delays. We also own an issued U.S. patent that claims crystalline
forms of ANAVEX<sup>®</sup>19-144, dosage forms and compositions containing the crystalline forms of ANAVEX<sup>®</sup>19-144,
and methods of treatment for Alzheimer’s disease. This patent is expected to expire in July 2036, absent any patent term
extension for regulatory delays. Further, we own one issued U.S. Patent with claims directed to methods of treating cardiac dysfunction
with ANAVEX<sup>®</sup>2-73 . This patent is expected to expire in July 2038, absent any patent term extension for regulatory
delays.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own two issued U.S. patents
related to ANAVEX<sup>®</sup>1066. The first of these two patents claims methods for treating or preventing pain using (+)
ANAVEX<sup>®</sup>1066 isomer. The second patent claims methods for treating or preventing pain using (-) ANAVEX<sup>®</sup>1066
isomer. Both patents are expected to expire in November 2036, absent any patent term extension for regulatory delays.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For ANAVEX<sup>®</sup>2-73, ANAVEX<sup>®</sup>19-144,
ANAVEX<sup>®</sup>1-41, and ANAVEX<sup>®</sup>1066, we also have granted or pending applications in Australia, Canada,
China, Europe, Japan, and Hong Kong, which are expected to expire after 2035.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">With regard to ANAVEX<sup>®</sup>3-71,
we own exclusive rights to two issued U.S. patents with claims respectively directed to the ANAVEX<sup>®</sup>3-71 compound
and methods of treating various diseases including Alzheimer’s with the same. These patents are expected to expire in April
2030, and January 2030, respectively, absent any patent term extension for regulatory delays. We also own exclusive rights to related
patents or applications that are granted or pending in Australia, Canada, China, Europe, Japan, Korea, New Zealand, Russia, and
South Africa, which are expected to expire in January 2030.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We also own other patent applications
directed to enantiomers, crystals, formulations, uses, and patient selection methods that may provide additional protection for
one or more of our product candidates.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We regard patents and other intellectual
property rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual property in developing our business
strategy including the selective development, protection, and exploitation of our intellectual property rights. In addition to
filings made with intellectual property authorities, we protect our intellectual property and confidential information by means
of carefully considered processes of communication and the sharing of information, and by the use of confidentiality and non-disclosure
agreements and provisions for the same in contractor’s agreements. While no agreement offers absolute protection, such agreements
provide some form of recourse in the event of disclosure, or anticipated disclosure.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our intellectual property position,
like that of many biomedical companies, is uncertain and involves complex legal and technical questions for which important legal
principles are unresolved. For more information regarding challenges to our existing or future patents, see “Risk Factors”.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Government regulation </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Government authorities in the United
States, at the federal, state and local levels, and other countries extensively regulate, among other things, the research, development,
testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution,
marketing and export and import of products such as those we are developing. A new drug must be approved by the FDA through the
NDA process before it may be legally marketed in the United States. We are subject to various government regulations in connection
with the development of our pipeline.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>U.S. Drug Development and Regulation </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, the FDA regulates drugs
under the federal Food, Drug, and Cosmetic Act and its implementing regulations (“FDCA”). The process of obtaining
regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations
require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at
any time during the product development process, approval process or after approval may subject an applicant to administrative
or judicial sanctions. These sanctions could include the FDA’s refusal to approve pending applications, withdrawal of an
approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution,
injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial
enforcement action could have a material adverse effect on us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Once a drug candidate is identified for development,
it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation,
as well as other preclinical studies. An Investigational New Drug application (“IND”) sponsor must submit the results
of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. The sponsor
must also include a protocol detailing, among other things, the objectives of the first phase of clinical trials, the parameters
to be used in monitoring the safety of the trial, and the effectiveness criteria to be evaluated should the first phase lend itself
to an efficacy evaluation. Some preclinical testing may continue even after the IND is filed. The IND automatically becomes effective
thirty (30) days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical
hold. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about ongoing
or proposed clinical trials or non-compliance with specific FDA requirements, and the trials may not begin or continue until the
FDA notifies the sponsor that the hold has been lifted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All clinical trials must be conducted under
the supervision of one or more qualified investigators in accordance with FDA good clinical practice (“GCP”) requirements,
which include a requirement that all research subjects provide their informed consent in writing for their participation in any
clinical trial. Clinical trials must be conducted under protocols detailing the objectives of the trial, dosing procedures, subject
selection inclusion and exclusion criteria and the safety and/or effectiveness criteria to be evaluated. Each protocol must be
submitted to the FDA as part of the IND, and timely safety reports must be submitted to the FDA and the investigators for serious
and unexpected adverse events. An Institutional Review Board (“IRB”) at each institution participating in the clinical
trial must review and approve each protocol before a clinical trial may commence at the institution and must also approve the information
regarding the trial as well as the consent form that must be provided to each trial participant or his or her legal representative,
monitor the study until completed and otherwise comply with all applicable IRB regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Human clinical trials are typically conducted
in three sequential phases that may overlap or be combined in certain cases:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phase 1: The compound is initially introduced
into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if
possible, to gain an early indication of its effectiveness. In most cases, initial Phase 1 clinical trials are conducted with healthy
volunteers. However, where the compound being evaluated is for the treatment of severe or life-threatening diseases, such as cancer,
and especially when the product may be too toxic to ethically administer to healthy volunteers, the initial human testing may be
conducted on patients with the target disease or condition. Sponsors sometimes subdivide their Phase 1 clinical trials into Phase
1a and Phase 1b clinical trials. Phase 1b clinical trials are typically aimed at confirming dosage, pharmacokinetics and safety
in a larger number of patients. Some Phase 1b studies evaluate biomarkers or surrogate markers that may be associated with efficacy
in patients with specific types of diseases or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phase 2: This phase involves clinical trials
in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of
the product for specific targeted diseases or conditions and to confirm dosage tolerance and appropriate dosage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phase 3: Phase 3 clinical trials are undertaken
to further evaluate dosage, clinical efficacy and safety in an expanded patient population, generally at geographically dispersed
clinical study sites. These clinical trials, often referred to as “pivotal” or “confirmatory” clinical
trials, are intended to establish the overall risk-benefit ratio of the compound and provide, if appropriate, an adequate basis
for product labeling.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA or the sponsor may suspend a clinical
trial at any time on various grounds, including any finding that the research subjects or patients are being exposed to an unacceptable
health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is
not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected, serious
harm to study subjects. In addition, clinical trials may be overseen by an independent group of qualified experts organized by
the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this committee may determine whether
a trial may move forward at designated check points based on access to certain data from the trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phase 4: Phase 4 or post-approval trials may
also be conducted after a drug receives initial marketing approval. These trials, often referred to as “Phase 4” trials,
are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances,
the FDA may mandate the performance of such clinical trials as a condition of approval of an NDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the development of a new drug, sponsors
are given several opportunities to meet with the FDA. These meetings can provide an opportunity for the sponsor to share information
about the progress of the application or clinical trials, for the FDA to provide advice, and for the sponsor and the FDA to reach
agreement on the next phase of development. These meetings may occur prior to the submission of an IND, at the end of Phase 2 clinical
trials, or before an NDA is ultimately submitted. Sponsors typically use the meetings at the end of the Phase 2 trials to discuss
Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the
new drug. Meetings at other times may be made upon request.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Concurrent with clinical trials, companies
typically complete additional, animal or other non-clinical studies, develop additional information about the chemistry and physical
characteristics of the drug, and finalize a process for manufacturing the product in commercial quantities in accordance with the
FDA’s current Good Manufacturing Practices (“cGMP”) requirements. The manufacturing process must consistently
produce quality batches of the drug and, among other things, the manufacturer must develop methods for testing the identity, strength,
quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must
be conducted to demonstrate the effectiveness of the packaging and that the compound does not undergo unacceptable deterioration
over its shelf life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While the IND is active, progress reports summarizing
the results of ongoing clinical trials and nonclinical studies performed since the last progress report must be submitted on at
least an annual basis to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and
unexpected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs,
findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important, increased incidence
of a serious adverse reaction compared to that listed in the protocol or investigator brochure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are also requirements governing the submission
of certain clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of FDA-regulated
products are required to register and disclose specified clinical trial registration and results information, which is made publicly
available at www.clinicaltrials.gov. Failure to properly report clinical trial results can result in civil monetary penalties.
Disclosure of clinical trial results can often be delayed until the new product or new indication being studied has been approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>U.S. review and approval process </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The results of product development, preclinical
and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted
on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of a New Drug Application
(“NDA”). The submission of an NDA is subject to the payment of substantial user fees; a waiver of which may be obtained
under certain limited circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA reviews NDAs to determine, among other
things, whether the product is safe and effective for its intended use and whether it is manufactured in a cGMP-compliant manner,
which will assure and preserve the product’s identity, strength, quality and purity. Under the Prescription Drug User Fee
Act (“PDUFA”), the FDA has a goal of ten months from the date of “filing” of a standard, completed NDA
for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA
is submitted to the FDA because the FDA has approximately two months to make a “filing” decision after the application
is submitted. The FDA conducts a preliminary review of all NDAs within the first sixty days after submission, before accepting
them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional
information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The
resubmitted application also is subject to review before the FDA accepts it for filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA may refer an application for a new
drug to an advisory committee within the FDA. An advisory committee is a panel of independent experts, including clinicians and
other scientific experts, that reviews, evaluates and provides a recommendation as to whether and under what conditions the application
should be approved. The FDA is not bound by the recommendations of such an advisory committee, but it considers advisory committee
recommendations carefully when making decisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Before approving an NDA, the FDA will also
inspect the facility where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing
processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product
within required specifications. Before approving an NDA, the FDA may also inspect one or more clinical trial sites to assure compliance
with GCP requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After the FDA evaluates an NDA, it will issue
an approval letter or a Complete Response Letter. A Complete Response Letter indicates that the review cycle of the application
is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes the specific
deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial
or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete
Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw
the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria
for approval. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Pediatric Research Equity Act (“PREA”),
requires IND sponsors to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage
form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment
unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the
product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric
subpopulation for which the product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical
trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that
the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness
data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor
that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric
formulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a drug receives FDA approval, the approval
may be limited to specific diseases and dosages, which could restrict the commercial value of the product. In addition, the FDA
may require testing and surveillance programs to monitor the safety of approved products which have been commercialized and may
require a sponsor to conduct post-marketing clinical trials, which are designed to further assess a drug’s safety and effectiveness
after NDA approval. The FDA may also place other conditions on approval, including a requirement for a risk evaluation and mitigation
strategy (“REMS”) to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA
must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication
guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries
and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution,
prescribing or dispensing of products. Marketing approval may be withdrawn for non-compliance with REMS or other regulatory requirements,
or if problems occur following initial marketing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Post-approval requirements </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Once an approval is granted, the FDA may withdraw
the approval if compliance with regulatory standards is not maintained or if problems occur after the drug reaches the market.
Later discovery of previously unknown problems with a drug may result in restrictions on the drug or even complete withdrawal of
the drug from the market. After approval, some types of changes to the approved drug, such as adding new indications, certain manufacturing
changes and additional labeling claims, are subject to further FDA review and approval. Manufacturers and other entities involved
in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state
agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations
and other laws and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any drug product manufactured or distributed
by us pursuant to FDA approval will be subject to continuing regulation by the FDA, including, among other things, record-keeping
requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug
sampling and distribution requirements, complying with certain electronic records and signature requirements, and complying with
FDA promotion and advertising requirements. FDA strictly regulates labeling, advertising, promotion and other types of information
regarding approved drugs that are placed on the market, and imposes requirements and restrictions on drug manufacturers, such as
those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that
are not described in the product’s approved labeling (known as “off-label use”), industry-sponsored scientific
and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the
failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product for a certain
indication or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with
the applicable governmental requirements at any time during the product development process, approval process or after approval,
may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. The FDA
sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-marketing clinical
trials, enforcement letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions,
fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution,
disgorgement of profits, or civil or criminal penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Expedited development and review programs
</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA has a fast track designation program
that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically,
new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition
and demonstrate the potential to address unmet medical needs for the disease or condition. With regard to a fast track product,
the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor
provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines
that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any product submitted to the FDA for approval,
including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development
and review, such as priority review and accelerated approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A product is eligible for priority review if
it is intended to treat a serious condition, and if approved, would provide a significant improvement in safety or efficacy compared
to currently marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new
drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority
review designations within six months of the filing date, as compared to ten months for review of NDAs under its current PDUFA
review goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, a product may be eligible for
accelerated approval. Drugs intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated
approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical
benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely
to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity,
or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may
require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials.
Drugs receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required
post-marketing trials or if such trials fail to verify the predicted clinical benefit. In addition, the FDA currently requires
as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial
launch of the product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Food and Drug Administration Safety and
Innovation Act (“FDASIA”) established a category of drugs referred to as “breakthrough therapies” that
may be eligible to receive breakthrough therapy designation. A sponsor may seek FDA designation of a compound as a “breakthrough
therapy” if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening
disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over
existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance.
The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be
granted to the same drug if relevant criteria are met. If a product is designated as breakthrough therapy, the FDA will work to
expedite the development and review of such drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fast track designation, priority review and
breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process.
However, even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets
the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Orphan drug designation </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Orphan Drug Act, the FDA may grant
orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer
than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no
reasonable expectation that the cost of developing and making a drug product available in the United States for this type of disease
or condition will be recovered from sales of the product. Orphan designation must be requested before an NDA is submitted. After
the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are publicly disclosed by
the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a product that has orphan designation subsequently
receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan
product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication
for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity
or inability to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial
incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. However,
competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain
approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan exclusivity also
could block the approval of one of our compounds for seven years if our compound is determined to be contained within the competitor’s
product for the same indication or disease, or if a competitor obtains approval of the same drug as defined by the FDA. In addition,
if an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled
to orphan exclusivity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Marketing exclusivity </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Market exclusivity provisions under the FDCA
can delay the submission or approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing
exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a
new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule
or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept
for review an abbreviated new drug application (“ANDA”), or an NDA submitted under Section 505(b)(2) (a “505(b)(2)
NDA”), submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended
for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal
right of reference to all the data required for approval. However, an application may be submitted after four years if it contains
a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDCA alternatively provides three years
of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability
studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application,
for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification
for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving
ANDAs or 505(b)(2) NDAs for drugs containing the active ingredient for the original indication or condition of use. Five-year and
three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would
be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical
trials necessary to demonstrate safety and effectiveness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pediatric exclusivity is another type of marketing
exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity
attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from
the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition,
orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Foreign Sales</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales outside the United States of potential
drug compounds we develop will also be subject to foreign regulatory requirements governing human clinical trials and marketing
for drugs. The requirements vary widely from country to country, but typically the registration and approval process takes several
years and requires significant resources. In most cases, if the FDA has not approved a potential drug compound for sale in the
United States, the potential drug compound may be exported for sale outside of the United States, only if it has been approved
in any one of the following: the European Union, Canada, Australia, New Zealand, Japan, Israel, Switzerland and South Africa. There
are specific FDA regulations that govern this process.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>U.S. coverage and reimbursement </i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Significant uncertainty exists as to
the coverage and reimbursement status of any compound for which we may seek regulatory approval. Sales in the United States will
depend in part on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government
health programs such as Medicare, Medicaid, CHIP, TRICARE and the Veterans Administration, as well as managed care organizations
and private health insurers. Prices at which we or our customers seek reimbursement for our therapeutic compounds can be subject
to challenge, reduction or denial by payors.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The process for determining whether
a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the
payor will pay for the product. A payor’s decision to provide coverage for a product does not imply that an adequate reimbursement
rate will be available. Additionally, in the United States there is no uniform policy among payors for coverage or reimbursement.
Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement
policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ
significantly from payor to payor. If coverage and adequate reimbursement are not available, or are available only at limited levels,
successful commercialization of, and obtaining a satisfactory financial return on, any product we develop may not be possible.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Third-party payors are increasingly
challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition
to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing,
we may need to conduct expensive studies in order to demonstrate the medical necessity and cost-effectiveness of any products,
which would be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider our compounds
to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure
favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize
an appropriate return on our investment in drug development.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Fraud and Abuse Laws </i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Federal and state health care laws and
regulations restrict business practices in the biopharmaceutical industry. In the biopharmaceutical industry, there are a number
of federal and state health care regulatory requirements that apply to entities, including, but not limited to, the federal and
state fraud and abuse laws. These laws include, but are not limited to, anti-kickback and self-referral law, civil false claims
act law, criminal false statement law, civil monetary penalty laws, exclusion law, and other civil, criminal, and administrative
laws. Health care laws, regulations, and guidance continuously evolve and are thereby subject to constant change.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Federal Anti-Kickback Statute, 42
U.S.C. § 1320a-7b(b), among other things, prohibits the knowing and willful offer, payment, solicitation or receipt of any
form of remuneration, whether directly or indirectly and overtly or covertly in cash or in kind, in return for, or to induce the
referral of an individual for the:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 3%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td><td style="text-align: justify; width: 97%"><span style="font: 10pt Times New Roman, Times, Serif">furnishing
                                            or arranging for the furnishing of items or services reimbursable in whole or in part under
                                            Medicare, Medicaid or other federal healthcare programs; or</span></td>
</tr></tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 3%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td><td style="text-align: justify; width: 97%"><span style="font: 10pt Times New Roman, Times, Serif">purchase,
                                            lease, or order of, or the arrangement or recommendation of the purchasing, leasing, or ordering
                                            of any item or service reimbursable in whole or in part under Medicare, Medicaid or other
                                            federal healthcare programs.</span></td>
</tr></tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There are a number of narrow safe harbors
to the Federal Anti-Kickback Statute. Such safe harbors permit certain payments and business practices that, although they would
otherwise potentially implicate the Federal Anti-Kickback Statute, are not treated as an offense under the same if all of the requirements
of the specific applicable safe harbor are met. Actual knowledge of the statute or specific intent to violate it is not required
in order for a person or entity to have committed a violation.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Federal Anti-Kickback Statute applies
to certain arrangements with healthcare providers, product end users and other parties, including marketing arrangements and discounts
and other financial incentives offered in connection with the sales of our products. Regulatory authorities may determine that
certain marketing, pricing, or other activities violate the Federal Anti-Kickback Statute or other applicable laws. Noncompliance
with the Federal Anti-Kickback Statute can result in civil, administrative and/or criminal penalties, restrictions on the ability
to operate in certain jurisdictions, and exclusion from participation in Medicare, Medicaid or other federal healthcare programs.
In addition, non-compliance can result in the need to curtail and/or restructure operations. Any penalties, damages, fines, exclusions,
curtailment or restructuring of operations could adversely affect the ability to operate a business, financial condition, and results
of operations. A violation of the Federal Anti-Kickback Statute can serve as a false or fraudulent claim for purposes of the civil
False Claims Act and the civil monetary penalties statute.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Ethics in Patient Referrals Act,
commonly known as the “Stark Law,” 42 U.S.C. § 1395nn, prohibits a physician from making referrals for certain
“designated health services” payable by Medicare to an entity in which the physician or an immediate family member
of such physician has an ownership or investment interest or with which the physician has entered into a compensation arrangement,
unless a statutory exception applies. There are a number of exceptions to the Stark Law. Such exceptions permit certain payments
and arrangements that, although they would otherwise potentially implicate the Stark Law, are not treated as a violation under
the same if the requirements of the specific exceptions are met. Violation of the Stark Law could result in denial of payment,
disgorgement of reimbursements received under a noncompliance arrangement, civil penalties, damages and exclusion from Medicare
or other governmental programs. These requirements are highly technical and there can be no guarantee that regulatory authorities
will not determine or assert that arrangements are in violation of the Stark Law and do not otherwise meet applicable Stark Law
exceptions.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The federal false statements statute,
42 U.S.C. § 1320a-7b(a), prohibits knowingly and willfully falsifying, concealing, or omitting a material fact or making any
materially false statement in connection with the delivery of health care benefits, items, or services. Similarly, 18 U.S.C. §
1035 prohibits a person or entity, in any matter involving a health care benefit program, from knowingly or willfully falsifying,
concealing, or covering up by any trick, scheme, or device a material fact; making any materially false, fictitious, or fraudulent
statements or representations; or making or using any materially false writing or document knowing the same to contain any materially
false, fictitious, or fraudulent statement or entry. In addition to criminal penalties, violation of these statutes may result
in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care
programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">18 U.S.C. § 669 prohibits knowingly
and willfully embezzling, stealing, or otherwise without authority converting to the use of any person or entity other than the
rightful owner, or intentionally misapplying any of the moneys, funds, securities, premiums, credits, property, or other assets
of a health care benefit program. In addition to criminal penalties, violation of this statute may result in collateral administrative
sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The criminal health care fraud statute,
18 U.S.C. § 1347, establishes criminal liability for whoever knowingly and willfully executes, or attempts to execute, a scheme
or artifice to defraud any health care benefit program, or to obtain, by means of false or fraudulent pretenses, representations,
or promises, any of the money or property owned by, or under the custody or control of, any health care benefit program, in connection
with the delivery of or payment for health care benefits, items, or services. In addition to criminal penalties, violation of this
statute may result in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid and other
federal health care programs. A person or entity need not have actual knowledge of this law or specific intent to commit a violation
of this law.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">18 U.S.C. § 1518 establishes criminal
liability for whoever willfully prevents, obstructs, misleads, delays or attempts to prevent, obstruct, mislead, or delay the communication
of information or records relating to a violation of a Federal health care offense to a criminal investigator. In addition to criminal
penalties, violation of this statute may result in collateral administrative sanctions, including exclusion from participation
in Medicare, Medicaid and other federal health care programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">18 U.S.C. § 286 establishes criminal
liability for whoever enters into any agreement, combination, or conspiracy to defraud the United States, or any department or
agency thereof, by obtaining or aiding to obtain the payment or allowance of any false, fictitious or fraudulent claim. In addition
to criminal penalties, violation of this statute may result in collateral administrative sanctions, including exclusion from participation
in Medicare, Medicaid and other federal health care programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">18 U.S.C. § 287 establishes criminal
liability for whoever knowingly makes or presents a false, fictitious or fraudulent claim to the United States Government, including
any department or agency thereof. In addition to criminal penalties, violation of this statute may result in collateral administrative
sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Federal False Claims Act, 31 U.S.C.
§ 3729, et seq., provides, in part, that the federal government—or a private party on behalf of the government—may
bring a lawsuit against any person whom it believes has knowingly presented, or caused to be presented, a false or fraudulent claim
for payment, or who has made a false statement or used a false record to get a claim paid or to avoid, decrease or conceal an obligation
to pay money to the federal government or who has knowingly retained an overpayment. Knowledge under the Federal False Claims Act
means actual knowledge, deliberate indifference, or reckless disregard. In addition, amendments in 1986 to the Federal False Claims
Act have made it easier for private parties to bring whistleblower lawsuits against companies.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The civil monetary penalties law, 42
U.S.C. § 1320a-7a, provides, in part, that the federal government may seek civil monetary penalties against any person who
presents or causes to be presented claims to a Federal health care program that the person knows or should know is for an item
or services that was not provided as claimed or is false or fraudulent, or the person has made a false statement or used a false
record to get a claim paid. The federal government may also seek civil monetary penalties for a wide variety of other conduct,
including offering remuneration to influence a Medicare or Medicaid beneficiary’s selection of providers and violations of
the Federal Anti-Kickback Statute.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Violations of the Federal False Claims
Act and/or the Civil Monetary Penalties Law can result in penalties ranging from $11,665 to $23,331 for each false claim violation
of the Federal False Claims Act and varying amounts based on the type of violation of the Civil Monetary Penalties Law, plus up
to three times the amount of damages that the federal government sustained. In addition, the federal government may also seek exclusion
from participation in all federal health care programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">42 U.S.C. Section 1320a-7 provides that
individuals and entities can be mandatorily or permissively excluded from participation in federal health care programs. The grounds
for mandatory exclusion include, but are not limited to, conviction for a criminal offense related to the delivery of an item or
service reimbursed under a federal or state health care program, and a conviction related to health care fraud. The grounds for
permissive exclusion include, but are not limited to, criminal offenses relating to fraud inside and outside of health care, convictions
related to obstruction of an investigation or audit, and/or failure to disclose certain required information. Exclusion from federal
health care programs—whether mandatory or permissive—may mean that we would not be entitled to participation in federal
and/or state health care programs for services rendered.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>State Fraud and Abuse Provisions</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Many states have also adopted some form
of anti-kickback and anti-referral laws and false claims acts and civil monetary penalties and other fraud and abuse provisions
that apply regardless of payer, in addition to items and services reimbursed under Medicaid and other state programs. A determination
of liability under such laws could result in fines, penalties, and exclusion, as well as restrictions on the ability to operate
in these jurisdictions.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Corporate liability can be present as
a result of the illegal activities of employees, representatives, contractors, collaborators, agents, subsidiaries, or affiliates,
even if they were not explicitly authorized. There can be no assurance that all employees, representatives, contractors, collaborators,
agents, subsidiaries or affiliates will comply with the foregoing laws at all times. Violation of the aforementioned and other
laws could result in whistleblower complaints, investigations, sanctions, settlements, prosecution, government oversight and reporting,
other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions
or other administrative remedies, suspension and/or debarment from contracting with certain governments or other persons, the loss
of privileges, reputational harm, contract damages, adverse media coverage and other collateral consequences. In addition, corporate
directors, officers, employees, and other representatives who engage in violations of these and other laws may face imprisonment,
fines, and penalties. If any subpoenas or investigations are launched, or governmental or other sanctions are imposed, or if a
company does not prevail in any possible civil or criminal litigation, business, financial condition, and results of operations
could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management’s
attention and resources and significant defense costs and other professional fees. Enforcement actions and sanctions could further
harm business, financial condition, and results of operations. Any of the consequences contained in this paragraph and section
could adversely affect the ability to operate the business, financial condition, and the results of operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Health Insurance Portability and
Accountability Act </i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Health Insurance Portability and
Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”),
and implementing regulations thereunder (collectively, “HIPAA”) requires certain healthcare providers, health plans
and healthcare clearinghouses who conduct specified electronic healthcare transactions (“covered entities”), as well
as their independent contractors and agents who conduct certain activities involving protected health information on their behalf
(“business associates”) to comply with enumerated requirements relating to the privacy, security and transmission of
protected health information. Failure to comply with HIPAA can result in corrective action, as well as civil fines and penalties
and government oversight. Among other changes, HITECH made HIPAA security standards directly applicable to business associates,
increased the tiered civil and criminal fines and penalties that may be imposed against covered entities, business associates and
possibly other persons, and gave state attorneys general new authority to file actions to enforce HIPAA. Further, the breach notification
rule implemented under HITECH requires covered entities to notify affected individuals, the U.S. Department of Health and Human
Services Office of Civil Rights (“OCR”), the agency that enforces HIPAA, and for breaches affecting more than 500 individuals,
the media, of any breaches of unsecured protected health information. HIPAA does not create a private right of action for individuals,
though individuals may submit complaints related to HIPAA to OCR.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Patient Protection and Affordable
Care Act </i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, there have been,
and continue to be multiple legislative and regulatory changes and proposed changes regarding the healthcare system that could
impact our business. Policymakers and third party reimbursement programs (i.e. payors) have articulated the goals of controlling
healthcare costs, improving quality and/or expanding access in connection with these healthcare reform efforts. As a leading example,
in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively,
the “ACA”), was passed, ushering in significant changes to the way healthcare is financed in the United States. With
respect to impacts specific to the U.S. pharmaceutical industry, among other things, the ACA:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
    <td style="width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="font: 10pt/115% Calibri, Helvetica, Sans-Serif; width: 97%"><span style="font: 10pt Times New Roman, Times, Serif">increased
the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program and extended the rebate program to
include Medicaid managed care organizations as well as Medicaid fee-for-service programs;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">●&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">expanded eligibility criteria for Medicaid programs by, among other
things, allowing states to offer Medicaid coverage to additional individuals, correspondingly increasing manufacturers’
Medicaid rebate liability;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">●&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">created a new methodology by which average manufacturing price is calculated
for drugs that are inhaled, infused, instilled, implanted or injected and not generally dispensed through retail community pharmacies;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">●&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">established an annual, nondeductible fee on any entity that manufactures
or imports certain specified branded prescription drugs and biologic products;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">●&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">expanded the availability of lower drug pricing under the 340B drug
pricing program to additional types of covered entities;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">●&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">created a new partial prescription drug benefit for Medicare recipients
under the Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off
negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer’s outpatient drugs to be covered under Medicare Part D;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">●&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">amended the Public Health Service Act to create an abbreviated approval
pathway for biological products that are demonstrated to be biosimilar to or interchangeable with an FDA-approved biological product;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">●&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">added a requirement to annually report product samples that manufacturers
and distributors provide to physicians;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">●&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">established new requirements, known as ―Sunshine Act requirements
for manufacturers of products reimbursed by Medicare, Medicaid or the Children’s Health Insurance Program (―CHIP )
to collect and annually report detailed data to the Centers for Medicare and Medicaid Services (―CMS ) regarding payments
or other transfers of value to physicians and teaching hospitals (―covered recipients ), as well as any ownership or investment
interest held by physicians and their immediate family members. The reporting data must be accompanied by an attestation as to
the accuracy of the data and failure to timely and accurately submit required information may result in civil monetary penalties;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">●&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">established a Center for Medicare &amp; Medicaid Innovation at CMS,
to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription
drugs;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">●&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">created a new Patient-Centered Outcomes Research Institute to oversee,
identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font: 10pt/115% Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">●&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">expanded healthcare fraud and abuse laws, including the civil False
Claims Act and the federal Anti- Kickback Statute, and enhanced penalties for noncompliance, which are applicable beyond the U.S.
pharmaceutical industry (e.g. to other types of healthcare entities) but also are of specific relevance to the U.S. pharmaceutical
industry.</span></td></tr>
</tbody></table>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Bipartisan Budget Act of 2018 amended
the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the “donut
hole.” Further, the Substance-Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities
Act (“SUPPORT Act”) amended the Sunshine Act to expand the definition of covered recipient for whom applicable manufacturers
must collect ad report data to include physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists
and certified nurse mid-wives for data reported on or after January 1, 2022.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been multiple judicial challenges
to certain aspects of the ACA, as well as Congressional efforts to repeal or replace the ACA, and efforts by the Trump administration
to delay or circumvent the implementation of certain ACA requirements. For example, the Tax Cuts and Jobs Act of 2017 repealed,
effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain
minimum essential health care insurance, commonly known as the “individual mandate.” On December 14, 2018, a U.S. District
Court in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the ACA, and
therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well.
On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit affirmed the District Court’s decision that the individual
mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of
the ACA are invalid as well. The U.S. Supreme Court has agreed to review the case and oral arguments heard oral arguments in November
2020. Therefore, ongoing force and effect of certain or all of the provisions of the ACA remain in a state of uncertainty at this
current time.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Historically, a significant portion
of our operating expenses has related to research and development. See our Consolidated Financial Statements contained elsewhere
in this Annual Report for costs and expenses related to research and development, and other financial information for fiscal years
2021 and 2020.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Scientific Advisors </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: black">We are advised
by scientists and physicians with experience relevant to our Company and our product candidates.</span> Our scientific advisors
include clinicians and scientists who are affiliated with a number of highly regarded medical institutions.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employees</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have twenty-five full-time
employees, and we retain several independent contractors on a regular or as-needed basis. We believe that we have good relations
with our employees.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Available Information</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: black">Our internet
website address is </span><span style="text-underline-style: none; color: windowtext">www.anavex.com</span><span style="color: black">.
Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed
or furnished pursuant to section 13(a) or 15(d) of the Exchange Act are available free of charge through our website. We include
our website address in this report only as an inactive textual reference and do not intend it to be an active link to our website.
The contents of our website are not incorporated into this report.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_003"></span>ITEM 1A. RISK
FACTORS</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to other information in
this Annual Report on Form 10-K, the following risk factors should be carefully considered in evaluating our business because such
factors may have a significant impact on our business, operating results, liquidity and financial condition. As a result of the
risk factors set forth below, actual results could differ materially from those projected in any forward-looking statements. Additional
risks and uncertainties not presently known to us, or that we currently consider to be immaterial, may also impact our business,
operating results, liquidity and financial condition. If any such risks occur, our business, operating results, liquidity and financial
condition could be materially affected in an adverse manner. Under such circumstances, the trading price of our securities could
decline, and you may lose all or part of your investment.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks Related to our Company</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have had a history of losses
and no revenue, which raises a risk regarding our ability to continue as a going concern in the future.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Since inception through September 30,
2021, we have accumulated a deficit of approximately $200 million. We can offer no assurance that we will ever operate profitably
or that we will generate positive cash flow in the future. To date, we have not generated any revenues from our operations. Our
history of losses and no revenues creates a greater risk of our continued ability to continue as a going concern in the future.
As a result, our management expects the business to continue to experience negative cash flows for the foreseeable future and cannot
predict when, if ever, our business might become profitable. We will need to raise additional funds, and such funds may not be
available on commercially acceptable terms, if at all. If we are unable to raise funds on acceptable terms, we may not be able
to execute our business plan, take advantage of future opportunities, or respond to competitive pressures or unanticipated requirements.
This may seriously harm our business, financial condition and results of operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are an early stage pharmaceutical
research and development company and may never be able to successfully develop marketable products or generate any revenue. We
have a very limited relevant operating history upon which an evaluation of our performance and prospects can be made. There is
no assurance that our future operations will result in profits. If we cannot generate sufficient revenues, we may suspend or cease
operations.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an early stage company and have
not generated any revenues to date and have no operating history. All of our potential drug compounds are in the concept stage
or early clinical development stage. Moreover, we cannot be certain that our research and development efforts will be successful
or, if successful, that our potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial
revenues. We have no relevant operating history upon which an evaluation of our performance and prospects can be made. We are subject
to all of the business risks associated with a new enterprise, including, but not limited to, risks of unforeseen capital requirements,
failure of potential drug compounds either in non-clinical testing or in clinical trials, failure to establish business relationships
and competitive disadvantages against larger and more established companies. If we fail to become profitable, we may suspend or
cease operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We will need additional funding
and may be unable to raise additional capital when needed, which would force us to delay, reduce or eliminate our research and
development activities.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We will need to raise additional funding
and the current economic conditions may have a negative impact on our ability to raise additional needed capital on terms that
are favorable to our Company or at all. We may not be able to generate significant revenues for several years, if at all. Until
we can generate significant revenues, if ever, we expect to satisfy our future cash needs through equity or debt financing. We
cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate funds are not available,
we may be required to delay, reduce the scope of, or eliminate one or more of our research and development activities.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks Related to our Business</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Even if we are able to develop
our potential drug compounds, we may not be able to receive regulatory approval, or if approved, we may not be able to generate
significant revenues or successfully commercialize our products, which will adversely affect our financial results and financial
condition and we will have to delay or terminate some or all of our research and development plans which may force us to cease
operations.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">All of our potential drug compounds
will require extensive additional research and development, including non-clinical testing and clinical trials, as well as regulatory
approvals, before we can market them. In particular, human therapeutic products are subject to rigorous non-clinical and clinical
testing and other approval procedures of the FDA and similar regulatory authorities in other countries. Various federal statutes
and regulations also govern or influence testing, manufacturing, safety, labeling, storage, and record-keeping related to such
products and their marketing. We cannot predict if or when any of the potential drug compounds we intend to develop will be approved
for marketing. There are many reasons that we may fail in our efforts to develop our potential drug compounds. These include:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">the possibility that non-clinical testing or clinical trials may show
that our potential drug compounds are ineffective and/or cause harmful side effects;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">regulators may not authorize us to commence or continue a clinical
trial or may impose a clinical hold or may limit the conduct of a clinical trial through the imposition of a partial clinical
hold;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">the number of patients required for clinical trials for our drug candidates
may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may drop
out of these clinical trials at a higher rate than we anticipate or the duration of these clinical trials may be longer than we
anticipate;</span></td></tr>
</tbody></table>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">our third-party contractors, including investigators, may fail to meet
their contractual obligations to us in a timely manner, or at all, or may fail to comply with regulatory requirements;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">our potential drug compounds may prove to be too expensive to manufacture
or administer to patients;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">our potential drug compounds may fail to receive necessary regulatory
approvals from the United States Food and Drug Administration or foreign regulatory authorities in a timely manner, or at all;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">even if our potential drug compounds are approved, we may not be able
to produce them in commercial quantities or at reasonable costs;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">even if our potential drug compounds are approved, they may not achieve
commercial acceptance;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">regulatory or governmental authorities may apply restrictions to any
of our potential drug compounds, which could adversely affect their commercial success; and</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">the proprietary rights of other parties may prevent us or our potential
collaborative partners from marketing our potential drug compounds.</span></td></tr>
</tbody></table>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If we fail to develop our potential
drug compounds, our financial results and financial condition will be adversely affected, we will have to delay or terminate some
or all of our research and development plans and may be forced to cease operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our research and development plans
will require substantial additional future funding which could impact our operations and financial condition. Without the required
additional funds, we will likely cease operations.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">It will take several years before we
can develop potentially marketable products, if at all. Our research and development plans will require substantial additional
capital, arising from costs to:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">conduct research, non-clinical testing and human studies;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">establish pilot scale and commercial scale manufacturing processes
and facilities; and</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">establish and develop quality control, regulatory, marketing, sales,
finance and administrative capabilities to support these programs.</span></td></tr>
</tbody></table>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our future operating and capital needs
will depend on many factors, including:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 20px">&nbsp;</td>
<td style="width: 20px">●</td>
<td>the pace of scientific progress in our research and development programs and the magnitude of these programs;</td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>●</td>
<td>the scope and results of pre-clinical testing and human studies;</td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>●</td>
<td>the time and costs involved in obtaining regulatory approvals;</td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>●</td>
<td>the time and costs involved in preparing, filing, prosecuting, securing, maintaining and enforcing patents;</td></tr>

<tr style="vertical-align: top">
<td style="width: 20px">&nbsp;</td>
<td style="width: 20px">●</td>
<td>competing technological and market developments;</td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>●</td>
<td>our ability to establish additional collaborations;</td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>●</td>
<td>changes in our existing collaborations;</td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>●</td>
<td>the cost of manufacturing scale-up; and</td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>●</td>
<td>the effectiveness of our commercialization activities.</td></tr>
</tbody></table>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We base our outlook regarding the need
for funds on many uncertain variables. Such uncertainties include the success of our research initiatives, regulatory approvals,
the timing of events outside our direct control such as negotiations with potential strategic partners and other factors. Any of
these uncertain events can significantly change our cash requirements as they determine such one-time events as the receipt or
payment of major milestones and other payments.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Additional funds will be required to
support our operations and if we are unable to obtain them on favorable terms, we may be required to cease or reduce further research
and development of our drug product programs, sell some or all our intellectual property, merge with another entity or cease operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have received fast track designation
for one of our compounds and may seek such designation or breakthrough therapy and priority review for other compounds in the future.
Fast track designation or breakthrough therapy designation may not actually lead to a faster FDA review and approval process.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For some of our compounds, including
ANAVEX<sup>®</sup>2-73, we hope to benefit from the FDA’s fast track and priority review programs. In February 2020,
the FDA granted Fast Track designation for the ANAVEX<sup>®</sup>2-73 clinical development program for the treatment of Rett
syndrome. However, the fast-track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer
supported by data emerging in the clinical trial process.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Under FDA policies, a compound is eligible
for priority review, or review within a six-month time frame from the time a complete NDA is accepted for filing, if the compound
provides a significant improvement compared to marketed drugs in the treatment, diagnosis or prevention of a disease. A fast-track
designated compound would ordinarily meet the FDA’s criteria for priority review.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;Fast track
or breakthrough therapy designation for our compounds may not actually lead to a faster review process, and a delay in the review
process or in the approval of our compounds will delay revenue from their potential sales and will increase the capital necessary
to fund these compound development programs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>We have received orphan drug designation for several
of our compounds, but we may be unable to maintain any benefits associated with orphan drug designation, including market exclusivity.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Orphan Drug Act, the FDA may
grant orphan designation to a drug intended to treat a rare disease or condition or for which there is no reasonable expectation
that the cost of developing and making available in the United States a drug for a disease or condition will be recovered from
sales in the United States for that drug. If a product that has orphan drug designation subsequently receives the first FDA approval
for the indication for which it has such designation, the product is entitled to orphan product exclusivity, which means that the
FDA may not approve any other applications, including a full NDA, to market the same drug or biologic for the same indication for
seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;We have received
orphan drug designation for several of our compounds, but exclusive marketing rights in the United States may be limited if we
seek FDA marketing approval for an indication broader than the orphan designated indication. Additionally, any compound with orphan
drug designation may lose such designation if the FDA later determines that the request for designation was materially defective
or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease
or condition. In addition, others may obtain orphan drug exclusivity for products addressing the same diseases or conditions as
products we are developing, thus limiting our ability to compete in the markets addressing such diseases or conditions for a significant
period of time.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to demonstrate efficacy
in our non-clinical studies and clinical trials our future business prospects, financial condition and operating results will be
materially adversely affected.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The success of our research and development
efforts will be greatly dependent upon our ability to demonstrate potential drug compound efficacy in non-clinical studies, as
well as in clinical trials. Non-clinical studies involve testing potential drug compounds in appropriate non-human disease models
to demonstrate efficacy and safety. Regulatory agencies evaluate these data carefully before they will approve clinical testing
in humans. If certain non-clinical data reveals potential safety issues or the results are inconsistent with an expectation of
the potential drug compound’s efficacy in humans, the regulatory agencies may require additional more rigorous testing before
allowing human clinical trials. This additional testing will increase program expenses and extend timelines. We may decide to suspend
further testing on our potential drug compounds if, in the judgment of our management and advisors, the non-clinical test results
do not support further development.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, success in non-clinical testing
and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the results
of later clinical trials will replicate the results of prior clinical trials and non-clinical testing. The clinical trial process
may fail to demonstrate that our potential drug compounds are safe for humans and effective for indicated uses. This failure would
cause us to abandon a drug candidate and may delay development of other potential drug compounds. Any delay in, or termination
of, our non-clinical testing or clinical trials will delay the filing of an IND and NDA with the FDA or the equivalent applications
with pharmaceutical regulatory authorities outside the United States and, ultimately, our ability to commercialize our potential
drug compounds and generate product revenues. In addition, we expect that our early clinical trials will involve small patient
populations. Because of the small sample size, the results of these early clinical trials may not be indicative of future results.
Also, the IND process may be extremely costly and may substantially delay the development of our potential drug compounds. Moreover,
positive results of non-clinical tests will not necessarily indicate positive results in subsequent clinical trials.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Following successful non-clinical testing,
potential drug compounds will need to be tested in a clinical development program to provide data on safety and efficacy prior
to becoming eligible for product approval and licensure by regulatory agencies. From the first human trial through to regulatory
approval can take many years and 10-12 years is not unusual for certain compounds.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If any of our future clinical development
potential drug compounds become the subject of problems, our ability to sustain our development programs will become critically
compromised. For example, efficacy or safety concerns may arise, whether or not justified, that could lead to the suspension or
termination of our clinical programs. Examples of problems that could arise include, among others:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 20px">&nbsp;</td>
<td style="width: 20px">●</td>
<td>efficacy or safety concerns with the potential drug compounds, even if not justified;</td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>●</td>
<td>manufacturing difficulties or concerns;</td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>●</td>
<td>regulatory proceedings subjecting the potential drug compounds to potential recall;</td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>●</td>
<td>publicity affecting doctor prescription or patient use of the potential drug compounds;</td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>●</td>
<td>pressure from competitive products; or</td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td>●</td>
<td>introduction of more effective treatments.</td></tr>
</tbody></table>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Each clinical phase is designed to test
attributes of the drug and problems that might result in the termination of the entire clinical plan can be revealed at any time
throughout the overall clinical program. The failure to demonstrate efficacy in our clinical trials would have a material adverse
effect on our future business prospects, financial condition and operating results.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we do not obtain the support
of qualified scientific collaborators, our revenue, growth and profitability will likely be limited, which would have a material
adverse effect on our business.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We will need to establish relationships
with leading scientists and research institutions. We believe that such relationships are pivotal to establishing products using
our technologies as a standard of care for various indications. Additionally, although in discussion, there is no assurance that
our current research partners will continue to work with us or that we will be able to attract additional research partners. If
we are not able to establish scientific relationships to assist in our research and development, we may not be able to successfully
develop our potential drug compounds. If this happens, our business will be adversely affected.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may not be able to develop,
market or generate sales of our products to the extent anticipated. Our business may fail and investors could lose all their investment
in our Company.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Assuming that we are successful in developing
our potential drug compounds and receiving regulatory clearances to market our products, our ability to successfully penetrate
the market and generate sales of those products may be limited by a number of factors, including the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 20px">●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">If our competitors receive regulatory approvals for and begin marketing
similar products in the United States, the European Union, Japan and other territories before we do, greater awareness of their
products as compared to ours will cause our competitive position to suffer;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">Information from our competitors or the academic community indicating
that current products or new products are more effective or offer compelling other benefits than our future products could impede
our market penetration or decrease our future market share; and</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">The pricing and reimbursement environment for our future products,
as well as pricing and reimbursement decisions by our competitors and by payers, may have an effect on our revenues.</span></td></tr>
</tbody></table>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If this happens, our business will be
adversely affected.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>None of our potential drug compounds
may reach the commercial market for a number of reasons and our business may fail.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Successful research and development
of pharmaceutical products is high risk. Most products and development candidates fail to reach the market. Our success depends
on the discovery of new drug compounds that we can commercialize. It is possible that our products may never reach the market for
a number of reasons. They may be found ineffective or may cause harmful side-effects during non-clinical testing or clinical trials
or fail to receive necessary regulatory approvals. We may find that certain products cannot be manufactured at a commercial scale
and, therefore, they may not be economical to produce. Our potential products could also fail to achieve market acceptance or be
precluded from commercialization by proprietary rights of third parties. Our patents, patent applications, trademarks and other
intellectual property may be challenged, and this may delay or prohibit us from effectively commercializing our products. Furthermore,
we do not expect our potential drug compounds to be commercially available for a number of years, if at all. If none of our potential
drug compounds reach the commercial market, our business will likely fail and investors will lose all of their investment in our
Company. If this happens, our business will be adversely affected.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If our competitors succeed in
developing products and technologies faster or that are more effective or with a better profile than our own, or if scientific
developments change our understanding of the potential scope and utility of our potential products, then our technologies and future
products may be rendered undesirable or obsolete.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We face significant competition from
industry participants that are pursuing technologies in similar disease states to those that we are pursuing and are developing
pharmaceutical products that are competitive with our products. Nearly all of our industry competitors have greater capital resources,
larger overall research and development staffs and facilities, and a longer history in drug discovery and development, obtaining
regulatory approval and pharmaceutical product manufacturing and marketing than we do. With these additional resources, our competitors
may be able to respond to the rapid and significant technological changes in the biotechnology and pharmaceutical industries faster
than we can. Our future success will depend in large part on our ability to maintain a competitive position with respect to these
technologies. Rapid technological development, as well as new scientific developments, may result in our products becoming obsolete
before we can recover any of the expenses incurred to develop them. For example, changes in our understanding of the appropriate
population of patients who should be treated with a targeted therapy like we are developing may limit the drug’s market potential
if it is subsequently demonstrated that only certain subsets of patients should be treated with the targeted therapy.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our reliance on third parties,
such as university laboratories, contract manufacturing organizations and contract or clinical research organizations, may result
in delays in completing, or a failure to complete, non-clinical testing or clinical trials if they fail to perform under our agreements
with them.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In the course of product development,
we may engage university laboratories, other biotechnology companies or contract or clinical manufacturing organizations to manufacture
drug material for us to be used in non-clinical and clinical testing and contract research organizations to conduct and manage
non-clinical and clinical studies. If we engage these organizations to help us with our non-clinical and clinical programs, many
important aspects of this process have been and will be out of our direct control. If any of these organizations we may engage
in the future fail to perform their obligations under our agreements with them or fail to perform non-clinical testing and/or clinical
trials in a satisfactory manner, we may face delays in completing our clinical trials, as well as commercialization of any of our
potential drug compounds. Furthermore, any loss or delay in obtaining contracts with such entities may also delay the completion
of our clinical trials, regulatory filings and the potential market approval of our potential drug compounds.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to compete successfully
with respect to partnering, licensing, mergers, acquisitions, joint venture and other collaboration opportunities, we may be limited
in our ability to research and develop our potential drug compounds.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our competitors compete with us to attract
established biotechnology and pharmaceutical companies or organizations for partnering, licensing, mergers, acquisitions, joint
ventures or other collaborations. Collaborations include contracting with academic research institutions for the performance of
specific scientific testing. If our competitors successfully enter into partnering arrangements or license agreements with academic
research institutions, we will then be precluded from pursuing those specific opportunities. Since each of these opportunities
is unique, we may not be able to find a substitute. Other companies have already begun many drug development programs, which may
target diseases that we are also targeting, and have already entered into partnering and licensing arrangements with academic research
institutions, reducing the pool of available opportunities.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Universities and public and private
research institutions also compete with us. While these organizations primarily have educational or basic research objectives,
they may develop proprietary technology and acquire patent applications and patents that we may need for the development of our
potential drug compounds. In some instances, we will attempt to license this proprietary technology, if available. These licenses
may not be available to us on acceptable terms, if at all. If we are unable to compete successfully with respect to acquisitions,
joint venture and other collaboration opportunities, we may be limited in our ability to develop new products.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The use of any of our products
in clinical trials may expose us to liability claims, which may cost us significant amounts of money to defend against or pay out,
causing our business to suffer.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The nature of our business exposes us
to potential liability risks inherent in the testing, manufacturing and marketing of our products. We currently have one drug compound
in clinical trials, however, when any of our products enter clinical trials or become marketed products, they could potentially
harm people or allegedly harm people possibly subjecting us to costly and damaging product liability claims. Some of the patients
who participate in clinical trials are already ill when they enter a trial or may intentionally or unintentionally fail to meet
the exclusion criteria. The waivers we obtain may not be enforceable and may not protect us from liability or the costs of product
liability litigation. Although we intend to obtain product liability insurance, which we believe is adequate, we are subject to
the risk that our insurance will not be sufficient to cover claims. The insurance costs along with the defense or payment of liabilities
above the amount of coverage could cost us significant amounts of money and management distraction from other elements of the business,
causing our business to suffer.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we are unable to safeguard
against security breaches with respect to our information systems, our business may be adversely affected.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In the course of our business, we gather,
transmit and retain confidential information through our information systems. Although we endeavor to protect confidential information
through the implementation of security technologies, processes and procedures, it is possible that an individual or group could
defeat security measures and access sensitive information about our business and employees. Any misappropriation, loss or other
unauthorized disclosure of confidential information gathered, stored or used by us could have a material impact on the operation
of our business, including damaging our reputation with our employees, third parties and investors. We could also incur significant
costs implementing additional security measures and organizational changes, implementing additional protection technologies, training
employees or engaging consultants. In addition, we could incur increased litigation as a result of any potential cyber-security
breach. We are not aware that we have experienced any material misappropriation, loss or other unauthorized disclosure of confidential
or personally identifiable information as a result of a cyber-security breach or other act, however, a cyber-security breach or
other act and/or disruption to our information technology systems could have a material adverse effect on our business, prospects,
financial condition or results of operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Even if we receive regulatory approval for one or more
compounds, we will be subject to continuing regulatory obligations and ongoing regulatory review, which may result in significant
additional expense. Additionally, our compounds, if approved, could be subject to labeling and other restrictions on marketing
or withdrawal from the market, and we may be subject to penalties, if we fail to comply with regulatory requirements or if we experience
unanticipated problems with our compounds, when and if any of them are approved. </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Following potential approval of any
our compounds, the FDA may impose significant restrictions on a drug’s indicated uses or marketing or require potentially
costly and time-consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy
of the drug. The FDA may also require a Risk Evaluation and Mitigation Strategy (“REMS”) as a condition of approval
of one or more of our compounds, which could include requirements for a medication guide, physician communication plans or additional
elements to ensure safe use of the drug. Additional REMS elements may include restricted distribution methods, patient registries
and other risk minimization tools.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, if the FDA or a comparable
foreign regulatory authority approves one or more of our compounds, the manufacturing processes, labeling, packaging, distribution,
adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for the approved drug will be subject
to additional and potentially extensive ongoing regulatory requirements. These requirements include submissions of safety and other
post-marketing information and reports, establishment registration, as well as continued compliance with cGMPs and GCP requirements
for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our products, including
adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure
to comply with regulatory requirements, may result in, among other things:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tbody><tr style="vertical-align: top">
<td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">restrictions on the marketing or manufacturing
of our products, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">fines, restitutions, disgorgement of profits
or revenues, warning letters, untitled letters or holds on clinical trials; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">restrictions on product distribution or
use, or requirements to conduct post-marketing studies or clinical trials; </span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">product seizure or detention, or refusal
to permit the import or export of our products;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">injunctions or the imposition of civil
or criminal penalties; and</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●</td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">refusal by the FDA to approve pending applications
or supplements to approved applications filed by us or suspension or revocation of approvals.</span></td></tr>
</tbody></table>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The occurrence of any event or penalty
described above may limit our ability to commercialize our compounds and generate revenue, and could require us to expend significant
time and resources in response or generate negative publicity.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If any of our compounds are approved,
our product labeling, advertising and promotion will also be subject to regulatory requirements and ongoing regulatory review.
The FDA strictly regulates the promotional claims that may be made about drug products. In particular, a drug may not be promoted
for uses that are not approved by the FDA as reflected in the drug’s approved labeling. If we receive marketing approval
for a compound, physicians may nevertheless lawfully prescribe it to their patients in a manner that is inconsistent with the approved
label. While the FDA recently clarified that mere knowledge that a physician is prescribing a drug for off label use is not sufficient
to constitute unlawful off-label promotion, if we are found to have actively promoted such off label uses, we may become subject
to significant liability under the FDCA. The federal government has levied large civil and criminal fines against companies for
alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested
that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA’s and other regulatory
authorities’ policies are subject to change at any time, and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of our compounds. If we are unable to timely adapt to changes in existing requirements
or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance post-marketing, we may
lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Finally, we cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative or executive action, either
in the United States or abroad. It is difficult to predict how any such legislative, administrative or executive actions will be
implemented, and the extent to which they will impact the FDA’s ability to exercise its regulatory authority. If these legislative
or executive actions impose constraints on the FDA’s ability to engage in oversight and implementation activities in the
normal course, our business may be negatively impacted.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The COVID-19 coronavirus could
adversely impact our business, including our clinical trials, and financial condition.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, a novel strain of
coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. Since then, the COVID-19 coronavirus has spread to multiple
countries, including the United States, Australia and European and Asia-Pacific countries, including countries in which we have
planned or active clinical trial sites. As the COVID-19 coronavirus continues to spread around the globe, we may experience disruptions
that could potentially impact our business and clinical trials.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the spread of COVID-19
coronavirus has had and may continue to severely impact the trading price of shares of our common stock and could further severely
impact our ability to raise additional capital on a timely basis or at all.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The global outbreak of the COVID-19
coronavirus continues to rapidly evolve. The extent to which the COVID-19 coronavirus may impact our future business operations,
including our clinical trials, and financial condition will depend on future developments, which are highly uncertain and cannot
be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions
and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness
of actions taken in the United States and other countries to contain and treat the disease.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks Related to our Common Stock</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>A decline in the price of our
common stock could affect our ability to raise further working capital and adversely impact our operations and would severely dilute
existing or future investors if we were to raise funds at lower prices.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A prolonged decline in the price of
our common stock could result in a reduction in our ability to raise capital. Because our operations have been financed through
the sale of equity securities, a decline in the price of our common stock could be especially detrimental to our continued operations.
Any reduction in our ability to raise equity capital in the future would force us to reallocate funds from other planned uses and
would have a significant negative effect on our business plans and operations, including our ability to develop new products and
continue our current operations. If our stock price declines, there can be no assurance that we can raise additional capital or
generate funds from operations sufficient to meet our obligations. We believe the following factors could cause the market price
of our common stock to continue to fluctuate widely and could cause our common stock to trade at a price below the price at which
you purchase your shares of common stock:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 20px"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">actual or anticipated variations in our quarterly operating results;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">announcements of new services, products, acquisitions or strategic
relationships by us or our competitors;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">changes in accounting treatments or principles;</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">changes in earnings estimates by securities analysts and in analyst
recommendations; and</span></td></tr>
<tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td>●</td>
<td><span style="font: 10pt Times New Roman, Times, Serif">general political, economic, regulatory and market conditions.</span></td></tr>
</tbody></table>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The market price for our common stock
may also be affected by our ability to meet or exceed expectations of analysts or investors. Any failure to meet these expectations,
even if minor, could materially adversely affect the market price of our common stock.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we issue additional shares
of common stock in the future, it will result in the dilution of our existing stockholders and may cause the share price of our
common stock to fall.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Recently, the stockholders of the Company
approved an amendment to our articles of incorporation, increasing the number of authorized shares of common stock to 200,000,000
shares. We also have 10,000,000 shares of preferred stock authorized. Our Board of Directors has the authority to issue additional
shares of preferred and common stock up to the authorized capital stated in the articles of incorporation. Our Board of Directors
may choose to issue some or all such shares of common stock to acquire one or more businesses or to provide additional financing
in the future. The issuance of any such shares of common stock will result in a reduction of the book value or market price of
the outstanding shares of our common stock. If we do issue any such additional shares of common stock, such issuance also will
cause a reduction in the proportionate ownership and voting power of all other stockholders. Further, any such issuance may result
in a change of control of our corporation. In the event we do issue or sell additional shares of common or preferred stock, it
may result in shareholder dilution and may cause our share price to fall.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may not be able to access sufficient
funds under the Sales Agreement when needed.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1, 2020, we entered into an Amended
and Restated<sup> </sup>Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald &amp; Co. and SVB Leerink LLC
(the “Sales Agents”), pursuant to which we may offer and sell shares of our common stock registered under an effective
registration statement from time to time through the Sales Agents (the “At-the-Market Offering”). The Sales Agents
are only obligated to act as our agent in the sale of shares pursuant to the Sales Agreement on a commercially reasonable efforts
basis and subject to certain conditions set forth in the Sales Agreement.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Therefore, we may not in the future,
have access to the full amount available to us under the Sales Agreement. Any amounts we sell under the Sales Agreement may not
satisfy all of our funding needs, even if we are able and choose to sell and issue all of our common stock currently registered.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our stock price has been volatile and
may be volatile in the future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our stock price has been volatile at certain
times historically, and may be volatile in the future. We may incur rapid and substantial increases or decreases in our stock price
in the foreseeable future that are do not coincide in timing with the disclosure of news or developments by us. The stock market
in general, and the market for biotechnology and pharmaceutical companies in particular, has experienced extreme volatility that
has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced
by many factors, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
<tbody><tr style="vertical-align: top">
<td style="width: 24px; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 24px; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">announcements
of new data, clinical trial results or those of companies that are perceived to be similar to us;</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">announcements
related to any delays in any preclinical or clinical trials related to our products;</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">announcements
related to our products’ ability to demonstrate efficacy or an acceptable safety profile of our product candidates or similar
announcements by companies that are perceived to be similar to us;</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">our
ability to meet or exceed expectations of analysts or investors;</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">news
that the number of patients required for clinical trials for our drug candidates may be larger than we anticipate, enrollment
in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate
than we anticipate or the duration of these clinical trials may be longer than we anticipate;</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">actions
taken by regulatory agencies with respect to our product candidates or the progress of our clinical studies, including with respect
to any fast track or orphan drug designations;</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">announcements
of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration
partners or our competitors;</span></td></tr>
</tbody></table>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
<tbody><tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">grants
awarded to us or companies that are perceived to be similar to us from outside entities;</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">variations
in our financial results or those of companies that are perceived to be similar to us;</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">trading
volume of our common stock;</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">developments
concerning our collaborations or partners;</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">the
impact of the COVID-19 outbreak and its effect on us;</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">the
perception of the biotechnology or pharmaceutical industries by the public, legislatures, regulators and the investment community;</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">developments
or disputes concerning intellectual property rights;</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">significant
lawsuits, including patent or stockholder litigation;</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">our
ability or inability to raise additional capital and the terms on which we raise it;</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">sales
of our common stock by us or our stockholders;</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">declines
in the market prices of stocks generally or of companies that are perceived to be similar to us; and</span></td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="text-align: justify; font-family: Times New Roman, Times, Serif; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">general
economic, industry and market conditions.</span></td></tr>
</tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, companies trading in the stock
market in general, and The Nasdaq Capital Market in particular, have experienced extreme price and volume fluctuations that have
often been unrelated or disproportionate to the operating performance of these companies. These broad market and industry factors
may seriously harm the market price of our common stock, regardless of our operating performance. In the past, following periods
of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if
instituted against us, could result in substantial costs and diversion of management’s attention and resources, which could
materially and adversely affect our business, financial condition, results of operations and growth prospects. There can be no
guarantee that our stock price will remain at current prices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our common stock may become the target
of a “short squeeze.”</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the past several months prior to the filing
of this Annual Report on Form 10-K, securities of certain companies have increasingly experienced significant and extreme volatility
in stock price due to short sellers of shares of common stock, known as a “short squeeze.” These short squeezes have
caused extreme volatility in those companies and in the market and have led to the price per share of those companies to trade
at a significantly inflated rate that is disconnected from the underlying value of the company. Many investors who have purchased
shares in those companies at an inflated rate face the risk of losing a significant portion of their original investment as the
price per share has declined steadily as interest in those stocks have abated. There can be no assurance that we will not, in the
future be, a target of a short squeeze, and you may lose a significant portion or all of your investment if you purchase our shares
at a rate that is significantly disconnected from our underlying value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks Related to our Intellectual
Property </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we are unable to obtain and
maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection
obtained is not sufficiently broad, our competitors could develop and commercialize product candidates similar or identical to
ours, and our ability to successfully commercialize our product candidates that we may pursue may be impaired. </i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our success depends in large part on
our ability to obtain and maintain protection of our intellectual property, particularly patents, in the United States and other
countries with respect to our product candidates and technology. We seek to protect our proprietary position by filing patent applications
in the United States and abroad related to our product candidates or by in-licensing intellectual property. U.S. patents related
to ANAVEX<sup>®</sup>2-73 are directed to a dosage form comprising certain doses of ANAVEX<sup>®</sup>2-73 and donepezil,
and the coverage is limited to the United States only. We may not be able to obtain patent protection for ANAVEX<sup>®</sup>2-73
as a single drug or in other jurisdictions.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, we may be subject to a third-party
preissuance submission of prior art to the United States Patent and Trademark Office, or the USPTO, or become involved in opposition,
derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or
the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of,
or invalidate, our patent rights, allow third parties to commercialize our product candidates and compete directly with us, without
payment to us, or result in our inability to manufacture or commercialize drugs without infringing on third-party patent rights.
In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless
of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product
candidates.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the issuance of a patent
is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or
patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent
claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from
using or commercializing similar or identical product candidates, or limit the duration of the patent protection of our product
candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents
protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio
may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We hold ownership or exclusive rights
to nine issued U.S. patent, ten U.S. patent applications, and various PCT or ex-U.S. patent applications relating to our drug candidates,
methods associated therewith, and to our research programs. Neither patents nor patent applications ensure the protection of our
intellectual property for a number of reasons, including the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr>
<td style="width: 5%; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; width: 5%; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Competitors may interfere
with our patenting process in a variety of ways. Competitors may claim that Anavex is not entitled to an issued patent for a variety
of legal reasons. Competitors may also claim that we are infringing their patents and restrict our freedom to operate. If a court
or, in some circumstances, a board of a national patent authority, agrees, we would lose some or all of our patent protection.
As a company, we have no meaningful experience with competitors interfering with our patents or patent applications.</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; line-height: 115%">&nbsp;</td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Because of the time,
money and effort involved in obtaining and enforcing patents, our management may spend less time and resources on developing potential
drug compounds than they otherwise would, which could increase our operating expenses and delay product programs.</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; line-height: 115%">&nbsp;</td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Issuance of a patent
may not provide significant practical protection. If we receive a patent of narrow scope, then it may be possible for competitors
to design products that do not infringe our patent(s).</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; line-height: 115%">&nbsp;</td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Anavex is seeking patent
protection for a number of indications, combination products and drug regimens. The lack of patent protection in global markets
for a specific end product or indication may inhibit our ability to advance our compounds and may make Anavex less attractive
to potential partners.</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; line-height: 115%">&nbsp;</td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Defending a patent lawsuit
takes significant time and can be very expensive.</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; line-height: 115%">&nbsp;</td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">6.</span></td>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">If a court decides that
an Anavex compound, its method of manufacture or use, infringes on the competitor’s patent, we may have to pay substantial
damages for infringement.</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; line-height: 115%">&nbsp;</td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">7.</span></td>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">A court may prohibit
us from making, selling or licensing the potential drug compound unless the patent holder grants a license. A patent holder is
not required to grant a license. If a license is available, we may have to pay substantial royalties or grant cross licenses to
our patents, and the license terms may be unacceptable.</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="text-align: justify; line-height: 115%">&nbsp;</td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">8.</span></td>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Redesigning our potential
drug compounds so that they do not infringe on other patents may not be possible or could require substantial funds and time.</span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">It is also unclear whether our trade
secrets are adequately protected. While we use reasonable efforts to protect our trade secrets, our employees or consultants may
unintentionally or willfully disclose our information to competitors. Enforcing a claim that someone illegally obtained and is
using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome is unpredictable. In addition,
courts outside the United States are sometimes less willing to protect trade secrets. Our competitors may independently develop
equivalent knowledge, methods and know-how.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We may also support and collaborate
in research conducted by government organizations, hospitals, universities or other educational institutions. These research partners
may be unable or unwilling to grant us exclusive rights to technology or products derived from these collaborations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: black">If we do
not obtain required intellectual property licenses or rights, we could encounter delays in our product development efforts while
we attempt to design around other patents or even be prohibited from developing, manufacturing or selling potential drug compounds
requiring these rights or licenses. There is also a risk that legal disputes may arise as to the rights to technology or potential
drug compounds developed in collaboration with other parties, all with attendant risk, distraction, expense, and lack of predictability.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to comply with our
obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions
to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We are party to an exclusive license
agreement with Life Science Research Israel Ltd., with respect to certain in-licensed intellectual property related to our ANAVEX<sup>®</sup>3-71
product candidate, and we may need to obtain additional licenses from others in the future. Our license agreement with Life Science
Research Israel Ltd. imposes, and we expect that future license agreements will impose, various development, diligence, commercialization,
and other obligations on us. In spite of our efforts, our licensors might conclude that we have materially breached our obligations
under such license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to
develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or
if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to
seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization
of ANAVEX<sup>®</sup>3-71<b><i> </i></b>or other product candidates covered by any such future licenses. Any of the foregoing
could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Moreover, disputes may arise regarding
intellectual property subject to a licensing agreement, including:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr>
<td style="width: 5%; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; width: 2%; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">●</span></td>
<td style="vertical-align: top; width: 1%; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">the
scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">the
extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not
subject to the licensing agreement;</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">the
sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">our
diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">the
inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our
licensors and us and our partners; and</span></td></tr>
<tr>
<td style="text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%">&nbsp;</td></tr>
<tr>
<td style="text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"></span>●</td>
<td style="vertical-align: top; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">the priority of invention of patented technology.
&nbsp; &nbsp;</span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the agreements under which
we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements
may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could
narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe
to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on
our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that
we have licensed prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may
be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect
on our business, financial conditions, results of operations, and prospects.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If we do not obtain required intellectual
property licenses or rights, we could encounter delays in our product development efforts while we attempt to design around other
patents or even be prohibited from developing, manufacturing or selling potential drug compounds requiring these rights or licenses.
There is also a risk that legal disputes may arise as to the rights to technology or potential drug compounds developed in collaboration
with other parties, all with attendant risk, distraction, expense, and lack of predictability.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Third-party claims of intellectual
property infringement may prevent or delay our development and commercialization efforts.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our success will also depend in part
on our ability to commercialize our compounds without infringing the proprietary rights of others. We have not conducted extensive
freedom of use patent searches and no assurance can be given that patents do not exist or could be issued which would have an adverse
effect on our ability to market our technology or maintain our competitive position with respect to our technology. If our compounds
or other subject matter are claimed under other United States patents or other international patents or are otherwise protected
by third party proprietary rights, we may be subject to infringement actions. In such event, we may challenge the validity of such
patents or other proprietary rights or we may be required to obtain licenses from such companies in order to develop, manufacture
or market our technology. There can be no assurances that we would be successful in a challenge or be able to obtain such licenses
or that such licenses, if available, could be obtained on commercially reasonable terms. Furthermore, the failure to succeed in
a challenge, develop a commercially viable alternative or obtain needed licenses could be materially adverse. Adverse consequences
include delays in marketing some or all of our potential drug compounds based on our drug technology or the inability to proceed
with the development, manufacture or sale of potential drug compounds requiring such licenses. If we defend ourselves against charges
of patent infringement or to protect our proprietary rights against third parties, substantial costs will be incurred regardless
of whether we are successful. Such proceedings are typically protracted with no certainty of success. An adverse outcome could
subject us to significant liabilities to third parties and force us to curtail or cease the research and development of our technology.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Parties making claims against us may
obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize ANAVEX<sup>®</sup>2-73
or our other product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense
and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement
against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement,
pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require
substantial time and monetary expenditure. Additionally, parties making claims against us may be able to sustain the costs of complex
patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk
that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the
initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise
have a material adverse effect on our business, results of operations, financial condition and prospects.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we are unable to protect the
confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would
be harmed.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">While we use reasonable efforts to protect
our trade secrets, our employees or consultants may unintentionally or willfully disclose our information to competitors. Enforcing
a claim that someone illegally obtained and is using our trade secrets, like patent litigation, is expensive and time consuming,
and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets.
Our competitors may independently develop equivalent knowledge, methods and know-how.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We seek to protect our confidential
proprietary information, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants,
scientific advisors, contractors and collaborators. These agreements are designed to protect our proprietary information. However,
we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade
secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access
to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties
may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain
adequate remedies for such breaches. We also seek to preserve the integrity and confidentiality of our confidential proprietary
information by maintaining physical security of our premises and physical and electronic security of our information technology
systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information
were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from
using that technology or information to compete with us, which could harm our competitive position.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Although we are not currently
involved in any litigation, we may become involved in lawsuits to protect or enforce our patents or other intellectual property,
which could be expensive, time consuming and unsuccessful.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Competitors may infringe our patents
or other intellectual property. Although we are not currently involved in any litigation, if we were to initiate legal proceedings
against a third party to enforce a patent covering ANAVEX<sup>®</sup>2-73 or our other product candidates, the defendant could
counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United
States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could
be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description
or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of
the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following
legal assertions of invalidity and unenforceability is unpredictable.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Interference or derivation proceedings
provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with
respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or
to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer
us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access
to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may
result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation
could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our
research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring
ANAVEX<sup>®</sup>2-73 or our other product candidates to market.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may be subject to claims challenging
the inventorship of our patents and other intellectual property.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We or our licensors may be subject to
claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade
secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes
arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation
may be necessary to defend against these and other claims challenging inventorship or our or our licensors’ ownership of
our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership
of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending
against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of
the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Obtaining and maintaining our
patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed
by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Periodic maintenance fees, renewal fees,
annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various
governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications.
We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these
fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number
of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable
law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late
fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result
in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant
jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse
effect on our business.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may not be able to protect
our intellectual property rights throughout the world.</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Filing, prosecuting and defending patents
on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property
rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws
of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United
States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United
States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors
may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also
export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United
States. These products may compete with our products and our patents or other intellectual property rights may not be effective
or sufficient to prevent them from competing.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The risk factors disclosed in this Annual
Report on Form 10-K could materially and adversely affect our business, financial condition and results of operations. The risks
described herein are not the only risks we face. Our operations could also be affected by additional factors that are not presently
known to us or by factors that we currently consider immaterial to our business.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_004"></span>ITEM 1B. UNRESOLVED
STAFF COMMENTS </span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="a_005"></span><span style="font-style: normal">ITEM 2. PROPERTIES</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not own any real property. We
maintain a corporate head office at 51 West 52nd Street, 7<sup>th</sup> Floor, New York, NY, USA. Our lease costs for this office
are approximately $4,500 per month. We believe our offices are suitable and adequate to operate our business currently, as they
provide us with sufficient space to conduct our operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_006"></span>ITEM 3. LEGAL
PROCEEDINGS</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We know of
no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our Company
or our subsidiary is a party or of which any of their property is subject. There are no proceedings in which any of our directors,
officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse party or
has a material interest adverse to our or our subsidiary’s interest.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_007"></span>ITEM 4. MINE
SAFETY DISCLOSURES</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="a_008"></span>PART II</p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_009"></span>ITEM 5. MARKET
FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Market information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock is quoted on the Nasdaq
Global Select Stock Market (“Nasdaq”) under the symbol “AVXL.”</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Holders of Common Stock </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of <span style="color: black">November
19, 2021</span>, there were approximately 49 holders of record, and 76,018,053 shares of our common stock were issued and outstanding.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Dividends </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have not paid any cash dividends
on our common stock and have no intention of paying any dividends on the shares of our common stock. Our current policy is to retain
earnings, if any, for use in our operations and in the development of our business. Our future dividend policy will be determined
from time to time by our Board of Directors.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Recent Sales of Unregistered Securities
</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Since the beginning of our fiscal year
ended September 30, 2021, we have not sold any equity securities that were not registered under the Securities Act of 1933 that
were not previously reported in a quarterly report on Form 10-Q or in a current report on Form 8-K.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Repurchases of Equity Securities by Our
Company and Affiliated Purchasers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">ITEM 6 <span style="text-transform: uppercase"><span id="a_010"></span>[Reserved]</span></span></p>

<p style="font: italic 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-weight: normal">&nbsp;</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_011"></span>ITEM 7 MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION </span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The following discussion should be read in conjunction with
our audited consolidated financial statements and notes thereto for the fiscal year ended September 30, 2021, included elsewhere
in this Annual Report on Form 10-K.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Financial Overview</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">We
are in the development stage and have not earned any revenues since our inception in 2004. We do not anticipate earning any revenues
until we can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">Our
operating costs consist primarily of research and development activities including the cost of clinical studies and clinical supplies
as well as clinical drug manufacturing and formulation.</span> <span style="font-family: Times New Roman, Times, Serif">Research
and development expenses also include personnel related costs such as salaries and wages, and third-party contract research organization
(CRO) expenses in support of these clinical studies.</span> <span style="font-family: Times New Roman, Times, Serif">Personnel
costs include salaries and wages, benefits, and non-cash stock-based compensation charges associated with options and other equity
awards granted to employees and consultants who are directly engaged in support of our research and development activities.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0"></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">General and administrative expenses consist of personnel
costs, expenses for outside professional services and expenses for associated with operating as a public company. Personnel costs
consist of salaries and wages, benefits and stock-based compensation for general and administrative personnel. Outside professional
services and public company expenses, include expenses related to compliance and reporting, additional insurance expenses, audit
and SOX compliance, expenses associated with patent research, applications and filings, investor and shareholder relations activities
and other administrative expenses and professional services</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt"><b>Year ended September 30, 2021 </b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">During
fiscal 2021, we made significant progress in the advancement of clinical studies for ANAVEX<sup>®</sup>2-73, including completing
enrollment of our international Phase 2b/3 Alzheimer</span>’<span style="font-family: Times New Roman, Times, Serif">s disease
trial, completion of our proof-of-concept Phase 2 Parkinson</span>’<span style="font-family: Times New Roman, Times, Serif">s disease
dementia trial, continued advancement of a multi-regional Phase 2/3 clinical program for the treatment of Rett syndrome, including completion
of the Phase 2 U.S. trial, expansion of the AVATAR Phase 2 study internationally into the United Kingdom and the commencement of the
EXCELLENCE Phase 2/3 pediatric Rett syndrome study and expansion of this trial into Canada and the United Kingdom. Additionally, we advanced
the first in human Phase 1 clinical trial of ANAVEX<sup>®</sup>3-71 with focus on the treatment of Frontotemporal Dementia (FTD).
</span>&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0"><i>Operating Expenses</i></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0"><i>&nbsp;</i></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">Our operating expenses for fiscal 2021 increased to $42.0
million, from $31.1 million in fiscal 2020. The increase is attributable to an increase in research and development expenses of
$7.8 million in 2021 to $33.0 million, primarily due to the advancement of our clinical programs, as described above.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">General and administrative expenses for fiscal 2021 increased
to $9.0 million, from $5.9 million in fiscal 2020, most significantly related to an increase in personnel and an increase in associated
non-cash stock option compensation charges.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">During
fiscal 2021, we utilized $30.4 million to fund our operations, compared to $21.3 million during fiscal 2020. Our cash position
increased to $152.1 million at September 30, 2021, an increase of $122.9 million over the prior year.</span> <span style="font-family: Times New Roman, Times, Serif">Cash
for operations was generated through the issuance of shares of common stock under financing arrangements described below, and through
the completion of a registered direct offering.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">We will continue to see an increase in our research and
development expenditures as we advance our ANAVEX<sup>®</sup>2-73 clinical studies, including adding extension studies to allow
us to continue to gather longer term data, continuing to advance our other pipeline compounds such as ANAVEX<sup>®</sup>3-71,
and as we continue to add additional staffing to manage and support these clinical studies.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><i>Other income </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">Net other income for the year ended September 30, 2021
was $4.4 million as compared to $4.8 million for fiscal 2020. The primary reason for the decrease in other income was due to an
increased foreign exchange loss associated with Incentive and other receivables denominated in Australian dollars, and related
impact from the fluctuation of the Australian dollar against the US dollar during the year.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">During fiscal 2021, we recorded $4.5 million in research
and development incentive income, consisting of the Australian research and development incentive credit administered through the
Australian Tax Office, in connection with fiscal 2021 eligible expenditures and fiscal 2020 expenditures for which an overseas
finding ruling was obtained during the current year. In comparison, research and development incentive income for fiscal 2020 was
$4.4 million in connection with fiscal 2020 eligible expenditures. We expect to continue to receive support from the Australian
government for various clinical trials being conducted within Australia.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0"><i>Net loss</i></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0"><i>&nbsp;</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">Net loss for fiscal 2021 was $37.9 million,
or $0.54 per share, compared to a net loss of approximately $26.3 million, or $0.45 per share for fiscal 2020.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Liquidity and Capital Resources </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Working Capital</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Current Assets</td><td style="width: 5%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">161,616,490</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%">&nbsp;</td>
    <td style="width: 5%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">34,542,197</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current Liabilities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,798,386</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,305,628</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Working Capital</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">150,818,104</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">27,236,569</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
</tbody></table>


<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt"><span style="font-family: Times New Roman, Times, Serif">At
September 30, 2021, we had $152.1 million in cash and cash equivalents, an increase of $122.9 million, from $29.2 million at September
30, 2020.</span> <span style="font-family: Times New Roman, Times, Serif">T<span style="color: black">he principal reason for
this increase is due to cash received from financing activities of $153.2 million from the issuance of common shares, offset by
cash utilized in operations of $30.4 million.</span></span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt"><span style="font-family: Times New Roman, Times, Serif"><span style="color: black"></span></span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="color: black">We intend to continue to
use our capital resources to advance our clinical trials for ANAVEX<sup>®</sup>2-73 and ANAVEX<sup>®</sup>3-71, and to
perform work necessary to prepare for future development of our pipeline compounds</span>.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash Flows</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">2020</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Cash flows used in operating activities</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(30,383,674</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(21,287,046</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash flows provided by financing activities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">153,242,401</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">28,350,434</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Increase in cash</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">122,858,727</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,063,388</td><td style="text-align: left">&nbsp;</td></tr>
</tbody></table>


<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">Cash flow used in operating activities</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">There was an increase in cash used in operating activities
of $9.1 million during fiscal 2021 due to an increase in clinical trial activities, as more fully described above.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">Cash flow provided by financing activities</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">Cash provided by financing activities <span style="color: black">in
fiscal 2021 </span>was $153.2 million, net of financing costs, primarily attributable to cash received from the issuance of common
shares at various market prices under the 2019 Purchase Agreement, the Sales Agreement and a direct registered offering we completed
for net proceeds of $46.9 million, after deducting expenses associated with the offering.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">Cash provided by financing activities <span style="color: black">in
fiscal 2020 </span>were $28.4 million, attributable to cash received from the issuance of common shares at various market prices
under the 2019 Purchase Agreement and under the Sales Agreement<span style="color: black">.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">Other Financings</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0"><b>Purchase Agreement</b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0">On June 7, 2019, we
entered into a Purchase Agreement (the “2019 Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln
Park”), as amended on July 1, 2020, pursuant to which Lincoln Park committed to purchase up to $50.0 million of our common
stock. Concurrently with the execution of the 2019 Purchase Agreement in 2019, we issued 324,383 shares of our common stock to
Lincoln Park as a fee for its commitment to purchase shares of our common stock under the 2019 Purchase Agreement and became obligated
to issue up to 162,191 shares pro rata, when and if Lincoln Park purchased, at our discretion, the $50.0 million aggregate commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">During fiscal year 2021, the Company
issued to Lincoln Park an aggregate of 4,086,209 shares of common stock under the 2019 Purchase Agreement, including 4,007,996
shares of common stock for an aggregate purchase price of $24.1 million and 78,213 commitment shares. As of<span style="color: black">
September 30, 2021, no shares of our common stock remain available for purchase by Lincoln Park under the 2019 Purchase Agreement.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"></p>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><b>Controlled Equity Offering Sales
Agreement</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">On May 1, 2020, we entered into an Amended
and Restated Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald &amp; Co. and SVB Leerink LLC (the “Sales
Agents”), pursuant to which we may offer and sell shares of common stock registered under an effective registration statement
from time to time through the Sales Agents (the “At-the-Market Offering”).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">Upon delivery of a placement notice based on
our instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell shares of common stock
by methods deemed to be an “at the market offering”, in negotiated transactions at market prices prevailing at the
time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated
transactions, subject to our prior written consent. We are not obligated to make any sales of shares under the Sales Agreement.
We or the Sales Agents may suspend or terminate the At-the-Market Offering upon notice to the other party, subject to certain conditions.
The Sales Agents will act as agents on a commercially reasonable efforts basis consistent with their normal trading and sales practices
and applicable state and federal law, rules and regulations and the rules of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">We have agreed to pay the Sales Agents commissions
for their services of 3.0% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. We have also agreed
to provide the Sales Agents with customary indemnification and contribution rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span>&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">During fiscal 2021, 5,634,576 shares were sold
pursuant to the At-the-Market Offering for gross proceeds of $79.1 million (net proceeds of $76.7 million after deducting commissions
and offering expenses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><b>Registered Direct Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">On June 24, 2021, the Company completed a registered
direct offering off of the Company’s shelf registration statement on Form S-3 filed with the SEC on July 3, 2019. The Company
issued 2,380,953 common shares at $21.00 per share for gross proceeds of $50.0 million (net proceeds of $46.9 million after deducting
offering fees and expenses).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><b><i>Off-Balance Sheet Arrangements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">We have no off-balance sheet arrangements
that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="text-transform: uppercase"><b>Application
of Critical Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><span style="text-transform: uppercase"><b>&nbsp;</b></span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">Our
financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United
States. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of
assets, liabilities, revenue and expenses. These estimates and assumptions are affected by management</span>’<span style="font-family: Times New Roman, Times, Serif">s
application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved
with the following aspects of our financial statements is critical to an understanding of our financial statements.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0"></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">We base our assumptions and estimates on historical experience
and other sources that we believe to be reasonable at the time. Actual results may vary from our estimates due to changes in circumstances,
politics, global economics, general business conditions and other factors. Our significant estimates are related to the valuation
of warrants and options.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">There are accounting policies that we believe are significant
to the presentation of our financial statements. The most significant of these accounting policies relates to the accounting for
our research and development expenses and stock-based compensation expense.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0"></p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">Research and Development Expenses</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">Research and development costs are expensed
as incurred. These expenses are comprised of the costs of the Company’s proprietary research and development efforts, including
preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and stock based compensation expense,
contract services including external research and development expenses incurred under arrangements with third parties such as contract
research organizations (“CROs”), facilities costs, overhead costs and other related expenses. Milestone payments made
by the Company to third parties are expensed when the specific milestone has been achieved. Manufacturing costs are expensed as
incurred in accordance with Accounting Standard Codification (“ASC”) 730, Research and Development, as these materials
have no alternative future use outside of their intended use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">Nonrefundable advance payments for goods or
services that will be used or rendered for future research and development activities are deferred and amortized over the period
that the goods are delivered, or the related services are performed, subject to an assessment of recoverability. The Company makes
estimates of costs incurred in relation to external CROs, and clinical site costs. The Company analyzes the progress of clinical
trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of the amount
expensed and the related prepaid asset and accrued liability. Judgments and estimates must be made and used in determining
the accrued balance and expense in any accounting period. The Company reviews and accrues CRO expenses and clinical trial study
expenses based on work performed and relies upon estimates of those costs applicable to the stage of completion of a study. Accrued
CRO costs are subject to revisions as such trials progress to completion. Revisions are charged to expense in the period in which
the facts that give rise to the revision become known. With respect to clinical site costs, the financial terms of these agreements
are subject to negotiation and vary from contract to contract. Payments under these contracts may be uneven and depend on factors
such as the achievement of certain events, the successful recruitment of patients, the completion of portions of the clinical trial
or similar conditions. The objective of our policy is to record expenses in our financial statements based on actual services received
and efforts expended. As such, expense accruals related to clinical site costs are recognized based on our estimate of the degree
of completion of the event or events specified in the specific clinical study or trial contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">In addition, we incur expenses in respect of the acquisition
of intellectual property relating to patents and trademarks. The probability of success and length of time to develop commercial
applications of the drugs subject to the acquired patents and trademarks is difficult to determine and numerous risks and uncertainties
exist with respect to the timely completion of the development projects. There is no assurance the acquired patents and trademarks
will ever be successfully commercialized. Due to these risks and uncertainties, we expense the acquisition of patents and trademarks.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">Stock-based Compensation</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">We account for all stock-based payments and awards under
the fair value-based method.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">The fair value of all share purchase options and warrants
are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards expected
to vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">Compensation costs for stock-based payments with graded
vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures of unvested
awards as they occur.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">We have granted share purchase
option awards that vest upon achievement of certain performance criteria, or milestone-based awards. We estimate an implicit service
period for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit service
period when we conclude that achieving the performance criteria is probable. We periodically review and update, as appropriate, our estimates
of implicit service periods and conclusions on achieving the performance criteria. Performance awards vest upon achievement of the performance
criteria.&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0"></p>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">We use the Black-Scholes option
valuation model to calculate the fair value of share purchase options and warrants at the date of the grant. This model requires the input
of subjective assumptions, including the expected price volatility, expected life and estimated forfeitures of each&nbsp;award. We use
the U.S. Treasury daily treasury yield curve rates for the expected term of the option as the risk-free rate. The expected term represents
the period that options granted are expected to be outstanding using the simplified method. Our historical share option exercise experience
does not provide a reasonable basis for estimating the expected term. Expected volatility is based on the average of the daily share price
changes over the expected term. We do not estimate forfeitures and elect to record actual forfeitures as they occur. We have not paid
any dividends on our common stock historically, therefore no assumption of dividend payments is made in the model. These assumptions consist
of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management’s judgment. Changes
in these assumptions can materially affect the fair value estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">The purchase price of options or warrants may
be paid in cash or, if approved by our compensation committee in advance, “net settled” in shares of our common stock. In
a net settlement of an option or warrant, we do not receive payment of the exercise price from the holder but reduce the number of shares
of common stock issued upon the exercise of the stock option or warrant by the smallest number of whole shares that have an aggregate
fair market value equal to or over the aggregate exercise price for the option shares covered by the option or warrant being exercised.
Shares issued pursuant to the exercise of options and warrants are issued from our treasury.</p>
<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b>RECENT ACCOUNTING PRONOUNCEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">For a discussion of recent accounting pronouncements
and their possible effect on our results, see Note 2(n) to our Consolidated Financial Statements found elsewhere in this Annual Report.</p>
<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-style: normal"><span id="a_012"></span>ITEM 7A QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">Not Applicable.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-style: normal"><span id="a_013"></span>ITEM 8. FINANCIAL
STATEMENTS AND SUPPLEMENTARY DATA</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-style: normal"></span></p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ANAVEX LIFE SCIENCES CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONSOLIDATED FINANCIAL STATEMENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">September 30, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Report of Independent Registered Public
Accounting Firm</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shareholders and Board of Directors</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">New York, New York</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><b>Opinion on the Consolidated
Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">We have audited the accompanying
consolidated balance sheets of Anavex Life Sciences Corp. (the “Company”) as of September 30, 2021 and 2020, the related
consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the two years
in the period ended September 30, 2021, and the related notes (collectively referred to as the “consolidated financial statements”).
In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company
at September 30, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended
September 30, 2021<b>,</b> in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also have audited, in accordance with the
standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company’s internal
control over financial reporting as of September 30, 2021, based on criteria established in <i>Internal Control – Integrated
Framework (2013)</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and our
report dated November 24, 2021 expressed an unqualified opinion thereon.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">These consolidated financial
statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s
consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the consolidated financial statements are free of material misstatement, whether due to error or fraud.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audits included performing procedures to
assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe
that our audits provide a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><b>Critical Audit Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Critical audit matters are matters arising
from the current period audit of the consolidated financial statements that were communicated or required to be communicated to
the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements
and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ BDO USA, LLP</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have served as the Company’s auditor
since 2013.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">New York, New York</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">November 24, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Report of Independent Registered Public Accounting Firm </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shareholders and Board of Directors</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Anavex Life Sciences Corp.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">New York, New York</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Opinion on Internal Control over Financial
Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited Anavex Life Sciences Corp.’s
(the “Company’s”) internal control over financial reporting as of September 30, 2021, based on criteria established
in <i>Internal Control – Integrated Framework (2013)</i> issued by the Committee of Sponsoring Organizations of the Treadway
Commission (the “COSO criteria”). In our opinion, the Company maintained, in all material respects, effective internal
control over financial reporting as of September 30, 2021, based on the COSO criteria<i>. </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also have audited, in accordance with the
standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated balance sheets
of the Company as of September 30, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders’
equity, and cash flows for each of the two years in the period ended September 30, 2021, and the related notes, and our report
dated November 24, 2021 expressed an unqualified opinion thereon.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s management is responsible
for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control
over financial reporting, included in the accompanying Item 9A, Management’s Report on Internal Control over Financial Reporting.
Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.
We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance
with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audit of internal control
over financial reporting in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material
respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a
material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed
risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that
our audit provides a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Definition and Limitations of Internal Control
over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A company’s internal control over financial
reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal
control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in
reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations
of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized
acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because of its inherent limitations, internal
control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ BDO USA, LLP</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="color: black">New York, New York</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">November 24, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>ANAVEX LIFE SCIENCES CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">CONSOLIDATED BALANCE SHEETS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">As at September 30,
2021 and 2020<b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_111_zjXNEzNHUnwb" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_492_20210930" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_491_20200930" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--AssetsAbstract_iB_zzCtX9454IWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--AssetsCurrentAbstract_i01B_zFOxjhZabWMh" style="vertical-align: bottom; background-color: White">
    <td>Current</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCz9Fo_z1Rzkx8ZDr2f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; width: 56%; text-align: left">Cash and cash equivalents</td><td style="width: 8%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">152,107,745</ix:nonfraction></span></td><td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,249,018</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxesReceivable_i02I_maCz9Fo_z2lPgIO7BiBj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Incentive and tax receivables</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxesReceivable" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,136,831</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxesReceivable" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-35" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,849,340</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--PrepaidExpenseCurrent_i02I_maCz9Fo_z0cB7w0p3Pyf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Prepaid expenses and deposits</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:PrepaidExpenseCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">355,549</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:PrepaidExpenseCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">443,839</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40E_eus-gaap--UnamortizedLossReacquiredDebtNoncurrent_i02I_d0_maCz9Fo_zF6SF5qUbLij" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 1pt 20pt; text-align: left">Deferred financing charges</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:UnamortizedLossReacquiredDebtNoncurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,365</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:UnamortizedLossReacquiredDebtNoncurrent" contextref="AsOf2020-09-30" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr id="xdx_40D_eus-gaap--Assets_i01TI_mtCz9Fo_zexpAldAKwse" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Assets</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-40" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">161,616,490</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,542,197</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zAhRtDTCcW8h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liabilities and Stockholders' Equity</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40F_eus-gaap--LiabilitiesCurrentAbstract_i01B_zs4MckU8E7K1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current Liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_406_eus-gaap--AccountsPayableCurrent_i02I_maCzWCs_zwl1WOnaZkG1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Accounts payable</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:AccountsPayableCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,739,781</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AccountsPayableCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-43" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,989,054</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzWCs_zvl9ijCUUqva" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Accrued liabilities - Note 3</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,614,774</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,316,574</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_409_eus-gaap--DeferredRentCredit_i02I_d0_maCzWCs_zp5mBzlycdw5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 1pt 20pt; text-align: left">Deferred grant income</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredRentCredit" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">443,831</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredRentCredit" contextref="AsOf2020-09-30" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--Liabilities_i02TI_mtCzWCs_maCzhIs_zEkoSak9rfR3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:Liabilities" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,798,386</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:Liabilities" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-49" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,305,628</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_eus-gaap--CommitmentsAndContingencies_i01I_zdFkddwT7ga" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Commitments and Contingencies - Note 6</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capital stock</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Authorized:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt"><span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_c20210930_pdd" title="Preferred stock, authorized"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_c20200930_zfzfWFAGevwl" title="Preferred stock, authorized"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-50" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000,000</ix:nonfraction></span></ix:nonfraction></span></span></span> preferred stock, par value $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_c20210930_pdd" title="Preferred stock, par value (in dollars per share)"><span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_c20200930_pdd" title="Preferred stock, par value (in dollars per share)"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-52" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></ix:nonfraction></span></span></span> per share</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--PreferredStockValue_i01I_c20210930_zZRN0I9J9S52" title="Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share" style="color: White; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0091"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2021-09-30" id="fact-identifier-54" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0091" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98C_eus-gaap--PreferredStockValue_iI_c20200930_zjhEYppmA2Y8" style="color: White; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0092"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2020-09-30" id="fact-identifier-55" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0092" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20210930_pdd" title="Common shares, authorized"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000,000</ix:nonfraction></span></span>
    common stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20210930_pdd" title="Common shares, par value (in dollars per share)"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-57" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></span>
    per share<br>
(2020: <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_c20200930_z6FFA4SQQrmk"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000,000</ix:nonfraction></span></span> common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20200930_pdd"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-59" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></span> per share)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issued and outstanding:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40E_eus-gaap--CommonStockValue_i01I_maSEzlXx_zUDoWEuIN4Jl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt"><span id="xdx_90B_eus-gaap--CommonStockSharesIssued_c20210930_pdd" title="Common shares, issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_c20210930_pdd" title="Common shares, outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,918,465</ix:nonfraction></span></ix:nonfraction></span></span></span> common shares (2020 -<span id="xdx_905_eus-gaap--CommonStockSharesIssued_c20200930_pdd" title="Common shares, issued"> <span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_c20200930_pdd" title="Common shares, outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-63" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">62,045,198</ix:nonfraction></span></ix:nonfraction></span></span></span>)</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--CommonStockValue_i01I_c20210930_zrSeH56ENZ0c" title="Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share (2020: 100,000,000 common stock, par value $0.001 per share) Issued and outstanding: 75,918,465 common shares (2020 - 62,045,198)" style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-65" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,920</ix:nonfraction></span></ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--CommonStockValue_iI_c20200930_zEZWxTFfjbse" title="Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share (2020: 100,000,000 common stock, par value $0.001 per share) Issued and outstanding: 75,918,465 common shares (2020 - 62,045,198)" style="text-align: right"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">62,047</ix:nonfraction></span></ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_maSEzlXx_z2bMFAoR3we6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional paid-in capital</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">348,328,048</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-69" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">186,851,752</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEzlXx_zB0At19f5Bm6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">197,585,864</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-71" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">159,677,230</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr id="xdx_402_eus-gaap--StockholdersEquity_i01TI_maCzhIs_mtSEzlXx_zdW0n19aiYGd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Stockholders' Equity</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-72" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,818,104</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-73" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,236,569</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzhIs_zrv6eeYjulO3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 1pt; text-align: left">Total Liabilities and Stockholders' Equity</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-74" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">161,616,490</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,542,197</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
</tbody></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">See Accompanying Notes to Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>ANAVEX LIFE SCIENCES CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">For
the years ended September 30, 2021 and 2020<b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_113_zoSfV9PVVCHc" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td id="xdx_49A_20201001__20210930_zkTu1BnVmU76" style="font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49B_20191001_20200930" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_zZtnEtxTHHg9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzt4A_z3r2AVeO3R4b" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">General and administrative</td><td style="width: 8%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:GeneralAndAdministrativeExpense" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-76" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,017,511</ix:nonfraction></span></td><td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:GeneralAndAdministrativeExpense" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-77" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,856,609</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzt4A_zGax5brcKf6j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-78" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,983,674</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-79" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,231,623</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr id="xdx_407_eus-gaap--OperatingExpenses_i01NT_di_mtCzt4A_msCzRUJ_zVWa8EIJ07n2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total operating expenses</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:OperatingExpenses" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-80" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42,001,185</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:OperatingExpenses" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,088,232</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zplPOSDb3QZ8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income (expenses)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40F_ecustom--NonOperatingIncomeFromGrants_i01_maCzWba_z9MWlmCYcha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Grant income</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="avxl:NonOperatingIncomeFromGrants" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-82" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">54,100</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:NonOperatingIncomeFromGrants" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-83" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">149,888</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_ecustom--ResearchAndDevelopmentIncentiveIncome_i01_maCzWba_zkVqNaDBWYBf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development incentive income</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-84" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,547,099</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-85" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,375,025</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_409_eus-gaap--InterestIncomeExpenseNet_i01_maCzWba_zhy7ZFvqrdl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income, net</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:InterestIncomeExpenseNet" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-86" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,261</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestIncomeExpenseNet" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-87" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">179,973</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maCzWba_zTIjeNWm2K26" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign exchange gain (loss), net</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-88" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">267,344</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-89" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,540</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr id="xdx_407_eus-gaap--NonoperatingIncomeExpense_i01T_mtCzWba_maCzRUJ_zCXlEB1reeec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total other income, net</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:NonoperatingIncomeExpense" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-90" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,360,116</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:NonoperatingIncomeExpense" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,830,426</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_mtCzRUJ_maCztMq_zMy8fgalnQw3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss before provision for income taxes</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-92" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,641,069</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-93" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,257,806</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40E_eus-gaap--CurrentIncomeTaxExpenseBenefit_iN_di_msCztMq_zhUSKm2oeD1i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income tax expense, current</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">267,565</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-95" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,664</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_ecustom--NetLossAndComprehensiveLoss_iT_mtCztMq_zvjzrRTnTR7e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss and comprehensive loss</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<span><ix:nonfraction name="avxl:NetLossAndComprehensiveLoss" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-96" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">37,908,634</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="avxl:NetLossAndComprehensiveLoss" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">26,280,470</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_401_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB_zezlgNJuSx7f" style="vertical-align: bottom; background-color: White">
    <td>Net Loss per share</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--EarningsPerShareBasicAndDiluted_i01_zYF3GEcYJAji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 1pt 20pt; text-align: left">Basic and diluted</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-98" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.54</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-99" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.45</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_iB_zNeXK4u9pS5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average number of shares outstanding</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i01_zd3eqztI6eHh" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 1pt 20pt; text-align: left">Basic and diluted</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-100" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">69,802,960</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-101" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">58,194,894</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
</tbody></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">See Accompanying Notes to Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>ANAVEX LIFE SCIENCES CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">CONSOLIDATED STATEMENTS OF CASH FLOWS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">For the years ended September
30, 2021 and 2020<b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_112_zIqPFbMloSj3" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td id="xdx_49A_20201001__20210930_zpYGokKKZWpg" style="font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49C_20191001__20200930_zTwED5w826t3" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_ztHJz4WyeNMi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash Flows used in Operating Activities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--NetIncomeLoss_i01_maCzKrB_zNSVP23fXgB8" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Net loss</td><td style="width: 8%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-102" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,908,634</ix:nonfraction></span></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-103" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,280,470</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zBG7SInmXyVi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operations:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_eus-gaap--ShareBasedCompensation_i02_maCzKrB_zHFzCNYCXSG4" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt">Stock-based compensation</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-104" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,231,403</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-105" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,876,906</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_406_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_z1PEZl71zIQk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in non-cash working capital balances related to operations:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--IncreaseDecreaseInIncomeTaxesReceivable_i02N_di_msCzKrB_zccuanB20qT8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Incentive and tax receivables</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-106" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,287,491</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-107" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,206,595</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCzKrB_zswcMauZydqb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Prepaid expenses and deposits</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-108" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">88,290</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-109" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57,159</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCzKrB_zx9I1NK5e4Ci" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt; text-align: left">Accounts payable</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-110" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">750,727</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-111" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">465,722</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCzKrB_z5tRwgaNcfDh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt; text-align: left">Accrued liabilities</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-112" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,298,200</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-113" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,800,232</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_406_ecustom--DeferredGrantIncome_i02N_di0_msCzKrB_z1adsfk326Zb" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 1pt 20pt; text-align: left">Deferred grant income</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span><ix:nonfraction name="avxl:DeferredGrantIncome" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-114" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">443,831</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="avxl:DeferredGrantIncome" contextref="From2019-10-012020-09-30" format="ixt:zerodash" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-115" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_mtCzKrB_maCzsIN_za90zqbFKTL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash used in operating activities</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-116" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,383,674</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-117" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,287,046</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_zpx1ukf0xdha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash Flows provided by Financing Activities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCz10l_z11SUvlZmvFl" style="vertical-align: bottom; background-color: White">
    <td>Issuance of common shares</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-118" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">153,218,762</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-119" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,754,198</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_eus-gaap--PaymentsOfStockIssuanceCosts_i01N_di_msCz10l_zyneUJNfqm4i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share issue costs</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-120" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,550,921</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-121" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">403,764</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--ProceedsFromWarrantExercises_i01_d0_maCz10l_zTn6359h9mC2" style="vertical-align: bottom; background-color: White">
    <td>Proceeds from exercise of warrants</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromWarrantExercises" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-122" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,466,500</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromWarrantExercises" contextref="From2019-10-012020-09-30" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-123" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_404_eus-gaap--ProceedsFromStockOptionsExercised_i01_d0_maCz10l_zDpmXE4Zdi7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from exercise of stock options</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromStockOptionsExercised" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-124" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,108,060</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromStockOptionsExercised" contextref="From2019-10-012020-09-30" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-125" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCz10l_maCzsIN_ztp8INXY9sD1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash provided by financing activities</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-126" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">153,242,401</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-127" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,350,434</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzsIN_z3T1778SrNkj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Increase in cash and cash equivalents during the period</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-128" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">122,858,727</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-129" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,063,388</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_400_eus-gaap--Cash_iS_zRYrW6NhbSjc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash and cash equivalents, beginning of period</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:Cash" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-130" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,249,018</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:Cash" contextref="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-131" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,185,630</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr id="xdx_402_eus-gaap--Cash_iE_z65Rwh5VbjVi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash and cash equivalents, end of period</td><td style="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:Cash" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-132" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">152,107,745</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:Cash" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-133" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,249,018</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--SupplementalCashFlowInformationRelatedText_iB_z4XJJ0x3VHPg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Supplemental Cash Flow Information</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_ecustom--CashPaidForStateAndLocalMinimumIncomeTaxes_i01_zTqQcEwVBTRg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for state and local minimum income taxes</td><td style="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span><ix:nonfraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-134" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">139,531</ix:nonfraction></span></td><td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="avxl:CashPaidForStateAndLocalMinimumIncomeTaxes" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-135" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">22,664</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td></tr>
</tbody></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">See Accompanying Notes to Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>ANAVEX LIFE SCIENCES CORP.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">For the
years ended September 30, 2021 and 2020<b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_114_z2SizXf5foli" summary="xdx: Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0; padding-right: 0; padding-bottom: 0; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zZCThrhc8PAg" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zF3Pgds8sb78" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_znoiYg5PbhE5" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4B9_z4qbPXChtJNd" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Additional</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Paid-in</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Accumulated</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Par Value</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Capital</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Total</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr id="xdx_43D_c20191001__20200930_eus-gaap--StockholdersEquity_iS_zuyytbnzZjul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Balance, September 30, 2019</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxEFhpx8zTG" title="Balance at beginning, shares" style="width: 9%; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-136" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,650,521</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-137" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,652</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-138" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">153,633,807</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-139" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">133,396,760</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-140" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,289,699</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued under 2019 purchase agreement</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_zAwzHHwDhbTf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 20pt">Purchase shares</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyoppkvOGq3g" title="Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-141" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,564,584</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-142" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,565</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextref="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-143" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,246,733</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0253"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextref="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-144" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0253" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-145" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,254,298</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40F_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_zjSRubdeI4i8" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt">Commitment shares</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98C_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVstWqrDoGQd" title="Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)" style="text-align: right"><span><ix:nonfraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-146" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">68,943</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-147" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">69</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextref="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-148" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">69</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260"><span><ix:nonfraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextref="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-149" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0260" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261"><span><ix:nonfraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextref="From2019-10-012020-09-30" id="fact-identifier-150" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0261" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_ecustom--SharesIssuedPursuantToCashlessExerciseOfOptionInShares_zatF9BpVFQhd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued pursuant to cashless exercise of stock options</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_984_ecustom--SharesIssuedPursuantToCashlessExerciseOptionInShares_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0NDOPPj1Mk9" title="Shares issued pursuant to cashless exercise of options (in shares)" style="text-align: right"><span><ix:nonfraction name="avxl:SharesIssuedPursuantToCashlessExerciseOptionInShares" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-151" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">721</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptionInShares" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-152" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptionInShares" contextref="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="Shares" inside-table="true" id="fact-identifier-153" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267"><span><ix:nonfraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptionInShares" contextref="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-154" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0267" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268"><span><ix:nonfraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptionInShares" contextref="From2019-10-012020-09-30" id="fact-identifier-155" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0268" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_406_ecustom--SharesIssuedDuringPeriodValueUnderSalesAgreement_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued under Sales Agreement, net of share issuance costs</td>
    <td>&nbsp; &nbsp;</td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td id="xdx_98A_ecustom--SharesIssuedDuringPeriodSharesUnderSalesAgreement_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Shares issued under Sales Agreement, net of shares issue costs (in shares)" style="text-align: right">&nbsp; <span><ix:nonfraction name="avxl:SharesIssuedDuringPeriodSharesUnderSalesAgreement" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-156" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,760,429</ix:nonfraction></span></td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td>&nbsp; &nbsp;</td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td style="text-align: right">&nbsp; <span><ix:nonfraction name="avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-157" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,760</ix:nonfraction></span></td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td>&nbsp; &nbsp;</td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td style="text-align: right">&nbsp; <span><ix:nonfraction name="avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement" contextref="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-158" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7,094,376</ix:nonfraction></span></td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td>&nbsp; &nbsp;</td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td style="text-align: right">&nbsp; <span style="-sec-ix-hidden: xdx2ixbrl0274"><span><ix:nonfraction name="avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement" contextref="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-159" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0274" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td>&nbsp; &nbsp;</td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td style="text-align: right">&nbsp; <span><ix:nonfraction name="avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-160" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7,096,136</ix:nonfraction></span></td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
</tr>
<tr id="xdx_40F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zt1GoAfRBvh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" id="fact-identifier-161" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0279" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextref="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-162" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,876,906</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0281"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextref="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-163" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0281" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-164" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,876,906</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_401_eus-gaap--NetIncomeLoss_z02B3HJycKE6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-10-012020-09-30_us-gaap_CommonStockMember" id="fact-identifier-165" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0284" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-166" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0285" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-167" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,280,470</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-168" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,280,470</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr id="xdx_435_c20201001__20210930_eus-gaap--StockholdersEquity_iS_z08MiiNODh41" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, September 30, 2020</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7YR2MjBHtJ8" title="Balance at beginning, shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-169" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">62,045,198</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-170" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">62,047</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-171" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">186,851,752</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-172" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">159,677,230</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-173" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,236,569</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_zRhTyh9PJCs8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued under 2019 purchase agreement Purchase shares</td>
    <td>&nbsp; &nbsp;</td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSpZXgZU5xOg" title="Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)" style="text-align: right">&nbsp; <span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-174" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,007,996</ix:nonfraction></span></td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td>&nbsp; &nbsp;</td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td style="text-align: right">&nbsp; <span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-175" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,008</ix:nonfraction></span></td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td>&nbsp; &nbsp;</td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td style="text-align: right">&nbsp; <span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextref="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-176" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,107,190</ix:nonfraction></span></td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td>&nbsp; &nbsp;</td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td style="text-align: right">&nbsp; <span style="-sec-ix-hidden: xdx2ixbrl0298"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextref="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-177" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0298" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td>&nbsp; &nbsp;</td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td style="text-align: right">&nbsp; <span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-178" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,111,198</ix:nonfraction></span></td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
</tr>
<tr id="xdx_408_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_zN7trONjz9nj" style="vertical-align: bottom; background-color: White">
    <td style="padding: 0 0 0 20pt">Commitment shares</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_pid_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zukxACZy7EPg" title="Commitment shares" style="text-align: right"><span><ix:nonfraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-179" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">78,213</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-180" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">78</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextref="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-181" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">78</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305"><span><ix:nonfraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextref="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-182" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0305" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306"><span><ix:nonfraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextref="From2020-10-01to2021-09-30" id="fact-identifier-183" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0306" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_ecustom--SharesIssuedPursuantToExerciseOfStockOptions_iP3custom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_zmbos9vrqYX1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued pursuant to exercise of stock options</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_988_ecustom--SharesIssuedPursuantToExerciseOfStockOptionsInShares_iP3custom--SharesIssuedPursuantToExerciseOfStockOptions_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zexxSgsrW1X1" title="Shares issued pursuant to exercise of stock options (in shares)" style="text-align: right"><span><ix:nonfraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptionsInShares" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-184" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,421,529</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-185" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,421</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextref="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-186" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,106,639</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312"><span><ix:nonfraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextref="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-187" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0312" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:SharesIssuedPursuantToExerciseOfStockOptions" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-188" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,108,060</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_ecustom--SharesIssuedDuringPeriodValueUnderSalesAgreement_iP3custom--SharesIssuedPursuantToExerciseOfStockOptionsInShares_zCas6tLzui98" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued under Sales Agreement, net of share issuance costs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_ecustom--SharesIssuedDuringPeriodSharesUnderSalesAgreement_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNKrEBjgyhPh" title="Shares issued under Sales Agreement, net of shares issue costs (in shares)" style="text-align: right"><span><ix:nonfraction name="avxl:SharesIssuedDuringPeriodSharesUnderSalesAgreement" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-189" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,634,576</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-190" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,635</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement" contextref="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-191" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">76,664,392</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319"><span><ix:nonfraction name="avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement" contextref="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-192" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0319" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-193" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">76,670,027</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40E_ecustom--SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts_zwNu70KbptXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued pursuant to registered direct offering, net of share issue costs</td>
    <td>&nbsp; &nbsp;</td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td style="text-align: right"><p id="xdx_98D_ecustom--SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCostsInShares_iP3custom--SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEwSzaJe0jr6" title="Shares issued pursuant to registered direct offering, net of share issue costs (in shares)" style="margin-top: 0; margin-bottom: 0">&nbsp;<span><ix:nonfraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCostsInShares" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-194" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,380,953</ix:nonfraction></span></p></td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td>&nbsp; &nbsp;</td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td style="text-align: right">&nbsp; <span><ix:nonfraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-195" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,381</ix:nonfraction></span></td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td>&nbsp; &nbsp;</td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td style="text-align: right">&nbsp; <span><ix:nonfraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" contextref="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-196" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">46,900,600</ix:nonfraction></span></td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td>&nbsp; &nbsp;</td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td style="text-align: right">&nbsp; <span style="-sec-ix-hidden: xdx2ixbrl0326"><span><ix:nonfraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" contextref="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-197" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0326" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td>&nbsp; &nbsp;</td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
    <td style="text-align: right">&nbsp; <span><ix:nonfraction name="avxl:SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCosts" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-198" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">46,902,981</ix:nonfraction></span></td>
    <td style="text-align: left">&nbsp; &nbsp;</td>
</tr>
<tr id="xdx_401_ecustom--SharesIssuedPusuantToExerciseOfWarrants_iP3custom--SharesIssuedPursuantToRegisteredDirectOfferingNetOfShareIssueCostsInShares_z7KjmEcXHQHc" style="vertical-align: bottom; background-color: White">
    <td>Shares issued pursuant to exercise of warrants</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98A_ecustom--SharesIssuedPusuantToExerciseOfWarrantsInShares_iP3custom--SharesIssuedPusuantToExerciseOfWarrants_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFFGiHizk7G4" title="Shares issued pusuant to exercise of warrants (in shares)" style="text-align: right"><span><ix:nonfraction name="avxl:SharesIssuedPusuantToExerciseOfWarrantsInShares" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-199" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">350,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:SharesIssuedPusuantToExerciseOfWarrants" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-200" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">350</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:SharesIssuedPusuantToExerciseOfWarrants" contextref="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-201" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,466,150</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333"><span><ix:nonfraction name="avxl:SharesIssuedPusuantToExerciseOfWarrants" contextref="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-202" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0333" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:SharesIssuedPusuantToExerciseOfWarrants" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-203" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,466,500</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" id="fact-identifier-204" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0338" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextref="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-205" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,231,403</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0340"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextref="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" id="fact-identifier-206" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0340" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-207" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,231,403</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_407_eus-gaap--NetIncomeLoss_zVRxcFMsCxQa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-10-012021-09-30_us-gaap_CommonStockMember" id="fact-identifier-208" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0343" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-10-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-209" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0344" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-10-012021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-210" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,908,634</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-211" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,908,634</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr id="xdx_43A_c20201001__20210930_eus-gaap--StockholdersEquity_iE_zFKjLKiSGjT8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, September 30, 2021</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20201001__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGo2EeUO3uO" title="Balance at ending, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-212" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,918,465</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-213" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,920</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-214" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">348,328,048</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-215" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">197,585,864</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 2.5pt">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-216" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,818,104</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td></tr>
</tbody></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">See Accompanying Notes to Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">September 30, 2021 – Page 1</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-217" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_801_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zcW6ikbvQdU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Note 1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span style="text-decoration: underline"><span id="xdx_821_zThCcZnecnS9">Business Description and Basis of
Presentation</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Business</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Anavex Life Sciences Corp. (“Anavex”
or the “Company”) <span style="color: black">is a clinical stage biopharmaceutical company engaged in the development
of differentiated therapeutics by applying precision medicine to central nervous system (“CNS”) diseases with high
unmet need. Anavex analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will
receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. </span>The Company’s
lead compound ANAVEX®2-73 <span style="color: black">is being developed to treat Alzheimer’s disease, Parkinson’s
disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological
monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (“MECP2”)</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">On May 25, 2021, the Company filed
a Certificate of Amendment to its Articles of Incorporation with the Secretary of the State of Nevada effecting an amendment to
increase the number of authorized shares of the Company’s common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210525_zpFa3MWKbcMj"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-05-25" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-218" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></span> per share, from 100,000,000 shares
to <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20210525_ztSb92YqRXB2"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-05-25" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-219" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000,000</ix:nonfraction></span></span> shares. The Certificate of Amendment was approved by the Company’s stockholders at an annual meeting of stockholders
on May 25, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify">Basis of
Presentation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These consolidated financial statements
have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and the
instructions to Form 10-K and have been prepared under the accounting principles generally accepted in the United States of America
(“U.S. GAAP”).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Liquidity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">All of the Company’s potential
drug compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts
will be successful or, if successful, that its potential drug compounds will ever be approved for sale or generate commercial revenues.
To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative
cash flows for the foreseeable future and cannot predict when, if ever, its business might become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Management believes that the current
working capital position will be sufficient to meet the Company’s working capital requirements beyond the next 12 months
after the date that these consolidated financial statements are issued. The process of drug development can be costly, and the
timing and outcomes of clinical trials is uncertain.&nbsp;The assumptions upon which the Company has based its estimates are routinely
evaluated and may be subject to change.&nbsp;The actual amount of the Company’s expenditures will vary depending upon a number
of factors including but not limited to the design, timing and duration of future clinical trials, the progress of the Company’s
research and development programs and the level of financial resources available. The Company has the ability to adjust its operating
plan spending levels based on the timing of future clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Other than our rights related to
the Sales Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when
needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional
financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and
development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<ix:exclude><p id="xdx_238_zJtUHhp8jrB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 55; Value: 1 -->
    <div id="xdx_23D_zHfm8LpNc6Da" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zYPc0NjkDzR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zVNPq58Fd8I8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_238_zjTInTImWQZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Consolidated Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_239_zklWLNsHv1lc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">September 30, 2021 – Page 2</p></ix:exclude>


<ix:exclude><p id="xdx_23F_z4zURTwJe9Ne" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zUY7b7hbk6F7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><p id="xdx_237_zoBOdXBK6xjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Note 1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;	<span style="text-decoration: underline">Business Description and Basis of
Presentation</span> – Continued</p></ix:exclude>

<ix:exclude><p id="xdx_235_zmbhxEKeJFSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_231_z3W4RhPN2bgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Coronavirus Disease 2019 (COVID-19)</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The recent global outbreak of COVID-19
has not had a material impact on the Company’s result of operations or financial condition for the year ended September 30,
2021. However, the pandemic continues to rapidly evolve as of the date these consolidated financial statements are issued and has
created a dynamic and uncertain situation in the global economy. As such, it is uncertain as to the full magnitude that the outbreak
will have on the Company’s financial condition and future results of operations. Management is actively monitoring the global
situation on its business, including on its clinical trials and operations and financial condition. Given the daily evolution of
the COVID-19 situation, and the global responses to curb its spread, the Company is not able to estimate the effects COVID-19 may
have on its future results of operations or financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-220" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_z8r0x1mWk49b" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 2	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span style="text-decoration: underline"><span id="xdx_820_zvqQGXWqBP6">Summary of Significant Accounting Policies</span></span></p>

<span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:UseOfEstimates" inside-table="false" id="fact-identifier-221" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_840_eus-gaap--UseOfEstimates_zVgcYsp0IFD" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tbody><tr style="vertical-align: top">
<td style="width: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">a)</span></td>
<td id="xdx_86C_z9imstW2xZTf" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i style="font-style: normal; font-weight: normal"><span id="xdx_862_zfujp8jcIlK1">Use of Estimates</span></i></span></td></tr>
</tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.55pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The preparation of financial statements
in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The
Company regularly evaluates estimates and assumptions related to accounting for research and development costs, incentive income
receivable, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation and loss contingencies.
The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes
to be reasonable under the circumstances, the results of which form the basis for making judgments about the book values of assets
and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced
by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-222" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_z8CNEygs7eA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 42.5pt"></td><td style="width: 18pt"><span style="font-size: 10pt">b)</span></td><td style="text-align: justify"><span style="font-size: 10pt"><i style="font-style: normal; font-weight: normal"><span id="xdx_864_ztWSNJOFvGJf">Principles of Consolidation</span></i></span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.5pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">These consolidated financial statements
include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited. (“Anavex
Australia”), a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws
of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company
transactions and balances have been eliminated.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-223" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_846_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zmt5m0Ys9K03" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font-size: 10pt">c)</span></td><td style="text-align: justify"><span style="font-size: 10pt"><i style="font-style: normal; font-weight: normal"><span id="xdx_86D_zs8z9PJUCaH4">Cash and equivalents</span></i></span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.55pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span><i style="font-style: normal; font-weight: normal">The
Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months
from the date of purchase to be cash equivalents</i></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><i style="font-style: normal; font-weight: normal">Highly liquid investments
that are considered cash equivalents include money market&nbsp;accounts, money market&nbsp;funds&nbsp;and&nbsp;certificates of
deposit. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. The
Company</i>’<i style="font-style: normal; font-weight: normal">s investment policy allows for investments in domestic money market certificates, certificates of deposit,
money market funds, commercial papers, bonds or commercial papers, and establishes diversification and credit quality requirements
and limits investments by maturity and issuer. The Company currently maintains its investments at one large well known financial
institution.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<ix:exclude><p id="xdx_235_zZdNtVYRhdAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: gray"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 56; Value: 1 -->
    <div id="xdx_239_zhV68oKNkP8" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zlxnTNDiN9e5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: gray">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_236_ztHgD8Lic8hl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zX3nQFlk73pl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Consolidated Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zGZ6lWngZxY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">September 30, 2021 – Page 3</p></ix:exclude>


<ix:exclude><p id="xdx_238_zKOS26H3ya8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: gray">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zgf0cfsTopJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;	<span style="text-decoration: underline">Summary of Significant Accounting Policies</span> –
(continued)</p></ix:exclude>

<ix:exclude><p id="xdx_231_zvcjK5WBzwJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_238_zjn301V7L3x8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font-size: 10pt">c)</span></td><td style="text-align: justify"><span style="font-size: 10pt"><i style="font-style: normal; font-weight: normal">Cash and equivalents </i></span><span style="font-size: 10pt">–
(continued)</span></td></tr></tbody></table></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.55pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><i style="font-style: normal; font-weight: normal">The Company maintains
its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the Federal
Deposit Insurance Corporation (FDIC) up to $<span id="xdx_904_eus-gaap--CashFDICInsuredAmount_iI_c20210930_zaCmXQGIMpAb" title="Federal Deposit Insurance Corporation"><span><ix:nonfraction name="us-gaap:CashFDICInsuredAmount" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-224" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">250,000</ix:nonfraction></span></span>, under current regulations. The Company mitigates this risk by maintaining
its cash balances in a large well known financial institutions.</i> <i style="font-style: normal; font-weight: normal">The Company has not experienced any losses in such accounts.</i></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" inside-table="false" id="fact-identifier-225" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zdaMvvqs4e19" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font-size: 10pt">d)</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span id="xdx_86F_z660KbqtR1W2">Research and Development Expenses</span></span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Research and development costs
are expensed as incurred. These expenses are comprised of the costs of the Company’s proprietary research and development
efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and stock-based compensation
expense, contract services including external research and development expenses incurred under arrangements with third parties
such as contract research organizations (“CROs”), facilities costs, overhead costs and other related expenses. Milestone
payments made by the Company to third parties are expensed when the specific milestone has been achieved. Manufacturing costs are
expensed as incurred in accordance with Accounting Standard Codification (“ASC”) 730, Research and Development, as
these materials have no alternative future use outside of their intended use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="color: black">Nonrefundable
advance payments for goods or services that will be used or rendered for future research and development activities are deferred
and amortized over the </span>period<span style="color: black"> that the goods are delivered, or the related services are performed,
subject to an assessment of recoverability. The Company makes estimates of costs incurred in relation to external CROs, and clinical
site costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies including the
phase or completion of events, invoices received and contracted costs. Judgments and estimates are made in determining
the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s
historical accrual estimates have not been materially different from actual costs. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">In addition, the Company incurs
expenses in respect of intellectual property costs relating to patents and trademarks. The probability of success and length of
time to develop commercial applications of the drugs subject to the underlying patent and trademark costs is difficult to determine
and numerous risks and uncertainties exist with respect to the timely completion of the development projects. There is no assurance
the drugs subject to the underlying patents and trademarks will ever be successfully commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Due to these risks and uncertainties,
the patent and trademark costs do not meet the definition of an asset and thus are expensed as incurred within general and administrative
expenses.</p>

<ix:exclude><p id="xdx_23A_zX3z6nyvYPee" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zGLyN1PUTm1d" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 57; Value: 1 -->
    <div id="xdx_23A_z2HLXisvJrX" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zLTHArhErSj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zi7IqpkHLOcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zXhfN5sXGBw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Consolidated Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zmUbJu0MIR9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0">September 30, 2021 – Page 4</p></ix:exclude>


<ix:exclude><p id="xdx_23A_z1YlWfaz7GIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zIyDSaP3eVag" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;	<span style="text-decoration: underline">Summary of Significant Accounting Policies</span> –
(continued)</p></ix:exclude>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:RevenueRecognitionIncentives" inside-table="false" id="fact-identifier-226" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84C_eus-gaap--RevenueRecognitionIncentives_zh5PSDlXCSxb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font-size: 10pt">e)</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span id="xdx_861_zuHWQs8ZUfU2">Research and Development Incentive Income</span></span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company is eligible to obtain
certain research and development tax credits, including the Australian research and development tax incentive credit (the “Australia
R&amp;D credit”) through a program administered through the Australian Tax Office (the “ATO”), which provides
for a cash refund based on a percentage of certain research and development activities undertaken in Australia by the Company’s
wholly owned subsidiary, Anavex Australia Pty Ltd. (“Anavex Australia”). The cash refund is available to eligible companies
with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The tax incentives are available
on the basis of specific criteria with which the Company must comply. Although the tax incentive may be administered through the
local tax authority, the Company has accounted for the incentives outside of the scope of ASC Topic 740, Income Taxes (“ASC
740”), since the incentives are not linked to the Company’s taxable income and can be realized regardless of whether
the Company has generated taxable income in the respective jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">With respect to the Australia R&amp;D
credit, Anavex Australia may be eligible to receive the cash refund for certain research and development expenses incurred by Anavex
Australia outside of Australia, to the extent such expenses are pre-approved by the Australian authority pursuant to an advanced
overseas finding application. The Company accrues for the amount of cash refund it expects to receive in relation to research and
development expenses outside of Australia only to the extent it has received advanced approval from the Department of Industry,
Innovation and Science in Australia, pursuant to an approved advanced overseas finding application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">In addition, Anavex Australia and
Anavex Canada incur Goods and Services Tax (GST) on certain services provided by local vendors. As a domestic entity in those jurisdictions,
Anavex Australia and Anavex Canada are entitled to a refund of the GST paid. Similarly, Anavex Germany incurs Value Added Tax (VAT)
on certain services provided by local vendors, to which it is entitled to a refund of such VAT paid. The Company’s estimate
of the amount of cash refund it expects to receive related to GST and VAT incurred is included in Incentive and tax receivables
in the accompanying consolidated balance sheets.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-227" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84B_eus-gaap--EarningsPerSharePolicyTextBlock_zxsWbMjI0LW4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font-size: 10pt">f)</span></td><td style="text-align: justify"><span style="font-size: 10pt"><i style="font-style: normal; font-weight: normal"><span id="xdx_86D_zkwAAVoy5mE8">Basic and Diluted Loss per Share</span></i></span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.55pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Basic income/(loss) per common
share is computed by dividing net income/(loss) available to common stockholders by the weighted average number of common shares
outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common
stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect
of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially
dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are potentially dilutive
securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<ix:exclude><p id="xdx_23C_zCrqpiHaVDUg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 58; Value: 1 -->
    <div id="xdx_230_zz6KVUbxamme" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_ztZ07atSOkYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_z0DvpZGCT8t6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_231_zv4f4drXFLy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Consolidated Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zxL3qFoOwzNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">September 30, 2021 – Page 5</p></ix:exclude>


<ix:exclude><p id="xdx_237_zkAetDIMu8Nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p></ix:exclude>




<ix:exclude><p id="xdx_233_zBJbd7XvT9u2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: lime"></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zdkCXTXHHpA6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;	<span style="text-decoration: underline">Summary of Significant Accounting Policies</span> –
(continued)</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zprUDXazlZ3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_235_zbShHvAHoX08" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font-size: 10pt">f)</span></td><td style="text-align: justify"><span style="font-size: 10pt"><i style="font-style: normal; font-weight: normal">Basic
                                                                                                                 and Diluted Loss
                                                                                                                 per Share</i>
                                                                                                                 – (continued)</span></td></tr></tbody></table></ix:exclude>

<ix:exclude><p id="xdx_233_z77ooXNUiA8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.55pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">As of September 30, 2021, diluted
loss per share excludes <span id="xdx_90A_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20201001__20210930_pdd" title="Loss per share for potentially dilutive common shares"><span><ix:nonfraction name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-228" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,540,903</ix:nonfraction></span></span> (2020 – <span id="xdx_90D_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20191001__20200930_pdd" title="Loss per share for potentially dilutive common shares"><span><ix:nonfraction name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-229" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,576,266</ix:nonfraction></span></span>) potentially dilutive common shares related to outstanding options
and warrants, as their effect was anti-dilutive.</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" inside-table="false" id="fact-identifier-230" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zJHHqfK4T0W1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; color: gray"><tbody><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font-size: 10pt; color: #000000">g)</span></td><td style="text-align: justify"><span style="font-size: 10pt; color: #000000"><i style="font-style: normal; font-weight: normal"><span id="xdx_86C_zwSmg4jXzafc">Financial
                                                                                                    Instruments</span></i></span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.55pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The book value of the Company’s
financial instruments, consisting of cash and equivalents, incentive and tax receivables, and accounts payable and accrued liabilities
approximate their fair value due to the short-term maturity of such instruments. Unless otherwise noted, it is management’s
opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-231" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84C_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zYI6GDSbgPe9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font-size: 10pt">h)</span></td><td style="text-align: justify"><span style="font-size: 10pt"><i style="font-style: normal; font-weight: normal"><span id="xdx_86E_zk3QMVah9BPk">Foreign Currency Translation</span></i></span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.55pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The functional currency of the
Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing
at the balance sheet date and non-monetary items are translated at exchange rates prevailing when the assets were acquired, or
obligations incurred. Foreign currency denominated expense items are translated at exchange rates prevailing on the transaction
date. Unrealized gains or losses arising from the translations are credited or charged to income in the period in which they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company has determined that
the functional currency of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd. is also the US dollar.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-232" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z1qoZvk0tDw" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font-size: 10pt">i)</span></td><td><span style="font-size: 10pt"><span id="xdx_865_z6jJR9Rejgih">Segment and Geographic Reporting</span></span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.55pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Operating segments are defined
as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision
maker or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations
and manages its business as one operating segment, which is the business of developing novel therapies for the management of CNS
diseases.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="avxl:GrantIncomePolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-233" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_843_ecustom--GrantIncomePolicyTextBlock_zww6LSOD1Li7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font-size: 10pt">j)</span></td><td style="text-align: justify"><span style="font-size: 10pt"><span id="xdx_861_zisWsujiWc7f">Grant Income</span></span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="color: black">Grant
income is recognized at the fair value of the grant when it is received, and all substantive conditions have been satisfied. </span>Grants
received from government and other agencies in advance of the specific research and development costs to which they relate are
deferred and recognized in the consolidated statement of operations in the period they are earned and when the related research
and development costs are incurred.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-234" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zlDUTsuyhY9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font-size: 10pt">k)</span></td><td style="text-align: justify"><span style="font-size: 10pt"><i style="font-style: normal; font-weight: normal"><span id="xdx_861_zBuHnjUwQVA2">Income Taxes</span></i></span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.55pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company follows the provisions
of ASC 740, which requires the asset and liability method of accounting for income taxes. Under the asset and liability method,
deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between
the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets
and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 59; Value: 1 -->
    <div id="xdx_237_zoFkJ6FeWIq5" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zgOKoQ82ZnH9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><p id="xdx_237_zoAXTTRB4eN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zsVHN7OSOtBj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_23A_ziwsDAJ5jZSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Consolidated Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_238_zcZdH9Ck5c2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0">September 30, 2021 – Page 6</p></ix:exclude>


<ix:exclude><p id="xdx_239_zrNXEsEcBIch" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_232_z2BvS3lDtyGd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 2	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span style="text-decoration: underline">Summary of
Significant Accounting Policies</span> – (continued)</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zFqdvl9WzTT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_230_zL6betQwQfp7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font-size: 10pt">k)</span></td><td style="text-align: justify"><span style="font-size: 10pt"><i style="font-style: normal; font-weight: normal">Income Taxes – (continued) </i></span></td></tr></tbody></table></ix:exclude>

<ix:exclude><p id="xdx_232_zopl3MJIc7Gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.55pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company follows the provisions
of ASC 740 regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial
statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions
are initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized
upon ultimate settlement with the tax authority assuming full knowledge of the position and all relevant facts. Application requires
numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions
and tax benefits, and its recognized tax positions and tax benefits may not accurately anticipate actual outcomes. As additional
information is obtained, there may be a need to periodically adjust the recognized tax positions and tax benefits. These periodic
adjustments may have a material impact on the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company recognizes interest
and penalties related to current income tax expense on the interest income, net line, in the accompanying consolidated statement
of operations. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated balance sheets.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-235" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_849_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_zr30DJuToXSj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font-size: 10pt">l)</span></td><td style="text-align: justify"><span style="font-size: 10pt"><i style="font-style: normal; font-weight: normal"><span id="xdx_866_zPKEXlNv64Sd">Stock-based Compensation</span></i></span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.55pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company accounts for all stock-based
payments and awards under the fair value method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The fair value of all share purchase
options and warrants are expensed over their contractual vesting period, or over the expected performance period for only the portion
of awards expected to vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Compensation costs for stock-based
payments with graded vesting are recognized on a straight-line basis. Stock based compensation expense is adjusted for actual forfeitures
of unvested awards as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company has granted share purchase
option awards that vest upon achievement of certain performance criteria, or milestone-based awards. The Company estimates an implicit
service period for achieving performance criteria for each award and recognizes the resulting fair value as expense over the implicit
service period when it concludes that achieving the performance criteria is probable. The Company periodically reviews and updates
as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance awards
vest upon achievement of the performance criteria.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company uses the Black-Scholes
option valuation model to calculate the fair value of share purchase options and warrants at the date of the grant. This model
requires the input of subjective assumptions, including the expected price volatility, expected life and estimated forfeitures of
each&nbsp;award. The Company uses the U.S. Treasury daily treasury yield curve rates for the expected term of the option as the
risk-free rate. The expected term represents the period that options granted are expected to be outstanding using the simplified
method. The Company’s historical share option exercise experience does not provide a reasonable basis for estimating the
expected term. Expected volatility is based on the average of the daily share price changes over the expected term. The Company does
not estimate forfeitures and elects to record actual forfeitures as they occur. The Company has not paid any dividends on its common
stock historically, therefore no assumption of dividend payments is made in the model. These assumptions consist of estimates of
future market conditions, which are inherently uncertain, and therefore, are subject to management’s judgment. Changes in
these assumptions can materially affect the fair value estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 42.55pt; text-align: justify">The purchase price
of options or warrants may be paid in cash or, if approved by the Company’s compensation committee in advance, “net settled”
in shares of the Company’s common stock. In a net settlement of an option or warrant, the Company does not receive payment of the
exercise price from the holder but reduces the number of shares of common stock issued upon the exercise of the stock option or warrant
by the smallest number of whole shares that have an aggregate fair market value equal to or over the aggregate exercise price for the
option shares covered by the option or warrant exercised. Shares issued pursuant to the exercise of options and warrants are issued from
the Company’s treasury.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;&nbsp;</p>

<ix:exclude><p id="xdx_230_zYGdBWz0EQVe" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 60; Value: 1 -->
    <div id="xdx_238_zkO5VylmTg57" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zNpb0b5VCNWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zwd7z1NnO1G2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_239_z0fOUmcnupd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Consolidated Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_232_zlIobTgvxHn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">September 30, 2021 – Page 7</p></ix:exclude>


<ix:exclude><p id="xdx_233_zfljiPMc3Dqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zOYm13LwFN6e" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: lime"></span></p>

<ix:exclude><p id="xdx_237_zN6qTJ7IaD11" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;	<span style="text-decoration: underline">Summary of Significant Accounting Policies</span> –
(continued)</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-236" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_849_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zpIz8jSs1lah" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tbody><tr style="vertical-align: top">
<td style="width: 42.55pt">&nbsp;</td>
<td style="width: 18pt"><span style="font-size: 10pt">m)</span></td>
<td style="text-align: justify"><span style="font-size: 10pt"><i style="font-style: normal; font-weight: normal"><span id="xdx_866_zVg4ra4P1uwh">Fair Value Measurements</span></i></span></td></tr>
</tbody></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Fair value is defined as the exchange
price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities
that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure
fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels
of inputs used to measure fair value are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt">Level 1 - 	quoted prices (unadjusted) in active markets
for identical assets or liabilities that the Company has the ability to access at the measurement date;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Level 2 - observable inputs other
than Level 1, quoted prices for similar assets or liabilities in active 		markets, quoted prices for identical or similar
assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant
value drivers are observable; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Level 3 - 	assets and liabilities
whose significant value drivers are unobservable by little or no market activity and that are significant to the fair value of
the assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">At September 30, 2021 and 2020,
the Company did not have any Level 3 assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-237" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFVC5RP8zSn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">n) <span id="xdx_864_zyWjZtLSTwo2">Recent Accounting Pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="background-color: white">In
December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes (ASC 740)", which is intended to simplify
various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying
and amending existing guidance to improve consistent application. ASU 2019-12 will be effective for the Company on October 1, 2021. The
Company does not expect such guidance to have a material impact on the Company’s operations, financial condition, or cash flows.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

</ix:nonnumeric></span></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="avxl:AccuredLiabilitiesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-238" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_806_ecustom--AccuredLiabilitiesTextBlock_zxoiNuv7Xnm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;	<span style="text-decoration: underline"><span id="xdx_827_zpW6e43zH2kd">Accrued Liabilities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt">The principal components of accrued liabilities consists
of:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-239" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zcPaN4hr67J7" summary="xdx: Disclosure - Accrued Liabilities (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B2_z7Plx4iSC8v5" style="display: none">Schedule of  components of accrued liabilities</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49E_20210930_zmnRgWiXLw8b" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49E_20200930_zFMXOQqm5Ro4" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
<tr id="xdx_40E_ecustom--ClinicalSiteCostsAndPatientVisits_iI_maALCz8Zv_maALCzYmb_zzdtVtjuyT9a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Clinical site costs and patient visits</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="avxl:ClinicalSiteCostsAndPatientVisits" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-240" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,035,800</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="avxl:ClinicalSiteCostsAndPatientVisits" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-241" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">760,900</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_eus-gaap--AccruedBonusesCurrent_iI_maALCz8Zv_maALCzYmb_zlAUMHeNrcxb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued compensation and benefits</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AccruedBonusesCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-242" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,201,903</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AccruedBonusesCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-243" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">567,805</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_402_ecustom--FixedContractAccruals_iI_maALCz8Zv_maALCzYmb_zzMYdLPwX1dl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed contract accruals</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:FixedContractAccruals" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-244" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">649,649</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:FixedContractAccruals" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-245" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">367,429</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40B_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCz8Zv_maALCzYmb_zNlgYQ8QbP9e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">All other accrued liabilities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-246" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,727,422</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-247" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,620,440</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCz8Zv_mtALCzYmb_zlSHflTHmft5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255)">&nbsp;Total accrued liabilities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-248" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,614,774</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-249" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,316,574</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
</tbody></table></ix:nonnumeric></span>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt">&nbsp;</p>

<ix:exclude><p id="xdx_237_zbL68PrONF7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 61; Value: 1 -->
    <div id="xdx_238_zBhbMNCG054k" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_z779TP3H9sz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt">&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Consolidated Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">September 30, 2021 – Page 8</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="avxl:OtherIncomeDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-250" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_805_ecustom--OtherIncomeDisclosureTextBlock_zeHzbIlcM8R2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;	<span style="text-decoration: underline"><span id="xdx_827_zZbEnjIjMebc">Other Income</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">Grant income</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">During the
year ended September 30, 2021, the Company received $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ParkinsonMember_zZtEAGTvxc4g" title="Research and development incentive income"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextref="From2020-10-012021-09-30_custom_ParkinsonMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-251" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">497,931</ix:nonfraction></span></span> of a $995,862 research grant awarded by the Michael J. Fox Foundation
for Parkinson’s Research. The grant will be used to fund a clinical trial of the Company’s lead compound, ANAVEX<sup>®</sup>2-73
related to Parkinson’s disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">The grant
income is being deferred when received and amortized to other income as the related research and development expenditures are incurred.
During the year ended September 30, 2021, the Company recognized $<span id="xdx_90A_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20201001__20210930_zRXdiIW8aJjl" title="Grant income"><span><ix:nonfraction name="avxl:NonOperatingIncomeFromGrant" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-252" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">54,100</ix:nonfraction></span></span> of this grant on its statements of operations within grant
income. At September 30, 2021 an amount of $<span id="xdx_906_eus-gaap--OtherIncome_c20201001__20210930_zfUywFWGth0b" title="Other income"><span><ix:nonfraction name="us-gaap:OtherIncome" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-253" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">443,831</ix:nonfraction></span></span> (2020: $<span id="xdx_90C_eus-gaap--OtherIncome_c20191001__20200930_zmP4eiI6UnPf" style="display: none"><span><ix:nonfraction name="us-gaap:OtherIncome" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-254" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span>Nil) of this grant is recorded as deferred grant income, representing
the amount of this grant which has not yet been amortized to other income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">During the
year ended September 30, 2017, the Company was awarded grant funding in the amount of $<span id="xdx_908_ecustom--NonOperatingIncomeFromGrant_c20161001__20170930_pp0p0" title="Grant income"><span><ix:nonfraction name="avxl:NonOperatingIncomeFromGrant" contextref="From2016-10-012017-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-255" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">597,886</ix:nonfraction></span></span>. The grant was received in equal
quarterly installments over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment
to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">The grant
income was deferred when received and amortized to other income as the related research and development expenditures were incurred.
During the year ended September 30, 2021, the Company recognized $<span style="display: none"></span>Nil (2020: $<span id="xdx_907_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20191001__20200930_z2FgzHyM9Hwh"><span><ix:nonfraction name="avxl:NonOperatingIncomeFromGrant" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-256" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">149,888</ix:nonfraction></span></span>) of this grant on its statement of operations
as a component of other income. At September 30, 2020, the Company had recognized the full amount of grant funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">Research
and development incentive income</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">Research
and development incentive income represents income earned by the Company’s Australian subsidiary, of the <span style="color: black">Australian
research and development incentive credit, </span>(the “ATO R&amp;D Credit”).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">During the
year ended September 30, 2021, the Company recorded research and development incentive income of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20201001__20210930_pp0p0" title="Research and development incentive income"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-257" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,547,099</ix:nonfraction></span></span> (AUD <span id="xdx_90E_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20210930__srt--CurrencyAxis__currency--AUD_z3TIsmO2ZRAa" title="Research and development incentive income"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextref="From2020-10-012021-09-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-258" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,068,993</ix:nonfraction></span></span>) (2020:
$<span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20191001__20200930_zGBaOig94O1i" title="Research and development incentive income"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-259" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,375,025</ix:nonfraction></span></span> (AUD <span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20191001__20200930__srt--CurrencyAxis__currency--AUD_zbPOgKNmw7P1" title="Research and development incentive income"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextref="From2019-10-012020-09-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-260" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,392,266</ix:nonfraction></span></span>)) in respect of the ATO R&amp;D Credit for eligible research and development expenses incurred during
the year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 45pt; text-align: justify; background-color: white">As
a matter of course, the Company may be subject to pre-issue review or audit by the ATO. The Company was notified that the ATO is performing
a pre-issue review of the 2020 research and development incentive income return. The Company is responding to questions and requests for
information and does not expect an adverse finding.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&nbsp;</p>

<ix:exclude><p id="xdx_23D_zthNO2lSelm7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 62; Value: 1 -->
    <div id="xdx_234_zkWUafPJleZ" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zkZ64qvi6m4g" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zQC06W3zGb4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zLLWlLlpSOfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Consolidated Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zO1gVlpaIHFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">September 30, 2021 – Page 9</p></ix:exclude>


<ix:exclude><p id="xdx_23B_z6Uy3qAf0LG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="avxl:EquityOfferingAgreementsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-261" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_80F_ecustom--EquityOfferingAgreementsTextBlock_z2RKhkU9kBo3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;	<span style="text-decoration: underline"><span id="xdx_823_zg8snibm26jd">Equity Offerings</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Common Stock</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Common shares are voting and are
entitled to dividends as declared at the discretion of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Preferred Stock</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company’s Board of Directors&nbsp;(the
“Board”)&nbsp;has the authority to issue preferred stock in one or more series and to fix the rights, preferences,
privileges, restrictions and the number of shares constituting any series or the designation of the series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Registered Direct Offering</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">On June 22, 2021, the Company and
Deep Track Capital entered into a securities purchase agreement pursuant to which the Company sold to Deep Track Capital an aggregate
of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210601__20210622__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Share issued for offering, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-06-012021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-262" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,380,953</ix:nonfraction></span> </span>shares of common stock at $<span id="xdx_906_eus-gaap--SharePrice_c20210622__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0d" title="Common stock price"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" unitref="USDPShares" inside-table="false" id="fact-identifier-263" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21</ix:nonfraction></span></span> per share in a registered direct offering, for gross proceeds of $<span id="xdx_90C_ecustom--GrossProceedsFromSaleOfCommonStock_c20210601__20210622__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross proceeds from sale of common stock"><span><ix:nonfraction name="avxl:GrossProceedsFromSaleOfCommonStock" contextref="From2021-06-012021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-264" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50,000,013</ix:nonfraction></span></span>. Net proceeds
of the offering were $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210601__20210622__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceed from offering"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextref="From2021-06-012021-06-22_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-265" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,902,981</ix:nonfraction></span></span> after deducting offering fees and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Sales Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company entered into a Controlled
Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020 (the “Sales Agreement”)
with Cantor Fitzgerald&nbsp;&amp; Co. and SVB Leerink LLC (together the “Sales Agents”), pursuant to which the Company
may offer and sell shares of common stock registered under an effective registration statement from time to time through the Sales
Agents (the “Offering”).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Upon delivery of a placement notice
based on the Company’s instructions and subject to the terms and conditions of the Sales Agreement, the Sales Agents may
sell the Shares by methods deemed to be an “at the market offering” offering, in negotiated transactions at market
prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by
law, including negotiated transactions, subject to the prior written consent of the Company. The Company is not obligated to make
any sales of Shares under the Sales Agreement. The Company or Sales Agents may suspend or terminate the offering of Shares upon
notice to the other party, subject to certain conditions. The Sales Agents will act as agent on a commercially reasonable efforts
basis consistent with their normal trading and sales practices and applicable state and federal law, rules&nbsp;and regulations
and the rules&nbsp;of Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company has agreed to pay
the Sales Agents commissions for their services of up to<span id="xdx_904_ecustom--PercentageOfGrossProceedsFromSales_dp_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zfLYMSF0I7Dh" title="Percentage of gross proceeds from sales"> <span><ix:nonfraction name="avxl:PercentageOfGrossProceedsFromSales" contextref="From2020-10-012021-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-266" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.0</ix:nonfraction></span></span>% of the gross proceeds from the sale of the Shares pursuant to the
Sales Agreement. The Company also agreed to provide the Sales Agents with customary indemnification and contribution rights. During
the year ended September 30, 2021, <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Share issued for offering, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-10-012021-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-267" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,634,576</ix:nonfraction></span></span> shares were sold pursuant to the Offering for gross proceeds of $<span id="xdx_901_ecustom--GrossProceedsFromSaleOfCommonStock_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross proceeds from sale of common stock"><span><ix:nonfraction name="avxl:GrossProceedsFromSaleOfCommonStock" contextref="From2020-10-012021-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-268" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">79,107,550</ix:nonfraction></span></span> (net
proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceed from offering"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextref="From2020-10-012021-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-269" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">76,670,027</ix:nonfraction></span></span> after deducting offering expenses) (2020: <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pdd" title="Share issued for offering, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-270" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,760,429</ix:nonfraction></span> </span>shares were sold for gross proceeds of $<span id="xdx_909_ecustom--GrossProceedsFromSaleOfCommonStock_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross proceeds from sale of common stock"><span><ix:nonfraction name="avxl:GrossProceedsFromSaleOfCommonStock" contextref="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-271" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7,499,900</ix:nonfraction></span></span>
(net proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Proceed from offering"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextref="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-272" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,096,136</ix:nonfraction></span></span>)). At September 30, 2021, an amount of $<span id="xdx_901_ecustom--SalesOfAgreementAmount_iI_c20210930_zZAmoCNnUkQ7" title="Sales of agreement amount"><span><ix:nonfraction name="avxl:SalesOfAgreementAmount" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-273" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">163,392,550</ix:nonfraction></span></span> was registered pursuant to an effective registration
statement and available to be sold under the Sales Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<ix:exclude><p id="xdx_230_zzTG6hqgN736" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 63; Value: 1 -->
    <div id="xdx_237_zsVMFGifelN" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zmYQYcq0hfba" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zzOyUMQQFcrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_237_zPXg5jXXdQGj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Consolidated Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zyRkOzAgxAw4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">September 30, 2021 – Page 10</p></ix:exclude>


<ix:exclude><p id="xdx_23F_zkmzSCnPN6of" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zZsXl842irq3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 5	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;	<span style="text-decoration: underline">Equity Offering Agreements</span> – (continued)</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zRrzIdawRY96" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zAJEyKkeRcrj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">2019 Purchase Agreement</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">On June 7, 2019, the Company entered
into a $<span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Total number of shares obligated to purchase"><span><ix:nonfraction name="avxl:ValueOfSharesObligatedToPurchase" contextref="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-274" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50,000,000</ix:nonfraction></span></span> purchase agreement (the “2019 Purchase Agreement”) with Lincoln Park, as amended on July 1, 2020,
pursuant to which the Company had the right to sell and issue to Lincoln Park, and Lincoln Park was obligated to purchase, up to
$<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Proceeds from Issuance or Sale of Equity"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextref="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-275" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000,000</ix:nonfraction></span></span> in value of its shares of common stock from time to time over a three-year period until July 1, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">In consideration for entering into
the 2019 Purchase Agreement, the Company issued to Lincoln Park <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-276" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">324,383</ix:nonfraction></span></span> shares of common stock as a commitment fee during the year
ended September 30, 2019 and agreed to issue up to <span id="xdx_90A_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Pro rata basic number of shares obligated to purchase"><span><ix:nonfraction name="avxl:NumberOfSharesObligatedToPurchaseProrataBasic" contextref="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-277" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">162,191</ix:nonfraction></span></span> shares pro rata, when and if, Lincoln Park purchased, at the Company’s
discretion, the $50,000,000 aggregate commitment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">During the year ended September
30, 2021, the Company issued to Lincoln Park an aggregate of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-278" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,086,209</ix:nonfraction></span></span> (2020 – <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Share issued for offering, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-279" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,633,527</ix:nonfraction></span></span>) shares of common stock under the
2019 Purchase Agreement, including <span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for aggregate purchase price"><span><ix:nonfraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextref="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-280" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,007,996</ix:nonfraction></span></span> (2020: <span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for aggregate purchase price"><span><ix:nonfraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextref="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-281" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7,564,584</ix:nonfraction></span></span>) shares of common stock for an aggregate purchase price of $<span id="xdx_908_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value"><span><ix:nonfraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextref="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-282" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">24,111,198</ix:nonfraction></span></span>
(2020: $<span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value"><span><ix:nonfraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextref="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-283" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">21,254,298</ix:nonfraction></span></span>) and <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20201001__20210930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for commitment"><span><ix:nonfraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextref="From2020-10-012021-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-284" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">78,213</ix:nonfraction></span></span> (2020: <span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pdd" title="Number of shares issued for commitment"><span><ix:nonfraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextref="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-285" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">68,943</ix:nonfraction></span></span>) commitment shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">At September 30, 2021, no shares
remained available for issuance under the 2019 Purchase Agreement (September 30, 2020: $<span id="xdx_900_ecustom--StockIssuedDuringPeriodValueNewIssues4_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Amount of shares remain available"><span><ix:nonfraction name="avxl:StockIssuedDuringPeriodValueNewIssues4" contextref="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-286" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">24,111,198</ix:nonfraction></span></span>
in value of shares).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-287" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_807_eus-gaap--CommitmentsDisclosureTextBlock_zmQI5m9B5Od4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;	<span style="text-decoration: underline"><span id="xdx_825_zcgxXYArPTge">Commitments and Contingencies</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tbody><tr style="vertical-align: top">
<td style="width: 42.75pt">&nbsp;</td>
<td style="width: 18pt"><span style="font-size: 10pt">a)</span></td>
<td><span style="font-size: 10pt"><i>Lease</i></span></td></tr>
</tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><i style="font-style: normal; font-weight: normal">During the year
ended September 30, 2021 the Company incurred office lease expense of $<span id="xdx_907_eus-gaap--LeaseAndRentalExpense_c20201001__20210930_pp0p0" title="Operating Leases, Rent Expense"><span><ix:nonfraction name="us-gaap:LeaseAndRentalExpense" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-288" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">130,784</ix:nonfraction></span></span> (2020:</i> <i style="font-style: normal; font-weight: normal">$<span id="xdx_90E_eus-gaap--LeaseAndRentalExpense_c20191001__20200930_pp0p0" title="Operating Leases, Rent Expense"><span><ix:nonfraction name="us-gaap:LeaseAndRentalExpense" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-289" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">233,423</ix:nonfraction></span></span>).</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font-size: 10pt">b)</span></td><td style="text-align: justify"><span style="font-size: 10pt"><i>Employee 401(k) Benefit Plan</i></span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.75pt; text-align: justify"><i style="font-style: normal; font-weight: normal">The Company has
a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers all United States based
employees.</i> <i style="font-style: normal; font-weight: normal">United States based employees eligible to participate in the plan may contribute up to the current statutory
limits under the Internal Revenue Service regulations.</i> <i style="font-style: normal; font-weight: normal">The 401(k) plan permits the Company to make additional matching contributions
on behalf of contributing employees.</i> <i style="font-style: normal; font-weight: normal">During the year ended September 30, 2021, the Company made $<span id="xdx_90C_eus-gaap--PensionContributions_c20201001__20210930_zfOuAGoI3FSk" title="Contribution amount"><span><ix:nonfraction name="us-gaap:PensionContributions" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-290" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,856</ix:nonfraction></span></span> (2020: $<span id="xdx_905_eus-gaap--PensionContributions_c20191001__20200930_zAEexDRACYd4"><span><ix:nonfraction name="us-gaap:PensionContributions" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-291" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">98,058</ix:nonfraction></span></span>)
in matching contributions under the 401(k) plan.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.75pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tbody><tr style="vertical-align: top">
<td style="width: 42.75pt">&nbsp;</td>
<td style="width: 18pt"><span style="font-size: 10pt">c)</span></td>
<td><span style="font-size: 10pt"><i>Litigation</i></span></td></tr>
</tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="background-color: white">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently uncertain,
and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that the resolution
of any such matter will not have a material adverse effect upon the Company’s consolidated financial statements. The Company
does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its consolidated
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="background-color: white">&nbsp;</span></p>

<ix:exclude><p id="xdx_23E_zcltIsZPw5c5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="background-color: white"></span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 64; Value: 1 -->
    <div id="xdx_235_zdRfW9ApdY04" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zRIwLvwpg9ra" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="background-color: white"></span>&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zQaejXAAE8ck" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_23C_z3CZ2vgzw7n6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Consolidated Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zXQc3sBG74Tg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">September 30, 2021 – Page 11</p></ix:exclude>


<ix:exclude><p id="xdx_235_zUNI3osOM7dl" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zMT415Ljf5kg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;		<span style="text-decoration: underline">Commitments and Contingencies</span> – (continued)</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zrAAeMuQMjte" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_233_zHUb8nVSXkmd" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tbody><tr style="vertical-align: top">
<td style="width: 42.75pt">&nbsp;</td>
<td style="width: 18pt"><span style="font-size: 10pt">d)</span></td>
<td><span style="font-size: 10pt"><i>Share Purchase Warrants</i></span></td></tr>
</tbody></table></ix:exclude>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The following table summarizes
the warrant activity during the years ended September 30, 2021 and 2020:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-292" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zwGd5neLNuU5" summary="xdx: Disclosure - Commitments and Contingencies (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0; padding-right: 0"><span id="xdx_8B6_zAekO7d3iN3e" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Weighted</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Average</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Exercise Price</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt">($)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 26%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance, September 30, 2019</span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zXdJlaUqWmq7" title="Share Purchase Warrants Balance, at beginning" style="width: 26%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextref="AsOf2019-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-293" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">350,000</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z9kanirbSEHl" title="Weighted Average Exercise Price Balance, at beginning" style="width: 26%; text-align: right"><span><ix:nonfraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2019-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-294" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4.19</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zHVHbzSNwNu" title="Share Purchase Warrants Granted" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" contextref="From2019-10-012020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-295" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">150,000</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zVBJejxe5Naf" title="Weighted Average Exercise Price, Granted" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" contextref="From2019-10-012020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-296" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.17</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance, September 30, 2020</span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zWG7rnr6NVse" title="Share Purchase Warrants Balance, at beginning" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextref="AsOf2020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-297" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z1VzWd4BhtG7" title="Weighted Average Exercise Price Balance, at beginning" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-298" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.88</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" title="Share Purchase Warrants Granted" style="text-align: right"><span><ix:nonfraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" contextref="From2020-10-012021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-299" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">60,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pdd" title="Weighted Average Exercise Price, Granted" style="text-align: right"><span><ix:nonfraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" contextref="From2020-10-012021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-300" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">12.00</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zhJ0PgnxktEe" title="Share Purchase Warrants Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextref="From2020-10-012021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-301" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">350,000</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z8ZXV63dbqdl" title="Weighted Average Exercise Price, Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" contextref="From2020-10-012021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-302" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4.19</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance, September 30, 2021</span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zQOA83IZiTb6" title="Share Purchase Warrants Balance, at ending" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextref="AsOf2021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-303" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">210,000</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_c20201001__20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zJ7G3pFeBz8e" title="Weighted Average Exercise Price Balance, at ending" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-304" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.69</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
</tbody></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

</ix:nonnumeric></span><p id="xdx_8A0_zO1uLMk63tpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: -0.8pt">At September
30, 2021 the Company had share purchase warrants outstanding as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: -0.8pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: -0.8pt"></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-305" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_ziXKQIkjqCi1" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&nbsp;</td><td style="text-align: left"><span id="xdx_8B6_zaYAmXVvgWF1" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right; padding-top: 0; padding-right: 0">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Expiry Date</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Number" style="width: 26%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextref="AsOf2021-09-30_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-306" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pdd" title="Exercise Price" style="width: 26%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-09-30_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-307" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.17</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 26%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zHceahn8kHe2" title="Expiry Date"><span><ix:nonnumeric contextref="AsOf2021-09-30_custom_PurchaseWarrants1Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" inside-table="true" id="fact-identifier-308" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">May 6, 2024</ix:nonnumeric></span></span></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Number" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextref="AsOf2021-09-30_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-309" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60,000</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pdd" title="Exercise Price" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-09-30_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-310" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.00</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_ztgJI57qbPC3" title="Expiry Date"><span><ix:nonnumeric contextref="AsOf2021-09-30_custom_PurchaseWarrants2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" inside-table="true" id="fact-identifier-311" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">April 21, 2026</ix:nonnumeric></span></span></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20210930_pdd" title="Number" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-312" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">210,000</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right; padding-top: 0; padding-right: 0"></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
</tbody></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: -0.8pt"></p>

</ix:nonnumeric></span><p id="xdx_8AD_z2JXgNIK9ac9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: -0.8pt">&nbsp;</p>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_23E_zhSOkeRPNVal" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tbody><tr style="vertical-align: top">
<td style="width: 42.75pt">&nbsp;</td>
<td style="width: 18pt">e)<span style="font: 7pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><i> </i></td>
<td style="text-align: justify">Stock–based Compensation Plan –(continued)</td></tr>
</tbody></table></ix:exclude>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">2015 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">On September 18, 2015, the Company’s
board of directors approved a 2015 Omnibus Incentive Plan (the “2015 Plan”), which provided for the grant of stock
options and restricted stock awards to directors, officers, employees and consultants of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The maximum number of our common
shares reserved for issue under the plan was <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Maximum number of common shares reserved for future issuance"><span><ix:nonfraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextref="AsOf2021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-313" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,050,553</ix:nonfraction></span></span> shares, subject to adjustment in the event of a change of the Company’s
capitalization. At September 30, 2021, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextref="AsOf2021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-314" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">146,371</ix:nonfraction></span></span> (2020: <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextref="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-315" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">133,036</ix:nonfraction></span></span>) options remain available for issue under the 2015 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">2019 Stock Option Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">On January 15, 2019, the Board
approved the 2019 Omnibus Incentive Plan (the “2019 Plan”), which provides for the grant of stock options and restricted
stock awards to directors, officers, employees, consultants and advisors of the Company. Under the terms of the 2019 Plan, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Additional shares of common stock available for issuance"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextref="From2020-10-012021-09-30_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-316" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,000,000</ix:nonfraction></span></span>
additional shares of Common Stock are available for issuance under the 2019 Plan, in addition to the shares available under the
2015 Plan. Any awards outstanding under the 2015 Plan or the Company’s 2007 Stock Option Plan (the “2007 Plan”)
will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and any shares subject to outstanding awards
under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards (other than by reason of settlement of
the awards in shares) will automatically become available for issuance under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<ix:exclude><p id="xdx_231_znuyr7k4AXs4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 65; Value: 1 -->
    <div id="xdx_23D_z77OyrWiaVI3" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zmMnG2qJEr01" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zhQG93vWQGO4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_235_zxpKI54fccK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Consolidated Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_237_zAqjfwcNYWke" style="font: 10pt Times New Roman, Times, Serif; margin: 0">September 30, 2021 – Page 12</p></ix:exclude>


<ix:exclude><p id="xdx_239_z5cpki1iaKV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_237_z7MSlWRbam1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;	<span style="text-decoration: underline">Commitments and Contingencies</span> – (continued)</p></ix:exclude>

<ix:exclude><p id="xdx_237_zpN6q5mwjO6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_23E_z98dMsUkPITg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tbody><tr style="vertical-align: top">
<td style="width: 42.75pt">&nbsp;</td>
<td style="width: 18pt">e)</td>
<td style="text-align: justify"><i>Stock–based Compensation Plan – (continued)</i></td></tr>
</tbody></table></ix:exclude>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60.75pt; text-align: justify; color: gray"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The 2019 Plan provides that it
may be administered by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined
by the board of directors at the time of grant shall be at least equal to the fair market value on such date. If the grantee is
a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company’s
shares of common stock on the grant date. Stock options may be granted under the 2019 Plan for an exercise period of up to ten
years from the date of grant of the option or such lesser periods as may be determined by the board, subject to earlier termination
in accordance with the terms of the 2019 Plan. At September 30, 2021, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextref="AsOf2021-09-30_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-317" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">456,332</ix:nonfraction></span></span> (2020: <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pdd" title="Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextref="AsOf2020-09-30_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-318" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,161,665</ix:nonfraction></span></span>) options remain available for issue
under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">A summary of the status of Company’s
outstanding stock purchase option activity during the years ended September 30, 2021 and 2020 is presented below:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 66pt"></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-319" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zdOuUD9oafx9" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B0_z2iW0QZlbdzd" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Weighted</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Average Grant</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Aggregate</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Average Exercise</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Date Fair</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">intrinsic value</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Price ($)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Value ($)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">($)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding, September 30, 2019</span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z5jXX81f93b3" title="Options Outstanding at beginning" style="width: 15%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-320" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,462,933</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRSkBsebdsBh" title="Weighted Average Exercise Price Outstanding at beginning" style="width: 15%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-321" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.58</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 15%; text-align: right">&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zBRTeqGFfJXd" title="Aggregate intrinsic value Outstanding at beginning" style="width: 15%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextref="AsOf2019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-322" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,115,032</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Options Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextref="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-323" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,695,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Exercise Price Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-324" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.96</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextref="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-325" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.27</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zazPZq058jWd" title="Options Forfeited" style="text-align: right">(<span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextref="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-326" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">68,332</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Exercise Price Forfeited" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextref="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-327" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.01</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zm4QSsNF00u7" title="Weighted Average Grant Date Fair Value Forfeited" style="text-align: right"><span><ix:nonfraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" contextref="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-328" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.44</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z3bcx2uWAnl4" title="Options Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-329" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,335</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zJ2bIaIJ1Qdh" title="Weighted Average Exercise Price Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextref="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-330" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.15</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zkdRFrkhbca5" title="Weighted Average Grant Date Fair Value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextref="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-331" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.61</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zpgiUhRAa7hl" title="Aggregate intrinsic value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextref="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-332" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,400</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding, September 30, 2020</span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zvq8V2ReKyIf" title="Options Outstanding at beginning" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-333" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,076,266</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbugzBQsd0Zd" title="Weighted Average Exercise Price Outstanding at beginning" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-334" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.48</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;</td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zt319bmAzPb9" title="Aggregate intrinsic value Outstanding at beginning" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextref="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-335" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,982,581</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Options Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextref="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-336" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,732,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Exercise Price Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-337" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.55</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextref="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-338" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.32</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zcFoHyvfJvgd" title="Options Forfeited" style="text-align: right">(<span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextref="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-339" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">55,834</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Exercise Price Forfeited" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextref="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-340" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.04</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zx97r4TxzN7e" title="Weighted Average Grant Date Fair Value Forfeited" style="text-align: right"><span><ix:nonfraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisesPrice" contextref="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-341" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.43</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zvYiuZi8Kg54" title="Options Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-342" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,421,529</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Exercise Price Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextref="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-343" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.89</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zS5PCDyQZfV9" title="Weighted Average Grant Date Fair Value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisesPrice" contextref="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-344" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.43</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z6mcDBpM3ijf" title="Aggregate intrinsic value Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextref="From2020-10-012021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-345" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,446,305</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding, September 30, 2021</span></td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zVVDzo2ISsv7" title="Options Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-346" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,330,903</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zrFwAZBNbL76" title="Weighted Average Exercise Price Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-347" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.74</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20201001__20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zXIBhEXW6Om7" title="Aggregate intrinsic value Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextref="AsOf2021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-348" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">140,132,451</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable, September 30, 2021</span></td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Options Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextref="AsOf2021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-349" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,228,488</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pdd" title="Weighted Average Exercise Price Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextref="AsOf2021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-350" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.73</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20210930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pp0p0" title="Aggregate intrinsic value Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextref="AsOf2021-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-351" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">102,786,851</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td></tr>
</tbody></table>

</ix:nonnumeric></span><p id="xdx_8A6_zTv6e5HuIMH6" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The following summarizes information about
stock options at September 30, 2021 by a range of exercise prices:</p>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-352" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zlkLYoEKkk0l" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_8B5_zsJF32cMyHl3" style="display: none">Summarizes information about
stock options</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Weighted average remaining</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Weighted average</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Weighted average</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="7" style="text-align: center">Range of exercise prices</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">outstanding</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">contractual life</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">exercise</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">vested</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">exercise</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">From</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">To</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">options</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">(in years)</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">price</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">options</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Range of exercise prices, lower range limit" style="width: 11%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-353" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.92</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Range of exercise prices, upper range limit" style="width: 11%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-354" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.96</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Number of outstanding options" style="width: 11%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-355" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,309,349</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_zXKhPbcGlxJ7" title="Weighted average remaining contractual life (in years)" style="width: 11%; text-align: right"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-356" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.25</ix:nonnumeric></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Weighted average exercise price" style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-357" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.31</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Number of vested options" style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-358" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,167,682</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice1Member_pdd" title="Weighted average exercise price" style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextref="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice1Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-359" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.10</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-360" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.15</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-361" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.80</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Number of outstanding options" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-362" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,117,500</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_z12C04nK6esl" title="Weighted average remaining contractual life (in years)" style="text-align: right"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-363" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.33</ix:nonnumeric></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Weighted average exercise price" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-364" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.30</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Number of vested options" style="text-align: right"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-365" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,830,836</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice2Member_pdd" title="Weighted average exercise price" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextref="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice2Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-366" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.29</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-367" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.04</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-368" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.98</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Number of outstanding options" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-369" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,397,054</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_zKuShWWtgfJ2" title="Weighted average remaining contractual life (in years)" style="text-align: right"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-370" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.45</ix:nonnumeric></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Weighted average exercise price" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-371" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.05</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Number of vested options" style="text-align: right"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-372" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,207,054</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice3Member_pdd" title="Weighted average exercise price" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextref="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice3Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-373" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.35</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-374" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.00</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-375" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13.01</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Number of outstanding options" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-376" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">230,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_zOjdJM6vWfl5" title="Weighted average remaining contractual life (in years)" style="text-align: right"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.52</ix:nonnumeric></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Weighted average exercise price" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-378" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.44</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Number of vested options" style="text-align: right"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-379" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,916</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice4Member_pdd" title="Weighted average exercise price" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextref="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice4Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-380" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.42</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Range of exercise prices, lower range limit" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-381" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18.11</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Range of exercise prices, upper range limit" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-382" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24.58</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Number of outstanding options" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-383" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,277,000</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_zOEbUCCEmtKg" title="Weighted average remaining contractual life (in years)" style="text-align: right"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-384" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.82</ix:nonnumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Weighted average exercise price" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-385" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19.33</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Number of vested options" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0775"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="fact-identifier-386" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0775" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionPrice5Member_pdd" title="Weighted average exercise price" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextref="AsOf2021-09-30_us-gaap_StockOptionMember_custom_OptionPrice5Member" id="fact-identifier-387" unitref="USDPShares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0777" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Number of outstanding options" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-388" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,330,903</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20201001__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" title="Number of vested options" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextref="From2020-10-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-389" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,228,488</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 66pt"></p>

</ix:nonnumeric></span><p id="xdx_8AA_z3aiHgGUS4H7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The weighted average grant date
fair value of options vested during the year ended September 30, 2021 was $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20201001__20210930_zcqtHEjR7tc2" title="weighted average grant date fair value of options vested"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-390" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.54</ix:nonfraction></span></span> (2020: $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20191001__20200930_zMOVwiN00Fb"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-391" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.55</ix:nonfraction></span></span>). At September 30, 2021, the weighted
average contractual life of options outstanding was <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zWDdjuMeN4s1" title="Weighted average contractual life of options outstanding"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="false" id="fact-identifier-392" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.79</ix:nonnumeric></span></span> years (2020: <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20191001__20200930_zbh8uOaGrkUl"><span><ix:nonnumeric contextref="From2019-10-012020-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="false" id="fact-identifier-393" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.96</ix:nonnumeric></span></span> years) and for options exercisable was<span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20201001__20210930_zUfvtchgcxic" title="Options exercisable"> <span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" inside-table="false" id="fact-identifier-394" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.51</ix:nonnumeric></span> </span>years (2020:
<span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20191001__20200930_zs8sVtyLmfa"><span><ix:nonnumeric contextref="From2019-10-012020-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" inside-table="false" id="fact-identifier-395" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.25</ix:nonnumeric></span></span> years).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The aggregate intrinsic value is
calculated as the difference between the exercise price of the underlying awards and the quoted market price of the Company’s
stock for the options that were in-the-money at September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">	The Company recognized stock-based
compensation expense of $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210930_pp0p0" title="Share based compensation"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-396" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,231,403</ix:nonfraction></span></span> during the year ended September 30, 2021 (2020: $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930_pp0p0" title="Share based compensation"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-397" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,876,906</ix:nonfraction></span></span>) in connection with the issuance
and vesting 	of stock options and warrants in exchange for services. These amounts have been included in general and 	administrative
expenses and research and development expenses on the Company’s consolidated statements of 	operations as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: center"></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-398" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zgsE91GN4ce4" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-top: 0; padding-right: 0"><span id="xdx_8BA_zGCiWiUylMQk" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">General and administrative</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2020-10-012021-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-399" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,571,335</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2019-10-012020-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-400" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,210,789</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2020-10-012021-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-401" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,660,068</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2019-10-012020-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-402" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,666,117</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total stock-based compensation</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20210930_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-403" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,231,403</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-404" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,876,906</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
</tbody></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: center"></p>

</ix:nonnumeric></span><p id="xdx_8AA_zDBQyB2z87ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 66; Value: 1 -->
    <div id="xdx_23D_zPvdgWq0xH03" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zt4l2R2IXIAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zb3d7nL50k0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_236_zVFBcRO45HGa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Consolidated Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_234_zjgt4c16lrMj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">September 30, 2021 – Page 13</p></ix:exclude>


<ix:exclude><p id="xdx_234_zv9V8yJi0Hz3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zPaJVMqhFJZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span style="text-decoration: underline">Commitments</span> – (continued)</p></ix:exclude>

<ix:exclude><p id="xdx_230_zm8Sl9EYS03j" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_238_zmadVUpXfNl5" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tbody><tr style="vertical-align: top">
<td style="width: 45pt">&nbsp;</td>
<td style="width: 18pt"><span><i>e)</i></span></td>
<td style="text-align: justify"><span><i>Stock–based Compensation Plan</i></span> – (continued)</td></tr>
</tbody></table></ix:exclude>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify; text-indent: -0.25in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">An amount of approximately $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c20210930_pp0p0" title="Remaining stock based compensation"><span><ix:nonfraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-405" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,650,000</ix:nonfraction></span></span>
in stock-based compensation is expected to be recorded over the remaining term 	of such options and warrants through fiscal
2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The fair value
of each option and warrant award is estimated on the date of grant using the Black Scholes option pricing model based on the following
weighted average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-406" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zPNxQ1mzqR3i" summary="xdx: Disclosure - Commitments and Contingencies (Details 5)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BE_zKvxubybRWd6" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk-free interest rate</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20201001__20210930_z6wsF1IajSoj" title="Risk-free interest rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-407" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.73</ix:nonfraction></span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20191001__20200930_zhnYw9m4iUI6" title="Risk-free interest rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-408" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.57</ix:nonfraction></span></span></td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life of options (years)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20210930_zIguDnHY5Elh" title="Expected life of options (years)"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-409" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.74</ix:nonnumeric></span></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20200930_ziKRGMy3eT33" title="Expected life of options (years)"><span><ix:nonnumeric contextref="From2019-10-012020-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-410" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.53</ix:nonnumeric></span></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20201001__20210930_zn4n3CkkMTRc" title="Annualized volatility"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-411" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">93.43</ix:nonfraction></span></span></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20191001__20200930_z6W2UWaZX7P8" title="Annualized volatility"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-412" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">95.99</ix:nonfraction></span></span></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20201001__20210930_zFXXXIZVx3d2" title="Dividend rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-413" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.00</ix:nonfraction></span></span></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20191001__20200930_zZ7a281lc7Ki" title="Dividend rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-414" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.00</ix:nonfraction></span></span></td><td style="text-align: left">%</td></tr>
</tbody></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

</ix:nonnumeric></span><p id="xdx_8A4_zo3jaR23dUg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The fair value of stock compensation
charges recognized during the years ended September 30, 2021 and 2020 was determined with reference to the quoted market price
of the Company’s shares on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-415" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zK3LQJz3inn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 7	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 	<span style="text-decoration: underline"><span id="xdx_823_zPw4klyIAuhf">Income Taxes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company’s U.S.
and foreign loss before income taxes are set forth below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Trebuchet MS, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: 0.5in"></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-416" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zjTxtVsxshC2" summary="xdx: Disclosure -  Income Taxes (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="padding-top: 0; padding-right: 0"><span id="xdx_8BD_znvmR7WVVDph" style="display: none">Schedule of Income before Income Tax, Domestic and Foreign</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_495_20201001__20210930_zEmdTiA4Rfx8" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49C_20191001__20200930_znKrh7FKJt9l" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
<tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">United States</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-417" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,850,926</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-418" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,096,148</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td>Foreign</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-419" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,790,143</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-420" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,161,658</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-421" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,641,069</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 2.5pt">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-422" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,257,806</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 2.5pt">)</td></tr>
</tbody></table>




<p style="font: 10pt/normal Trebuchet MS, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify; text-indent: 0.5in"></p>

</ix:nonnumeric></span><p id="xdx_8A0_zMRPxhKLV3Ne" style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt">The components of net deferred income tax assets as
of September 30, 2021 and 2020 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: 0.5in"></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-423" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zzFivN3OpKrk" summary="xdx: Disclosure - Income Taxes (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B5_zYaeV8MCYQB1" style="display: none">Schedule of deferred tax asset and liabilities</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_493_20210930_zpZl6c4gWQli" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49C_20200930_ztvm0qxWFBJ7" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Net operating loss carryforwards</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-424" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,982,000</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-425" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,397,000</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_zGb55q7J6hS4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development tax credit carryforwards</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-426" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,577,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-427" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,069,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Stock-based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-428" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,453,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-429" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,283,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unpaid charges</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:DeferredTaxAssetsUnpaidCharges" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-430" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">89,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="avxl:DeferredTaxAssetsUnpaidCharges" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-431" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">83,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible asset costs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-432" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">323,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-433" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">132,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign exchange and other</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-434" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">62,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-435" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_402_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zLIgUstViuP9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Valuation allowance deferred tax assets</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-436" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">47,486,000</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-437" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33,991,000</ix:nonfraction></span></td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0874"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsNet" contextref="AsOf2021-09-30" id="fact-identifier-438" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0874" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0875"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsNet" contextref="AsOf2020-09-30" id="fact-identifier-439" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0875" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span></td><td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td></tr>
</tbody></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: 0.5in"></p>

</ix:nonnumeric></span><p id="xdx_8A7_z3yBAybd3m76" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 67; Value: 1 -->
    <div id="xdx_235_zej0O0W7G6G5" style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zaRRnXPpeD64" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zhawggABAEHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Anavex Life Sciences Corp.</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zScHSqZErSMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to the Consolidated Financial Statements</p></ix:exclude>

<ix:exclude><p id="xdx_230_zFWChJdq5Fsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0">September 30, 2021 – Page 14</p></ix:exclude>


<ix:exclude><p id="xdx_237_zg14D7nKm91e" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zmqAlkVLm8c8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 7	 &nbsp;&nbsp;&nbsp;&nbsp;	<span style="text-decoration: underline">Income Taxes</span> – (Continued)</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zEixeGZg3wHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zhjORnON1Nl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">A reconciliation of income tax
expense at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements for the
years ended September 30, 2021 and 2020 is as follows:</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-indent: 0.5in"></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-440" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zDcQdPTw8BVj" summary="xdx: Disclosure - Income Taxes (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td id="xdx_497_20201001__20210930_zmuZdwnuOOi6" style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td id="xdx_499_20191001__20200930_zpHi4d15mX84" style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
<tr id="xdx_404_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_zXwQLnGfYDa3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 56%; text-align: left">Income tax benefit at statutory federal rate</td>
<td style="width: 8%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-441" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,934,000</ix:nonfraction></span></td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 8%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-442" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,519,000</ix:nonfraction></span></td>
<td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Foreign income taxed at other rates</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-443" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">353,000</ix:nonfraction></span></td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-444" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">723,000</ix:nonfraction></span></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_406_ecustom--PermanentDifferencesRelatingToStockBasedCompensation_zpnvrjID1ioe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Permanent differences relating to stock based compensation&nbsp;&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(<span><ix:nonfraction name="avxl:PermanentDifferencesRelatingToStockBasedCompensation" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-445" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,379,000</ix:nonfraction></span></td>
<td style="text-align: left">)&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;<span style="-sec-ix-hidden: xdx2ixbrl0894"><span><ix:nonfraction name="avxl:PermanentDifferencesRelatingToStockBasedCompensation" contextref="From2019-10-012020-09-30" id="fact-identifier-446" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0894" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td>
<td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40E_ecustom--PermanentDifferencesRelatingToSection162m_zxXnnHrYHyK6" style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Permanent differences relating to Section 162(m)&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;<span><ix:nonfraction name="avxl:PermanentDifferencesRelatingToSection162m" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-447" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">816,000</ix:nonfraction></span></td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;<span style="-sec-ix-hidden: xdx2ixbrl0897"><span><ix:nonfraction name="avxl:PermanentDifferencesRelatingToSection162m" contextref="From2019-10-012020-09-30" id="fact-identifier-448" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0897" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td>
<td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Other permanent differences</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-449" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">741,000</ix:nonfraction></span></td>
<td style="text-align: left"></td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-450" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,000</ix:nonfraction></span></td>
<td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40D_ecustom--AdjustmentToTaxAssetsBasedOnSection382_ztsPT1ABi6u7" style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Adjustment to tax assets based on Section 382</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right"><span><ix:nonfraction name="avxl:AdjustmentToTaxAssetsBasedOnSection382" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-451" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3,330,000</ix:nonfraction></span></td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0903"><span><ix:nonfraction name="avxl:AdjustmentToTaxAssetsBasedOnSection382" contextref="From2019-10-012020-09-30" id="fact-identifier-452" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0903" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span></span></td>
<td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40A_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet_zcJRFMkWBW14" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Research and development credits, net</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right"><span><ix:nonfraction name="avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-453" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,042,000</ix:nonfraction></span></td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right"><span><ix:nonfraction name="avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditNet" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-454" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,267,000</ix:nonfraction></span></td>
<td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="text-align: left">State and local taxes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-455" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,022,000</ix:nonfraction></span></td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-456" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,911,000</ix:nonfraction></span></td>
<td style="text-align: left">)</td></tr>
<tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Adjustment and true up to prior years' tax provision</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-457" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">48,000</ix:nonfraction></span></td>
<td style="text-align: left"></td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-458" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">373,000</ix:nonfraction></span></td>
<td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--EffectOfExchangeRateOnCash_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Effect of change in statutory rates</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right"><span><ix:nonfraction name="us-gaap:EffectOfExchangeRateOnCash" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-459" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">216,000</ix:nonfraction></span></td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right"><span><ix:nonfraction name="us-gaap:EffectOfExchangeRateOnCash" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-460" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36,000</ix:nonfraction></span></td>
<td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_408_eus-gaap--TaxesExcludingIncomeAndExciseTaxes_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">State minimum and exise taxes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right"><span><ix:nonfraction name="us-gaap:TaxesExcludingIncomeAndExciseTaxes" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-461" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">267,565</ix:nonfraction></span></td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right"><span><ix:nonfraction name="us-gaap:TaxesExcludingIncomeAndExciseTaxes" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-462" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,664</ix:nonfraction></span></td>
<td style="text-align: left">&nbsp;</td></tr>
<tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Change in valuation allowances</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-463" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,495,000</ix:nonfraction></span></td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-464" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,442,000</ix:nonfraction></span></td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td></tr>
<tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Income tax expense</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-465" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">267,565</ix:nonfraction></span></td>
<td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td>
<td style="padding-bottom: 2.5pt">&nbsp;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-466" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,664</ix:nonfraction></span></td>
<td style="text-align: left; padding-bottom: 2.5pt">&nbsp;</td></tr>
</tbody></table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-indent: 0.5in"></p>

</ix:nonnumeric></span><p id="xdx_8AF_z7E1KAqOS9R6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-indent: 20pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">As of September 30, 2021, the
Company had U.S. federal net operating loss carryforwards of approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20210930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zVUcMjmcw2zi" title="Operating loss carryforwards"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2021-09-30_custom_FederalMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-467" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">101.6</ix:nonfraction></span> </span>million
(2020: $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20200930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_zVJsqTkQPrf6"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2020-09-30_custom_FederalMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-468" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">77.0</ix:nonfraction></span> </span>million)
of which <span id="xdx_900_ecustom--OperatingLossCarryforwardsDescription_c20201001__20210930__us-gaap--IncomeTaxAuthorityAxis__custom--FederalMember_z4e2Ai0yq6Jj" title="Operating loss carryforwards description"><span><ix:nonnumeric contextref="From2020-10-012021-09-30_custom_FederalMember" name="avxl:OperatingLossCarryforwardsDescription" inside-table="false" id="fact-identifier-469" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">$37.7 will begin to expire in 2025 and $63.9 can be carried forward indefinitely</ix:nonnumeric></span></span>, state and local net operating loss carryforwards of approximately $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20210930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zepjnSs8Ivik"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2021-09-30_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-470" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">177.7</ix:nonfraction></span> </span>million
(2020: $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20200930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zj7nX62cGox4"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2020-09-30_us-gaap_StateAndLocalJurisdictionMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-471" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">103.1</ix:nonfraction></span> </span>million)
which will begin to expire in <span id="xdx_90D_ecustom--OperatingLossCarryForwardsExpirationYear_c20201001__20210930_ziYdT3dCDqUg" title="Operating loss carry forwards expiration year"><span><ix:nonnumeric contextref="From2020-10-01to2021-09-30" name="avxl:OperatingLossCarryForwardsExpirationYear" inside-table="false" id="fact-identifier-472" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2036</ix:nonnumeric></span></span>,
and Research and Development tax credits of $<span id="xdx_90B_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pp0n3_dm_c20201001__20210930_zAVtipTZPC1i" title="Research and Development tax credits"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-473" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.6</ix:nonfraction></span></span>
million (2020: $<span id="xdx_906_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_pp0n3_dm_c20191001__20200930_zOfIj5m5GJlf"><span><ix:nonfraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextref="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-474" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.1</ix:nonfraction></span></span>
million) which will begin to expire in 2029. The Company had approximately $<span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20210930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_znCnzkJUcUy7"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2021-09-30_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-475" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.9</ix:nonfraction></span> </span>million
(approximately AU$ <span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20210930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_zqiPra7Oeo12"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2021-09-30_us-gaap_ForeignCountryMember_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-476" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.2</ix:nonfraction></span> </span>million)
(2020: $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20200930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zMAMVhoR88R4"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2020-09-30_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitref="USD" inside-table="false" id="fact-identifier-477" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.3</ix:nonfraction></span> </span>million)
of net operating loss carryforwards in Australia, which have an indefinite life, available to offset future taxable income in those
jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company evaluates its valuation
allowance requirements based on available evidence. When circumstances change, and this causes a change in management’s judgment
about the recoverability of deferred tax assets, the impact of the change on the valuation allowance is reflected in current income.
Because management of the Company does not currently believe that it is more likely than not that the Company will receive the
benefit of these assets, a valuation allowance has been established at September 30, 2021 and 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Uncertain Tax Positions</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">The Company files income tax returns
in the U.S. federal jurisdiction and various state and local and foreign jurisdictions. The Company’s tax returns are subject
to tax examinations by U.S. federal and state tax authorities, or examinations by foreign tax authorities until the respective
statutes of limitation expire. The Company is subject to tax examinations by tax authorities for all taxation years commencing
on or after 2014.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Under the provisions of the Internal
Revenue Code, the net operating loss (“NOL”) carryforwards are subject to review and possible adjustment by the Internal
Revenue Service and state tax authorities. Under Section 382 of the Internal Revenue Code, NOL and tax credit carryforwards may
become subject to an annual limitation in the event of an over 50% cumulative change in the ownership interest of significant stockholders
over a three-year, as well as similar state tax provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-size: 10pt">The
Company conducted a Section 382 study during the year ended September 30, 2021 and determined that, during the year ended September
30, 2015, there was a change in ownership which resulted in $25.8 million of federal NOLs being subject to an annual limitation.
During the year ended September 30, 2021, the Company reduced its federal NOLs by $12.1 million and its Research and development tax
credit carryforwards by $0.8 million, which are the amount of tax assets that will expire unutilized pursuant to the Section 382
study. This resulted in a reduction of $2.5&nbsp;million of NOLs and&nbsp;$0.8&nbsp;million&nbsp;of research and development credits
and a corresponding reduction in the valuation allowance of $<span id="xdx_903_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0n3_c20201001__20210930_zsvO71a7CVfh" title="Decrease in vaution allowance"><span><ix:nonfraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextref="From2020-10-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="3" unitref="USD" inside-table="false" id="fact-identifier-478" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.3</ix:nonfraction></span></span>
million, which was recorded in the current fiscal year. Subsequent ownership changes in future years could trigger additional
limitations of the Company’s NOLs. </span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="color: black; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="background-color: white">As
of September&nbsp;30, 2021, the Company did not provide any foreign withholding taxes related to its foreign subsidiaries’
undistributed earnings, as such earnings have been retained and are intended to be indefinitely reinvested to fund ongoing
operations of the foreign subsidiaries. It is not practicable to estimate the amount of taxes that would be payable upon remittance
of these earnings, because such tax, if any, is dependent upon circumstances existing if and when remittance occur.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="color: black; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="color: black; background-color: white">&nbsp;</span></p>
</ix:nonnumeric></span><p id="xdx_81E_z3dSDBDptOk2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"></p>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-style: normal"><span id="a_014"></span>ITEM 9. CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS </span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">Not Applicable</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-style: normal"><span id="a_015"></span>ITEM 9A. CONTROLS
AND PROCEDURES</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><b><i>Disclosure Controls and Procedures</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">We maintain disclosure controls and procedures
that are designed to provide reasonable assurance that material information required to be disclosed in our periodic reports filed
under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules
and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, our chief
executive officer and our principal financial officer, to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">We carried out an evaluation, under the supervision
and with the participation of our management, including our principal executive and principal financial officer, of the effectiveness
of the design and operation of our disclosure controls and procedures, as defined in&nbsp;Rule&nbsp;13(a)-15(e) under the Exchange
Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls
and procedures were effective as of September 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><b><i>Management’s Annual Report on Internal
Control over Financial Reporting </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting as defined in Rules&nbsp;13a-15(f) and 15d-15(f) under the Exchange
Act. Under the supervision and with the participation of our management, including our Principal Executive Officer and Principal
Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on criteria
established in the framework in&nbsp;Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (“COSO”).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">Because of its inherent limitations,
internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness
to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">Based on this evaluation, our management
concluded that our internal controls over financial reporting were effective as of September 30, 2021.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in Internal Control over Financial
Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the quarter ended September 30,
2021, there were no changes in our internal control over financial reporting identified in management’s evaluation pursuant
to Rules 13a 15(d) or 15d 15(d) of the Exchange Act that materially affected, or are reasonably likely to materially affect, our
internal controls over financial reporting.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_016"></span>ITEM 9B OTHER
INFORMATION</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="a_017"></span>PART III</p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_018"></span>ITEM 10 DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Directors and Executive Officers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our directors are to be elected at our
annual meeting and each director elected is to hold office until his or her successor is elected and qualified. Our Board of Directors
may remove our officers at any time.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our directors and executive officers,
their ages, positions held, and duration of such, are as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 28%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name</b></span></td>
<td style="width: 37%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Position</b></span></td>
<td style="width: 10%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Age</b></span></td>
<td style="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date first appointed</b></span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Christopher Missling, PhD</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Director, President, Chief Executive Officer, Secretary</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">56</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">July 5, 2013</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Athanasios Skarpelos</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">54</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">January 9, 2013</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Claus van der Velden, PhD</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">49</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">March 2, 2018</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Steffen Thomas, PhD</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">55</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">June 15, 2015</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Peter Donhauser, D.O.</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">56</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">February 8, 2017</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Jiong Ma, PhD</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">57</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">May 25, 2021</span></td></tr>
<tr style="vertical-align: top">
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Sandra Boenisch, CPA, CGA</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">Principal Financial Officer, Treasurer</span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">40 </span></td>
<td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">October 1, 2015</span></td></tr>
</tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Business Experience</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a brief account of
the education and business experience of directors and executive officers during at least the past five years, indicating their
principal occupations during the period, and the names and principal businesses of the organizations by which they were employed.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Christopher Missling, PhD</span>. Christopher
Missling has over twenty years of healthcare industry experience in big pharmaceutical, biotech industry and investment banking.
Most recently, from March 2007 until his appointment by our Company, Dr. Missling served as the head of healthcare investment banking
at Brimberg &amp; Co. in New York, New York. Also, Dr. Missling served as the Chief Financial Officer of Curis, Inc. (NASDAQ:CRIS)
and ImmunoGen, Inc. (NASDAQ:IMGN). Dr. Missling earned his MS and PhD from the University of Munich and an MBA from Northwestern
University Kellogg School of Management and WHU Otto Beisheim School of Management.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Athanasios Skarpelos</span>. Athanasios
(Tom) Skarpelos is a self-employed investor with 20 years of experience working with private and public companies with a focus
on biotechnology companies involved in drug discovery and drug development projects. His experience has led to relationships with
researchers at academic institutes in Europe and North America. Mr. Skarpelos is a founder of Anavex.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Claus van der Velden, PhD</span>. Claus
van der Velden, PhD, brings significant expertise in management, accounting, internal controls, information security and risk management.
Since May 2021, he has served as <span style="background-color: white">Managing Director (Chief Financial Officer) of NetCologne
GmbH, a regional telecommunication provider in Germany</span>. From July 2011 to May 2021, he served as corporate head of Management
Accounting, Internal Audit and Risk Management at Stroeer SE &amp; Co KGaA, a publicly listed German digital media company. Previously,
Dr. van der Velden served as the Director of Corporate Business Controlling for the Nutrition &amp; Health business unit at Cognis,
a worldwide supplier of global nutritional ingredients and specialty chemicals. In this position, he was also a compliance representative
and a member of the global leadership team. After the acquisition of Cognis by BASF, he was responsible for the management accounting
processes of the BASF Nutrition &amp; Health division, developing and producing mostly natural-source ingredients for the food
and healthcare industries. Dr. van der Velden started his career as a strategy consultant at an international marketing and strategy
consultancy firm. He studied in Kiel and Stockholm and received a degree in economics from the University of Kiel and later obtained
his doctorate in business management from the WHU-Otto Beisheim School of Management where he also previously taught economics.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Steffen Thomas, PhD</span>. <span style="color: black">Steffen
Thomas, has over 15 years of experience as a European patent attorney and is currently practicing at Epping Hermann Fischer, a
major intellectual property law firm in Europe. Previously, he worked for Japan-based Takeda Pharmaceutical Company, the largest
pharmaceutical company in Asia and a top firm worldwide, as an in-house patent attorney. Prior to that, he worked for Nycomed Pharma,
acquired by Takeda in 2011 for approximately USD $10 billion. Dr. Thomas’ legal practice covers drafting of patent applications,
prosecuting patent applications before national and international patent offices, defending and challenging patents in opposition,
appeal, and nullity proceedings, enforcing patents before the infringement courts, and preparing opinions on patentability and
infringement in the technical field of chemistry. Dr. Thomas has particular expertise in small molecule pharmaceuticals. He holds
MS and PhD degrees in Chemistry from the University of Munich.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Peter Donhauser, D.O.</span> Peter Donhauser,
had more than 20 years of expertise in clinical research prior to practicing osteopathic medicine with an integrated medical approach
in private practice beginning in 2000. He worked at the University Hospital of Munich in the fields of geriatrics and neuromusculoskeletal
diseases. During this time, he was a clinical trial investigator in multiple Phase 3 studies, including studies sponsored by Merck
Sharp &amp; Dohme, Merck, Boehringer Mannheim, Roche, Servier and Sanofi. He received his human medicine degree at the University
of Munich and Doctor of Osteopathic Medicine (D.O.) from the German-American Academy for Osteopathy, or DAAO, a member of the European
Register for Osteopathic Physicians, or EROP, at the Philadelphia College of Osteopathic Medicine.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Jiong Ma, PhD.</span> Jiong Ma has over 25
years of experience in investing, building and scaling of companies with a focus on innovative product launches in digital health,
technology and the new energy transition. Dr. Jiong Ma serves and served as a Board Director of LinkinVax, Aledia, Voxel8, Lo3
Energy, mc10, acquired by Medidata, Storiant, Fulham, Convey Computer, acquired by Micron Technology, Powervation, acquired by
RHOM Semiconductor, Laser Light Engine and Carbonite, Inc., which went public via IPO in 2011 and was subsequently acquired by
OpenText in 2019 for approximately $1.45 billion. As a Partner at Braemar Energy Ventures, where she has worked since 2008, Dr.
Ma has focused on investments in digitization of industry, resource efficiency, mobility, renewable energy infrastructure, and
deeptech. She was on the firm’s investment committee and has led more than 15 investments in growth stage companies with
focus on innovative product launches, as well as fund raising, negotiating and structuring investments, hiring management teams,
and assembling boards. As a result of her investment experience, Dr. Ma has significant knowledge and expertise in the technology
industry, including information security. Prior to Braemar Energy Ventures, she was with the Venture Capital Group at 3i, a global
private equity firm, where she led investments across multiple stages in Digital Health, TMT and Cleantech. Among them TransMedics
Group and ImpactRx/Symphony Health Solutions, which was later acquired by PRA Health Sciences. Preceding the Venture Capital Group
at 3i, Dr. Ma held several senior positions at Lucent Technologies and Bell Labs. Her responsibilities included lead roles in product
portfolio strategy, new product launches for Optical and Data Networking, and research and product development. Dr. Ma was also
a founding team member of Onetta Inc., a fiber networks company. She has a PhD in Electrical and Computer Engineering from the
University Colorado at Boulder and an MS in Electrical Engineering from Worcester Polytechnic Institute. Dr. Ma is a Kauffman Fellow.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Sandra Boenisch, CPA, CGA.</span><span style="color: black">
Ms. Boenisch is a Chartered Professional Accountant (CPA, CGA) with over 15 years of accounting, audit, and financial reporting
experience in a variety of industries, both in the United States and Canada. Ms. Boenisch was an independent consultant, providing
financial reporting services to a range of public companies in the United States and Canada since January 2012. From 2008 until
2012, Ms. Boenisch was employed at BDO Canada LLP (Vancouver, BC) where she was hired as a Senior Accountant and was later promoted
to Manager, Audit Assurance. Ms. Boenisch specialized in managing assurance engagements for public companies in the United States
and Canada. Prior to that, Ms. Boenisch worked for another public accounting firm from 2001 to 2008. As an independent consultant,
Ms. Boenisch has acquired considerable experience in finance, governance, and regulatory compliance. She holds a BComm from Laurentian
University.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Family Relationships</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no family relationships between
any director or executive officer.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Involvement in Certain Legal Proceedings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no material proceedings to
which any director or executive officer or any associate of any such director or officer is a party adverse to our Company or has
a material interest adverse to our Company.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Delinquent Section 16(a) Reports </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">None<span style="color: black">.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Code of Ethics</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We have adopted a code of ethics that
applies to our directors, principal executive officer, principal financial officer, principal accounting officer or controller,
or persons performing similar functions, and to all employees. We have posted our policy on our website at <span style="text-decoration: underline">www.anavex.com</span>.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Audit Committee and Audit Committee Financial
Experts </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The members of the Audit Committee are
Claus van der Velden (Chairman), Athanasios Skarpelos, Steffen Thomas and Jiong Ma. Our Board of Directors has determined that
Claus van der Velden is an “audit committee financial expert” as defined by applicable SEC and Nasdaq rules.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Audit Committee oversees and reports
to our Board of Directors on various auditing and accounting-related matters, including, among other things, the maintenance of
the integrity of our financial statements, reporting process and internal controls; the selection, evaluation, compensation and
retention of our independent registered public accounting firm; legal and regulatory compliance, including our disclosure controls
and procedures; and oversight over our risk management policies and procedures.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Audit Committee operates under a
charter that was adopted by our Board of Directors. The Audit Committee met four times during fiscal 2021.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Audit Committee has reviewed and
discussed the audited consolidated financial statements with management.<span style="color: #333333; background-color: white">
</span>The Audit Committee has discussed with BDO USA, LLP the matters required to be discussed by the applicable requirements
of the Public Company Accounting Oversight Board (“PCAOB”) and the Securities and Exchange Commission (the “Commission”).
In addition, the Audit Committee has received the written disclosures and the letter from BDO USA, LLP required by applicable requirements
of the PCAOB regarding the independent accountant’s communications with the Audit Committee concerning independence, and
has discussed with BDO USA, LLP its independence from the Company and management. Based on the reviews and discussions referred
to above, the Audit Committee recommended that the audited consolidated financial statements for the Company for the fiscal year
ended September 30, 2021 be included in this Annual Report on Form 10-K for the year ended September 30, 2021 for filing with the
Commission.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">MEMBERS OF THE AUDIT COMMITTEE</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Claus van der Velden (Chairman)<br>
Athanasios Skarpelos<br>
Steffen Thomas<br>
Jiong Ma</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Nominating and Corporate Governance
Committee</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The members of our Nominating and Corporate
Governance Committee are Claus van der Velden (Chairman), Steffen Thomas and Peter Donhauser.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Nominating and Corporate Governance
Committee is appointed by the board to oversee and evaluate the Board’s performance and the Company’s compliance with
corporate governance regulations, guidelines and principles, to identify individuals qualified to become Board members, to recommend
to the Board proposed nominees for board membership, and to recommend to the Board directors to serve on each standing committee.
The Nominating and Corporate Governance Committee operates under a charter that was adopted by our Board of Directors. The Nominating
and Corporate Governance Committee met one time during fiscal 2021.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><i>Compensation Committee</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The members of our Compensation Committee
are Claus van der Velden (Chairman), Steffen Thomas and Peter Donhauser.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee assists our
Board of Directors in discharging its responsibilities relating to compensation of our directors and executive officers. Its responsibilities
include, among other things: reviewing, approving and recommending compensation programs and arrangements applicable to our officers;
determining the objectives of our executive officer compensation programs; overseeing the evaluation of our senior executives;
administering our incentive compensation plans and equity-based plans, including reviewing and granting equity awards to our executive
officers; and reviewing and approving director compensation and benefits. The Compensation Committee can delegate to other members
of our Board of Directors, or an officer or officers of the Company, the authority to review and grant stock-based compensation
for employees who are not executive officers.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee has the responsibilities
and authority designated by Nasdaq rules. Specifically, the Compensation Committee has the sole discretion to select and receive
advice from a compensation consultant, legal counsel or other adviser and is directly responsible for oversight of their work.
The Compensation Committee must also determine reasonable compensation to be paid to such advisors by us.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee operates
under a charter that was adopted by our Board of Directors. The Compensation Committee met two times during fiscal 2021 and also
acted by written consent as required.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_019"></span>ITEM 11. EXECUTIVE
COMPENSATION</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">The Company’s compensation objectives
are to offer our executive officers’ compensation and benefits that are competitive and meet our goals of attracting, retaining
and motivating highly skilled, talented management, which is necessary for the Company to achieve its financial and strategic objectives
and create long-term value for our stockholders.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">A significant portion
of the Company’s executive compensation opportunity is related to factors that directly and indirectly influence shareholder
value, including long-term stock performance and operational performance. We believe the levels of compensation we provide should
be competitive, reasonable and appropriate for our business needs and circumstances.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525"><b><i>Our Executive
Compensation Program and Philosophy</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The intent of the Company’s compensation
program is to attract and retain talent, to create incentives for and to reward excellent performance. We seek to compensate our
executives in a manner that is competitive, rewards performance that creates shareholder value, recognizes individual contributions,
and encourages long-term value creation.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: lime"></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: black">The Compensation
Committee meets at least twice per year to review and evaluate executive compensation and each executive officer’s performance.
The Compensation Committee utilizes quantitative and qualitative factors, including the accomplishment of initiatives, attitude,
and leadership and applies overall judgment to assess performance, taking into account the financial condition of the Company.
Ultimately, the Compensation Committee seeks to </span>evaluate, based on the achievement of financial and nonfinancial objectives,
the variable compensation, including special awards, of executive officers of the Company and decide on the base salary and target
discretionary bonus for such persons taking into account relevant benchmark data<span style="color: black">.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee believes
that a significant portion of each executive’s compensation opportunity should be tied to variable compensation and value
creation for shareholders. The Compensation Committee believes this mix provides an appropriate balance between the financial security
required to attract and retain qualified individuals, and the Compensation Committee’s goal of ensuring that executive compensation
rewards performance that benefits shareholders over the long term.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525"><b><i>Compensation Consultants</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Compensation Committee makes recommendations
to the Board for all compensation for executives, including the structure and design of the compensation programs. The Compensation
Committee is responsible for retaining and terminating compensation consultants and determining the terms and conditions of their
engagement. During fiscal 2021, the Compensation Committee did not engage any compensation consultants.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525"><b><i>Annual Discretionary
Cash Bonuses</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has an annual discretionary
cash bonus program. The Compensation Committee, or Board of Directors works with the Chief Executive Officer to evaluate the Company’s
financial performance and overall financial condition to determine if discretionary bonuses are to be paid.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525"><b><i>Benefits</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s executives are entitled
to participate in employee benefit plans, programs and arrangements implemented by the Company and generally available to all salaried
employees, such as medical, dental and insurance programs. Executives are also allowed to participate in the Company’s tax-qualified
401(k) Plan offered to all similarly situated full-time employees.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Summary Compensation </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The particulars of compensation paid
to our named executive officers for the last two completed fiscal years:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
  <td style="text-align: left"><b>Name and Principal Position</b></td>
  <td><b>&nbsp; &nbsp; &nbsp; &nbsp;</b></td>
  <td colspan="3" style="text-align: center"><b>Year</b></td>
  <td><b>&nbsp; &nbsp; &nbsp; &nbsp;</b></td>
  <td colspan="3" style="text-align: center"><b>Salary ($)</b></td>
  <td><b>&nbsp; &nbsp; &nbsp; &nbsp;</b></td>
  <td colspan="3" style="text-align: center"><b>Bonus ($)</b></td>
  <td><b>&nbsp; &nbsp; &nbsp; &nbsp;</b></td>
  <td colspan="3" style="text-align: center"><b>Option Awards ($)</b></td>
  <td style="font-weight: bold"><b>&nbsp; &nbsp; &nbsp; &nbsp;</b></td>
  <td colspan="3" style="font-weight: bold; text-align: center"><b>All other Compensation ($)</b></td>
  <td><b>&nbsp; &nbsp; &nbsp; &nbsp;</b></td>
  <td colspan="3" style="text-align: center"><b>Total ($)</b></td>
</tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Christopher Missling, PhD</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 6%; text-align: right">2021</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 6%; text-align: right">550,000</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 6%; text-align: right">110,000</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 6%; text-align: right">8,745,457</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 6%; text-align: right">11,600</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 6%; text-align: right">9,417,057</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">President, Chief Executive Officer, and</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2020</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">550,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">55,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,224,648</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">11,400</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,841,048</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Director</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Sandra Boenisch<sup>(1)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2021</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">158,300</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">724,314</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">882,614</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Principal Financial Officer and Treasurer</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2020</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">117,041</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">22,313</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">155,864</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">295,218</td><td style="text-align: left">&nbsp;</td></tr>
</tbody></table>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 5%; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify; width: 95%"><span style="font-size: 10pt">Compensation to Ms. Boenisch denominated in Canadian
Dollars and has been translated to US dollars at an exchange rate of 0.7915 during the year ended September 30, 2021 (2020: 0.7438).</span></td>
</tr></tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employment Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Christopher Missling</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We and Dr. Missling entered into an
employment agreement dated July 5, 2013, as amended and extended (the “CEO Employment Agreement”), whereby we currently
pay to Dr. Missling an annual base salary of $550,000. In addition, Dr. Missling is eligible to earn an annual cash bonus for each
whole or partial calendar year of up to twenty percent of his base salary, and to participate in our employee benefit plans. We
have agreed to indemnify Dr. Missling in connection with his provision of services to us.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Sandra Boenisch</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We and Ms. Boenisch entered into an
amended and restated employment agreement dated October 4, 2017, as amended and extended, whereby we currently pay Ms. Boenisch
an annual base salary of $200,000 Canadian dollars. Ms. Boenisch is eligible for discretionary salary increases.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Outstanding Equity Awards at Fiscal Year-End
</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth for each
named executive officer and director certain information concerning the outstanding equity awards as of September 30, 2021.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td colspan="21" style="text-align: center">Option Awards</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Equity Incentive</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Plan Awards:</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Number of</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Securities</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Securities</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Securities</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Underlying</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Underlying</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Underlying</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Unexercised</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Option</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Exercisable</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Unexercisable</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Unearned</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center"> Exercise</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Option</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Options</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Options</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Options</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Price</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Expiration</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">Name</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">(#)</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">(#)</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">(#)</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">($)</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">Date</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Christopher Missling</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: right">500,000</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: right">—</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: right">—</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: right">1.60</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">July 5, 2023</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 24%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">73,380</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">—</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">—</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">1.32</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 20%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">May 8, 2024</span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">500,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">0.92</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">April 2, 2025</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">187,500</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5.04</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Sept 18, 2025</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">379,625</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">6.26</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">July 5, 2026</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">861,429</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7.06</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">July 18, 2026</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">500,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3.28</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Sept 22, 2026</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">450,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5.92</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">May 12, 2027</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">400,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3.30</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Dec 13, 2027</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">450,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2.30</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">May 15, 2028</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">409,500</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2.58</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Oct. 1, 2028</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">500,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">250,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3.15</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">May 3, 2029</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">550,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2.96</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">January 6, 2030</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">550,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5.49</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">December 30, 2030</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">500,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">18.11</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">August 2, 2031</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sandra Boenisch</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">30,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3.30</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Dec 13, 2027</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">30,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2.30</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">May 15, 2028</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">27,300</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2.58</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Oct. 1, 2028</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">35,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2.93</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">June 4, 2029</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">70,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2.96</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">January 6, 2030</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">50,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5.49</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">December 30, 2030</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">40,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">18.11</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">August 2, 2031</span></td><td style="text-align: left">&nbsp;</td></tr>
</tbody></table>




<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Compensation of Directors </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below shows the compensation
of our directors who were not our named executive officers for the fiscal year ended September 30, 2021:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Name</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Fees Earned or Paid in Cash<br> ($)</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Stock&nbsp;<br> Awards&nbsp;<br> ($)</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b><b>&nbsp;</b><b>Option&nbsp;</b><br> <b>Awards&nbsp;</b><br> <b>($) <sup>(1)</sup></b></span></td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Non-Equity Incentive Plan Compensation ($)</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Nonqualified Deferred Compensation Earnings ($)</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">All Other Compensation&nbsp;($)</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Total&nbsp;<br> ($)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left">Athanasios Skarpelos</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right">18,750</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right">—</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right">458,960</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right">—</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right">—</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right">—</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right">477,710</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Claus van der Velden</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">34,750</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">458,960</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">493,710</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Elliot Favus</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">142,860</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">142,860</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Steffen Thomas</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">18,750</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">458,960</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">477,710</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Peter Donhauser</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">18,750</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">458,960</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">477,710</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Jiong Ma</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8,750</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">677,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">685,750</td><td style="text-align: left">&nbsp;</td></tr>
</tbody></table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: lime"></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: lime"></span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) At September 30, 2021, the aggregate
number of outstanding vested and unvested stock option awards held by each director was: Mr. Skarpelos options to purchase 305,500
shares, Dr. van der Velden options to purchase 205,500 shares, Dr. Thomas options to purchase 305,500 shares, Dr. Donhauser options
to purchase 205,500 shares and Dr. Ma options to purchase 60,000 shares.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently compensate non-employee
directors $25,000 per year, paid quarterly, effective January 1, 2021. We compensate Claus van der Velden an additional $4,000
per quarter for performing the functions of Chairman of our Audit Committee, Compensation Committee and Nominating and Corporate
Governance Committee.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, directors are entitled
to participate in our long term incentive plans adopted by our Board of Directors and are entitled to reimbursement for reasonable
travel and other out-of-pocket expenses incurred in connection with attendance at meetings of our Board of Directors. Our Board
of Directors may award further special remuneration to any director undertaking any special services on our behalf other than services
ordinarily required of a director.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Retirement or Similar Benefit Plans</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no arrangements or plans in
which we provide retirement or similar benefits for our directors or executive officers.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Resignation, Retirement, Other Termination,
or Change in Control Arrangements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Employment Agreement with Dr. Missling
contains provisions regarding our obligations upon his termination and upon a change of control. In the event of a change of control,
as such term is defined in the employment agreement, all previously granted but unvested stock options held by Dr. Missling shall
vest. Depending on the nature of the termination of Dr. Missling’s services, certain of his salary, bonus and granted securities
shall vest in the amounts at such time as set forth in the Employment Agreement. A copy of Dr. Missling’s Employment Agreement
and all amendments thereto are set forth as exhibits hereto.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our employment agreement with Sandra
Boenisch contains provisions regarding our obligations to Ms. Boenisch upon a change of control. In the event of a change of control,
as such term is defined in the employment agreement, all of the remaining unvested option shares granted to Ms. Boenisch will immediately
vest with no restrictions on purchase or sales. A copy of Ms. Boenisch’s employment agreement is set forth in its entirety
as an exhibit hereto.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_020"></span>ITEM 12. SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND<span style="text-transform: uppercase"> RELATED STOCKHOLDER MATTERS.</span></span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal; text-transform: uppercase">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth, as of
November 19, 2021, certain information with respect to the beneficial ownership of our common stock by each stockholder known by
us to be the beneficial owner of more than 5% of our common stock and by each of our current directors and our named executive
officers and by our current directors and executive officers as a group. We have determined the number and percentage of shares
beneficially owned by such person in accordance with Rule 13d-3 under the Securities Exchange Act of 1934. This information does
not necessarily indicate beneficial ownership for any other purpose.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Title of class</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">Name and address of<br> beneficial owner</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Amount and nature of<br> beneficial ownership</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Percent of</b><br> <b>class <sup>(1)</sup></b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; text-align: left">Common Stock</td><td style="width: 5%">&nbsp;</td>
    <td style="width: 21%; text-align: left">Christopher Missling (CEO/Director)</td><td style="width: 5%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 19%; text-align: right">6,229,644</td><td style="width: 1%; text-align: left"><sup>(2)</sup></td><td style="width: 5%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 19%; text-align: right">7.7</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common Stock</td><td>&nbsp;</td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Athanasios Skarpelos<b> </b>(Director)</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,586,958</td><td style="text-align: left"><sup>(3)</sup></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2.1</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common Stock</td><td>&nbsp;</td>
    <td style="text-align: left">Claus van der Velden (Director)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">180,500</td><td style="text-align: left"><sup>(4)</sup></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common Stock</td><td>&nbsp;</td>
    <td style="text-align: left">Steffen Thomas (Director)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">280,500</td><td style="text-align: left"><sup>(5)</sup></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common Stock</td><td>&nbsp;</td>
    <td style="text-align: left">Peter Donhauser (Director)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">182,665</td><td style="text-align: left"><sup>(6)</sup></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common Stock</td><td>&nbsp;</td>
    <td style="text-align: left">Jiong Ma (Director)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left"><sup>(7)</sup></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common Stock</td><td>&nbsp;</td>
    <td style="text-align: left">Sandra Boenisch (Principal Financial Officer)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">145,263</td><td style="text-align: left"><sup>(8)</sup></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common Stock</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Directors &amp; Executive Officers as a group (7 persons)<sup> </sup></b></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8,605,530</td><td style="text-align: left"><sup>&nbsp;</sup></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">10.5</td><td style="text-align: left">%</td></tr>
</tbody></table>



<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt; line-height: 115%; width: 18%"><span style="font: 10pt Times New Roman, Times, Serif">*Less than 1%</span></td>
<td style="padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt; line-height: 115%; width: 31%">&nbsp;</td>
<td style="padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt; text-align: right; line-height: 115%; width: 21%">&nbsp;</td>
<td style="padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt; line-height: 115%; width: 9%">&nbsp;</td>
<td style="padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt; text-align: center; line-height: 115%; width: 21%">&nbsp;</td></tr>
</tbody></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Percentage of ownership is based on 76,018,053 of our common stock
issued and outstanding as of November 19, 2021. Except as otherwise indicated, we believe that the beneficial owners of the common
stock listed above, based on information furnished by such owners, have sole investment and voting power with respect to such shares,
subject to community property laws where applicable. Beneficial ownership is determined in accordance with the rules of the Commission
and generally includes voting or investment power with respect to securities. Shares of common stock subject to options or warrants
currently exercisable or exercisable within 60 days, are deemed outstanding for purposes of computing the percentage ownership
of the person holding such option or warrants but are not deemed outstanding for purposes of computing the percentage ownership
of any other person.</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td><td>&nbsp;</td><td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td></td><td><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt; color: black">Includes options to purchase 500,000 shares of our
common stock at $1.60 per share, options to purchase 73,380 shares of our common stock at $1.32 per share, options to purchase
500,000 shares of our common stock at $0.92 per share, options to purchase 187,500 shares of our common stock at $5.04 per share,
options to purchase 379,625 shares of our common stock at $6.26 per share, options to purchase 861,429 shares of our common stock
at $7.06 per share, options to purchase 500,000 shares of our common stock at $3.28 per share, options to purchase 450,000 shares
of our common stock at $5.92 per share, options to purchase 400,000 shares of our common stock at $3.30 per share, options to purchase
450,000 shares of our common stock at $2.30 per share, options to purchase 409,500 shares of our common stock at $2.58 per share,
and options to purchase 500,000 shares of our common stock at $3.15 per share that are vested or are vesting within 60 days. Excludes
options to purchase 250,000 shares of our common stock at $3.15 per share, options to purchase 550,000 shares of our common stock
at $2.96 per share, options to purchase 550,000 shares of our common stock at $5.49 per share, and options to purchase 500,000
shares of our common stock at $18.11 that do not vest within 60 days.</span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td><td>&nbsp;</td><td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td></td><td><span style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Includes options to purchase 50,000 shares of our common stock at
$0.92 per share and options to purchase 100,000 shares of our common stock at $3.28 per share, <span style="color: black">options
to purchase 45,500 shares of our common stock at $2.58 per share</span>, options to purchase 50,000 shares of our common stock
at $2.96 per share, and options to purchase 35,000 shares of our common stock at $5.49 per share that have vested or are vesting
within 60 days.<span style="color: black"> Excludes options to purchase 25,000 shares of our common stock at $18.11 that do not
vest within 60 days.</span></span></td></tr>
<tr style="vertical-align: top">
<td>&nbsp;</td><td>&nbsp;</td><td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td></td><td><span style="font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-size: 10pt; color: black">Includes options to purchase 50,000 shares of our common
stock at $2.60 per share, options to purchase 45,500 shares of our common stock at $2.58 per share,</span><span style="font-size: 10pt">
options to purchase 50,000 shares of our common stock at $2.96 per share, and options to purchase 35,000 shares of our common stock
at $5.49 that have vested or are vesting within 60 days<span style="color: black">. Excludes&nbsp;options to purchase 25,000 shares
of our common stock at $18.11 per share that are not vesting within 60 days.</span></span><br>
<br>
</td></tr>
</tbody></table>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<tbody><tr style="vertical-align: top">
<td style="padding: 0; width: 0.25in; text-indent: 0">&nbsp;</td>
<td style="padding: 0; width: 0.25in; text-indent: 0"><span style="font-size: 10pt">(5)</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt; color: black">Includes options to purchase 50,000 shares of our common stock at $1.76 per share and options to purchase 100,000 shares of our common stock at $3.28 per share, options to purchase 45,500 shares of our common stock at $2.58 per share, options to purchase 50,000 shares of our common stock at $2.96 per share, and options to purchase 35,000 shares of our common stock at $5.49 per share that have vested or are vesting within 60 days. Excludes options to purchase 25,000 shares of our common stock at $18.11 per share that are not vesting within 60 days.</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0">&nbsp;</td>
<td style="padding: 0; text-indent: 0">&nbsp;</td>
<td style="padding: 0; text-align: justify; text-indent: 0">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0">&nbsp;</td>
<td style="padding: 0; text-indent: 0"><span style="font-size: 10pt">(6)</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">Includes options to purchase 50,000 shares of our common stock at $5.39 per share, options to purchase 45,500 shares of our common stock at $2.58 per share, options to purchase 50,000 shares of our common stock at $2.96 per share, and options to purchase 35,000 shares of our common stock at $5.49 per share that have vested or are vesting within 60 days<span style="color: black">. Excludes options to purchase 25,000 shares of our common stock at $18.11 per share that are not vesting within 60 days.</span></span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0">&nbsp;</td>
<td style="padding: 0; text-indent: 0">&nbsp;</td>
<td style="padding: 0; text-align: justify; text-indent: 0">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0">&nbsp;</td>
<td style="padding: 0; text-indent: 0">(7)</td>
<td style="padding: 0; text-align: justify; text-indent: 0">Excludes options to purchase 35,000 shares of common stock at $13.01 per share and options to purchase 25,000 shares of our
common stock at $18.11 per share that do not vest within 60 days.</td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0">&nbsp;</td>
<td style="padding: 0; text-indent: 0">&nbsp;</td>
<td style="padding: 0; text-align: justify; text-indent: 0">&nbsp;</td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; text-indent: 0">&nbsp;</td>
<td style="padding: 0; text-indent: 0"><span style="font-size: 10pt">(8)</span></td>
<td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-size: 10pt">Includes options to purchase 30,000 shares of our common stock at $3.30 per share, and options to purchase 30,000 shares of our common stock at $2.30 per share, options to purchase 27,300 shares of our common stock at $2.58 per share, options to purchase 35,000 shares of our common stock at $2.93 that have vested or are vesting within 60 days. Excludes options to purchase 70,000 shares of our common stock at $2.96 per share, options to purchase 50,000 shares of our common stock at $5.49 and options to purchase 40,000 shares of our common stock at $18.11 that do not vest within 60 days.</span></td></tr>
</tbody></table>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Change in Control</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We are unaware of any contract or other
arrangement, the operation of which may at a subsequent date result in a change of control of our Company.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Securities Authorized for Issuance under
Equity Compensation Plans or Individual Compensation Arrangements </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes certain
information regarding our equity compensation plan or individual compensation arrangements at September 30, 2021:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td colspan="13" style="font-weight: bold; text-align: center">Equity Compensation Plan Information</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">Plan Category</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number of securities to be issued upon exercise of outstanding options, warrants and rights<br> (a)</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted-average exercise price of outstanding options, warrants and rights<br> (b)</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number of securities remaining available for future issuances under equity compensation plans (excluding securities reflected in column (a))<br> (c)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Equity compensation plans approved by security holders</td><td style="width: 5%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 11%; text-align: right">12,050,553</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 11%; text-align: right">6.26</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 11%; text-align: right">602,703</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equity compensation plans not approved by security holders</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">12,050,553</td><td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">6.26</td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">602,703</td><td style="text-align: left">&nbsp;</td></tr>
</tbody></table>


<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2019 Stock Option Plan</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 15, 2019, the Board approved
the 2019 Omnibus Incentive Plan (the “2019 Plan”), which provides for the grant of stock options and restricted stock
awards to directors, officers, employees, consultants and advisors of the Company. The 2019 Plan was approved by our stockholders
on April 5, 2019.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the 2019 Plan, 6,000,000
shares of Common Stock were made available for issuance[, in addition to the shares available under the 2015 Plan]. Any awards
outstanding under the Company’s 2015 Omnibus Incentive Plan (the “2015 Plan”) or the Company’s 2007 Stock
Option Plan (the “2007 Plan”) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively,
and any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such
awards (other than by reason of settlement of the awards in shares) will automatically become available for issuance under the
2019 Plan.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2019 Plan provides that it may be
administered by the Board, or the Board may delegate such responsibility to a committee. The exercise price will be determined
by the Board of Directors at the time of grant shall be at least equal to the fair market value on such date. If the grantee is
a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value of the Company’s
shares of common stock on the grant date. Stock options may be granted under the 2019 Plan for an exercise period of up to ten
years from the date of grant of the option or such lesser periods as may be determined by the board, subject to earlier termination
in accordance with the terms of the 2019 Plan.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The purpose of the 2019 Plan is to retain
the services of valued key employees and consultants of our Company and such other persons, and to encourage such persons to acquire
a greater proprietary interest in our Company, thereby strengthening their incentive to achieve the objectives of the shareholders
of our Company. The purpose is also to serve as an aid and inducement in the hiring of new employees and to provide an equity incentive
to consultants.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_021"></span>ITEM 13. CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Transactions with related persons</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: black">There have
been no transactions</span>, since October 1, 2020, or currently proposed transactions, in which we were or are to be a participant
and the amount involved exceeds the lesser of $120,000 or one percent of the average of the smaller reporting company’s total
assets at year end for the last two completed fiscal years, and in which any of the following persons had or will have a direct
or indirect material interest.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="font: 10pt/115% Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">i.</span></td>
<td style="font: 10pt/115% Calibri, Helvetica, Sans-Serif; width: 90%"><span style="font: 10pt Times New Roman, Times, Serif">any
director or executive officer of our Company;</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">ii.</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">any beneficial owner of shares carrying more than 5% of the voting
rights attached to our outstanding shares of common stock; and</span></td></tr>
<tr style="vertical-align: top">
<td style="font: 10pt/115% Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">iii.</span></td>
<td><span style="font: 10pt Times New Roman, Times, Serif">any member of the immediate family (including spouse, parents, children,
siblings and in-laws) of any of the foregoing persons.</span></td></tr>
</tbody></table>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Compensation of Named Executive Officers
and Directors</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For information regarding compensation
of named executive officers and directors, please see “Item 11. Executive Compensation.”</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Director Independence</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the NASDAQ Stock Market Rules, the Board
has a responsibility to make an affirmative determination that those members of its Board that serve as independent directors do
not have any relationships with the Company and its businesses that would impair their independence. The Board has determined that
that Christopher Missling, PhD is not independent as that term is defined by NASDAQ 5605(a)(2) because Mr. Missling serves as our
President, Chief Executive Officer, and Secretary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="color: black">The Board has determined
that that Claus van der Velden, </span>Athanasios Skarpelos,<span style="color: black"> Steffen Thomas, Peter Donhauser and Jiong
Ma are independent as that term is defined by NASDAQ 5605(a)(2) and the applicable rules of the</span> Commission<span style="color: black">.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_022"></span>ITEM 14. PRINCIPAL
ACCOUNTING FEES AND SERVICES </span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Fees Paid to Our Independent Registered
Public Accounting Firm </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the aggregate
fees billed or expected to be billed to our Company for professional services rendered by our independent registered public accounting
firm, for the fiscal years ended September 30, 2021 and 2020:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2021</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Audit Fees</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">392,676</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">305,751</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Audit Related Fees</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax Fees</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">All Other Fees</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total Fees</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">392,676</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">305,751</td><td style="text-align: left">&nbsp;</td></tr>
</tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Audit Fees</span>. Consist of fees
billed for professional services rendered for the audits of our financial statements, reviews of our interim financial statements
included in quarterly reports, services performed in connection with regular filings with the Commission for the fiscal years
ended September 30, 2021 and 2020 in connection with statutory and regulatory filings or engagements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Policy on Pre-Approval by Audit Committee
of Services Performed by Independent Registered Public Accounting Firm </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Audit Committee pre-approves all
services provided by our independent registered public accounting firm. All of the above services and fees were reviewed and approved
by our Audit Committee before the respective services were rendered.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Audit Committee has considered the
nature and amount of fees billed or expected to be billed by BDO USA, LLP and believes that the provision of services for activities
unrelated to the audit was compatible with maintaining BDO USA, LLP’s independence.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>




<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span id="a_023"></span>PART IV</p>

<p style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"><span id="a_024"></span>ITEM 15. EXHIBITS,
FINANCIAL STATEMENT SCHEDULES</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0"><span style="font-style: normal"></span><span style="text-transform: uppercase"><b>&nbsp;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="border: windowtext 1pt solid; padding: 0; width: 12%; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit
</b><br> <b>Number </b></span></td>
<td style="border-top: windowtext 1pt solid; border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; width: 88%; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><br><b>Description</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(3)
</b></span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Articles
of Incorporation and Bylaws </b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">3.1
</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/e3306_ex3-1.htm" tabindex="18">Articles of Incorporation, as amended*</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">3.3</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm" tabindex="18">Bylaws (incorporated by reference to our Current Report on Form 8-K filed on September 28, 2007)</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(10)
</b></span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Material
Contracts</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">10.1^</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577415003756/s102397_ex10-91.htm" tabindex="18">2015 Omnibus Incentive Plan (incorporated by reference to our Annual Report on Form 10-K filed on December 29, 2015)</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">10.2^</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419002242/s115994_def14a.htm" tabindex="18">2019 Omnibus Incentive Plan (incorporated by reference to our Proxy Statement, dated February 11, 2019, as filed on February 11, 2019)</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">10.3^</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000106299314004769/exhibit31-1.htm" tabindex="18">Employment Agreement, dated as of July 5, 2013, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Quarterly Report on Form 10-Q filed on August 13, 2014)</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">10.4^</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577416006259/s103666_ex10-1.htm" tabindex="18">First Amendment to Employment Agreement, dated as of July 5, 2016, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on July 7, 2016)</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">10.5^</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577416006410/s103735_ex10-1.htm" tabindex="18">Amended and Restated First Amendment to Employment Agreement, dated as of July 18, 2016, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on July 22, 2016)</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">10.6^</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex10-1.htm" tabindex="18">Second Amendment to Employment Agreement, dated as of May 3, 2019 by and between the Company and Christopher Missling, PhD (incorporated by reference to our Quarterly Report on Form 10-Q filed on May 9, 2019)</a> </span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">10.7^</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577417007272/s108360_ex10-7.htm" tabindex="18">Amended and Restated Employment Agreement by and between the Company and with Sandra Boenisch (incorporated by reference to our Annual Report on Form 10-K filed on December 11, 2017)</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">10.8^</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112220000103/e1699_10-1.htm" tabindex="18">Amendment No. 1 to Amended and Restated Employment Agreement between the Company and Sandra Boenisch, dated February 4, 2020 (incorporated by reference to our Quarterly Report on Form 10-Q filed on February 6, 2020)</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">10.9</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112220000432/e1889_ex1-1.htm" tabindex="18">Amended and Restated Sales Agreement, dated May 1, 2020, by and among the Company, Cantor Fitzgerald&nbsp;&amp; Co. and SVB Leerink LLC (incorporated by reference to our Current Report on Form 8-K filed on May 1, 2020)</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">10.10</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112221001090/e2871_ex10-1.htm" tabindex="18">Letter Agreement, dated June 22, 2021 between the Company and H.C. Wainwright &amp; Co., LLC (incorporated by reference to our Current Report on Form 8-K filed on June 24, 2021)</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">10.11</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112221001090/e2871_ex10-2.htm" tabindex="18">Form of Securities Purchase Agreement, dated June 22, 2021 between the Company and the investor named therein (incorporated by reference to our Current Report on Form 8-K filed on June 24, 2021)</a></span></td></tr>
</tbody></table>

<p style="margin: 0">&nbsp;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 12%; text-align: left"><b>Exhibit</b></td><td style="border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; width: 88%"><b>Number Description</b></td>
</tr></tbody></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="border: Black 1pt solid; padding: 0; line-height: 115%; text-indent: 0; width: 12%"><span style="font: 10pt Times New Roman, Times, Serif"><b>14</b></span></td>
<td style="border: Black 1pt solid; padding: 0; line-height: 115%; text-indent: 0; width: 88%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Code
of Ethics</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">14.1</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577416008914/s104917_ex14-1.htm" tabindex="18">Code of Ethics Adopted on September 13, 2016 (incorporated by reference to our Annual Report on Form 10-K filed on December 14, 2016)</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(21)</b></span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Subsidiaries</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">21.1*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/e3306_ex21-1.htm" tabindex="18">Subsidiaries of the Registrant</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(23)</b></span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Consent</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">23.1*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/e3306_ex23-1.htm" tabindex="18">Consent of Independent Registered Public Accounting Firm</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(31)
</b></span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Section
302 Certifications</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">31.1*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/e3306_ex31-1.htm" tabindex="18">Section 302 Certification of Christopher Missling, PhD.</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">31.2*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/e3306_ex31-2.htm" tabindex="18">Section 302 Certification of Sandra Boenisch</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(32)
</b></span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Section
906 Certifications</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">32.1*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000173112221002062/e3306_ex32-1.htm" tabindex="18">Section 906 Certification of Christopher Missling, PhD and Sandra Boenisch</a></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(101)</b></span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>XBRL</b></span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.INS*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
INSTANCE DOCUMENT</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.SCH*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
TAXONOMY EXTENSION SCHEMA</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.CAL*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
TAXONOMY EXTENSION CALCULATION LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.DEF*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
TAXONOMY EXTENSION DEFINITION LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.LAB*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
TAXONOMY EXTENSION LABEL LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.PRE*</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
TAXONOMY EXTENSION PRESENTATION LINKBASE</span></td></tr>
<tr style="vertical-align: top">
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; border-left: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">104</span></td>
<td style="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Cover
Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr>
</tbody></table>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">* Filed herewith.&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">^ Denotes a management contract or compensatory plan
or arrangement.</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-style: normal"><span id="a_025"></span>ITEM 16. FORM
10-K SUMMARY</span></p>

<p style="font: italic bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font-style: normal">&nbsp;</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Not Applicable.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></tbody></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tbody><tr><td style="text-align: center; width: 100%">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>




<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Pursuant
to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date: November 24, 2021</b></span></td>
<td colspan="2" style="padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX LIFE SCIENCES CORP.</b></span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; width: 50%; line-height: 115%; font-size: 10pt; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; width: 7%; line-height: 115%; font-size: 10pt; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; width: 43%; line-height: 115%; font-size: 10pt; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; line-height: 115%; font-size: 10pt; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
<td style="border-bottom: Black 1pt solid; padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Christopher Missling, PhD</i></span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; line-height: 115%; font-size: 10pt; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Name:</span></td>
<td style="padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Christopher Missling, PhD</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; line-height: 115%; font-size: 10pt; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Title:</span></td>
<td style="padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer (Principal Executive</span></td></tr>
<tr style="vertical-align: top">
<td style="padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Officer)</span></td></tr>
</tbody></table>



<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: bottom">
<td style="border-bottom: Black 1pt solid; padding: 0; white-space: nowrap; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Signatures</b></span></td>
<td style="padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="border-bottom: Black 1pt solid; padding: 0; white-space: nowrap; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title(s)</b></span></td>
<td style="padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td colspan="2" style="border-bottom: Black 1pt solid; padding: 0; white-space: nowrap; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0; white-space: nowrap; text-align: center; text-indent: 0">&nbsp;</td>
<td style="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; white-space: nowrap; text-align: center; text-indent: 0">&nbsp;</td>
<td style="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</td>
<td colspan="2" style="padding: 0; white-space: nowrap; text-align: center; text-indent: 0">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1pt solid; padding: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Christopher Missling, PhD</i></span></td>
<td style="padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td colspan="2" style="padding: 0; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">November 24, 2021</span></td></tr>
<tr style="vertical-align: bottom">
<td style="padding: 0; text-indent: 0">&nbsp;</td>
<td style="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</td>
<td colspan="2" style="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</td></tr>
<tr>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Christopher Missling,
PhD</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer
(Principal Executive Officer)</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td colspan="2" style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td colspan="2" style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0">&nbsp;</td></tr>
<tr>
<td style="border-bottom: Black 1pt solid; padding: 0; vertical-align: top; width: 29%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Sandra Boenisch</i></span></td>
<td style="padding: 0; vertical-align: bottom; width: 1%; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: top; width: 46%; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: bottom; width: 1%; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: bottom; width: 22%; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">November
24, 2021</span></td>
<td style="padding: 0; width: 1%; font-size: 10pt; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="padding: 0; vertical-align: top; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0">&nbsp;</td></tr>
<tr>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Sandra Boenisch, CPA,
CGA</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Principal Financial
Officer and Treasurer (Principal Accounting Officer)</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td colspan="2" style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="border-bottom: Black 1pt solid; padding: 0; vertical-align: top; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Athanasios Skarpelos</i></span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">November 24, 2021</span></td>
<td style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="padding: 0; vertical-align: top; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0">&nbsp;</td></tr>
<tr>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Athanasios Skarpelos</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td colspan="2" style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td colspan="2" style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0">&nbsp;</td></tr>
<tr>
<td style="border-bottom: Black 1pt solid; padding: 0; vertical-align: top; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Claus van der Velden, PhD</i></span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">November 24, 2021</span></td>
<td style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="padding: 0; vertical-align: top; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0">&nbsp;</td></tr>
<tr>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Claus van der Velden,
PhD</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td colspan="2" style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td colspan="2" style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0">&nbsp;</td></tr>
<tr>
<td style="border-bottom: Black 1pt solid; padding: 0; vertical-align: top; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Steffen Thomas, PhD</i></span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">November 24, 2021</span></td>
<td style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="padding: 0; vertical-align: top; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0">&nbsp;</td></tr>
<tr>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Steffen Thomas, PhD</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td colspan="2" style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td colspan="2" style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td></tr>
<tr>
<td style="border-bottom: Black 1pt solid; padding: 0; vertical-align: top; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Peter Donhauser, D.O.</i></span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">November 24, 2021</span></td>
<td style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="padding: 0; vertical-align: top; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0">&nbsp;</td></tr>
<tr>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Peter Donhauser, D.O.</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td colspan="2" style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td colspan="2" style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td></tr>
<tr>
<td style="border-bottom: Black 1pt solid; padding: 0; vertical-align: top; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/ Jiong Ma, PhD</i></span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">November 24, 2021</span></td>
<td style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
<tr>
<td style="padding: 0; vertical-align: top; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0">&nbsp;</td>
<td style="padding: 0; font-size: 10pt; line-height: 115%; text-indent: 0">&nbsp;</td></tr>
<tr>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Jiong Ma, PhD</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
<td style="padding: 0; vertical-align: bottom; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td>
<td colspan="2" style="padding: 0; vertical-align: top; line-height: 115%; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">&nbsp;</span></td></tr>
</tbody></table>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">79</p>

<!-- Field: Rule-Page --><div style="text-align: left; margin-top: 3pt; margin-bottom: 3pt"><div style="border-top: Black 2pt solid; font-size: 1pt; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>



<p style="margin: 0"></p>



<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->

</body>
</html>